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Abstract 
The haemoglobinopathies are complex inherited disorders of haemoglobin 
synthesis. Although carriers are generally asymptomatic, homozygous or 
compound heterozygous inheritance of globin gene mutations may result in severe 
conditions, identified as a major burden of disease worldwide. The main means of 
control of the conditions is by carrier screening using specialist laboratory testing, 
allowing individuals an informed reproductive choice. UK NEQAS Haematology 
provides a comprehensive external quality assessment service for the 
haemoglobinopathies and is in a unique position to provide an overview of 
laboratory performance. The increased emphasis on laboratory quality and a shift 
in the profile of the participating laboratories from mainly UK-based to more than 
half non-British Isles in the past decade are drivers for continued improvement in 
performance assessment methods. The project looked at aspects of performance 
of both UK NEQAS and the participants. A review of historical quantitation data for 
haemoglobin (Hb) A2, the standard biomarker for beta thalassaemia carrier 
identification, showed there remains a need for standardisation between methods 
of analysis. The survey material distributed for testing was examined to exclude 
commutability and stability as confounding factors in performance assessment. 
Changes to Hb A2 performance scoring have been suggested including the 
identification of one-off analytical EQA errors that could represent misdiagnosis of 
a beta thalassaemia carrier. In newborn screening, a difference was seen in the 
sensitivity of different analysers at the low levels of adult haemoglobin (Hb A) seen 
in a newborn infant with homozygous beta thalassaemia. A significant difference in 
performance in result interpretation was seen between English NHS laboratories 
and those outside the British Isles. The scheme should extend performance 
management in interpretation to all laboratories including the non-British Isles 
group, to ensure that the scheme remains credible to participants and fulfils its 
remit to improve performance wherever patients are tested. This will however 
require the scheme to develop the EQA data capture methods better to reflect 
current laboratory practice.  
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1.1 Introduction 
This project examines aspects of the performance assessment tools used by the 
UK National External Quality Assessment Scheme for Haematology for the 
external quality assessment (EQA) of the laboratory diagnosis of the 
haemoglobinopathies. The purpose is to improve the feedback given to 
participating laboratories and indirectly the quality of the service they provide. 
1.2 Haemoglobin structure and function 
Haemoglobin (Hb) is a complex, globular, protein tetramer (molecular weight 64-
64.5 kDa) comprising two pairs of unlike globin chains, each with a haem group 
attached. In post-natal life, all normal human haemoglobins contain two alpha and 
two non-alpha globin chains. Alpha globin chain synthesis is directed by two alpha 
globin genes (1 and 2) in the alpha globin gene cluster located on chromosome 
16. Synthesis of the non-alpha globin chains is directed by the beta globin gene 
cluster located on chromosome 11. The beta globin gene cluster contains one 
beta, one delta and two gamma globin genes (Gγ and Aγ) that code for alternative 
gamma globin chains with either glycine or alanine respectively at position 136. 
The arrangement of the globin gene clusters is shown in Figure 1.1. Both globin 
gene clusters contain pseudogenes (segments of DNA that resemble genes in 
structure but do not result in the production of a protein) and genes that are only 
expressed early in intrauterine life. 
Haemoglobin carries oxygen (O2) from the lungs to the tissues, binding one O2 
molecule reversibly to each of the four haem groups. It also transports 
approximately 10% of the carbon dioxide (CO2) produced in the body back to the 
lungs.   
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Chromosome 11: beta globin gene cluster 
 
Chromosome 16: alpha globin gene cluster 
 
Figure 1.1. Diagram of the alpha and beta globin gene clusters.  
The beta globin gene cluster (chromosome 11) shows the locus control region B 
(LCRB), the , G, A,  and  globin genes with the pseudogene . The globin 
gene is expressed early in intrauterine life. The alpha globin gene cluster 
(chromosome 16) shows the locus control region A (LCRA), the  and 
globin genes and the pseudogenes and. The globin gene is 
expressed in early intrauterine life and the function of the gene in the alpha 
globin gene cluster is unknown. 
 
Adapted from: Variant Haemoglobins: A Guide to Identification (Bain, 2010) 
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The quaternary structure of haemoglobin, shown in Figure 1.2 for Hb A, facilitates 
the rapid uptake of O2 (oxygenation) by Hb in the lungs and release 
(deoxygenation) in the tissues. The oxygen dissociation curve of Hb has a 
characteristic sigmoid shape, reflecting the alteration of the affinity of the molecule 
for O2 according to the partial pressure (p50) of O2 in the surrounding tissues.  
As soon as the first O2 molecule binds to deoxygenated Hb, the quaternary 
structure of the molecule undergoes a conformational change that facilitates the 
binding of the subsequent three O2 molecules more rapidly than the first (Baldwin, 
1980; Perutz, 1980). In the tissues, the reverse happens as the p50 in the 
surrounding tissues falls, allowing the rapid release of O2 where it is needed. The 
rapid deoxygenation of the molecule is supported by stabilisation of the 
deoxygenated form by the reversible binding of CO2 to the N-terminal of the alpha 
globin chains (Kilmartin, 1969). The affinity of Hb for O2 is also sensitive to 
changes in pH (Bohr, 1904), with the deoxygenated form of Hb stabilised by 
hydrogen ions (H+) in the tissues (Perutz, 1978).  
The ability of Hb to bind O2 reversibly depends upon the iron in the haem group 
remaining in the reduced or ferrous form, as the oxidised or ferric form combines 
irreversibly with O2 forming non-functional methaemoglobin (MetHb). The iron is 
protected against oxidation by the location of the haem group in a hydrophobic 
pocket formed by the tertiary folding of the globin chain, which excludes the water 
necessary for oxidation. The exterior of the Hb molecule is hydrophilic, however, 
making the molecule soluble. 
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Figure 1.2 Diagram of the quaternary structure of adult haemoglobin (Hb A)  
The Hb A molecule comprises two  and two  globin chains arranged in two  
dimers. The haem groups are shown in green in the hydrophobic interior of the 
molecule. 
 
Adapted from: Variant Haemoglobins: A Guide to Identification (Bain, 2010) 
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1.3 Haemoglobin patterns in infancy and adulthood 
Several Hb types are synthesised in the normal individual and the Hb pattern 
varies at different stages of development. In the first few weeks of gestation 
embryonic zeta (ζ) and epsilon (ε) globin chains, as well as alpha and gamma 
chains, are synthesised by primitive erythroblasts in the yolk sac, with the 
formation of the transient, early intrauterine Hbs Gower 1 (ζ2ε2), Gower 2 (α2ε2) 
(Huehns, 1961) and Portland 1 (ζ2γ2 ) (Hecht, 1968). The embryonic Hbs have a 
particularly high oxygen affinity (Fantoni, 1981). The liver and spleen become the 
most significant sites of haemopoiesis from six weeks until the sixth to seventh 
month of fetal life, when the bone marrow takes over, although haemopoiesis 
continues in the liver and spleen until about two weeks after birth (Kelemen, 1981) 
as shown in Figure 1.3. 
In the normal adult, the major Hb present is haemoglobin A (Hb A), with the 
remainder of the Hb made up of the minor adult Hb fraction, Hb A2 (Hb A2) and 
traces of fetal Hb (Hb F). First described by Linus Pauling (Pauling, 1949), Hb A 
comprises two alpha and two beta globin chains (α2β2), of 141 and 146 amino 
acids respectively. The synthesis of Hb A starts early in the second trimester of 
pregnancy and forms approximately 20% of the total Hb at birth; thereafter, the 
proportion of Hb A increases rapidly, reaching adult levels of more than 95% of 
total Hb within 1 to 2 years of birth, as shown in Figure 1.4. 
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Figure 1.3 Diagram of the changes in sites of erythropoiesis during embryonic life 
and infancy showing the changes in the proportions of different globin chain 
synthesised and the erythroid cell type  
 
Adapted from: The Thalassaemia Syndromes (Weatherall and Clegg, 2001) 
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Fetal Hb comprises two alpha and two gamma chains (α2γ2) and has a higher 
affinity for O2 than Hb A, facilitating the transfer of O2 across the placenta from the 
maternal to the fetal circulatory systems. At birth, Hb F concentration ranges from 
60 to 95% at full term gestation, falling to near adult levels by one year of age 
(Colombo, 1976). The change from Hb F to Hb A production occurs as a result of 
switching from the gamma to the beta globin genes during fetal life; in the adult, 
Hb F forms less than 1% of the total Hb present.  
Haemoglobin A2 (Hb A2) has two alpha and two delta globin chains (α2δ2) (Kunkel 
and Wallenius, 1955). The mean Hb A2 level at birth is between zero and 1% but 
increases during the first year of life to form approximately 2.0 to 3.5% of the total 
Hb (Steinberg and Adams, 1991; Bain, 2010; Weatherall and Clegg, 2001; Van 
Delft, 2009). Haemoglobin A2 is functionally similar to Hb A but its physiological 
significance, if any, is unclear. The low level of Hb A2 in the red blood cell is due to 
decreased transcription of the delta globin gene in comparison with the beta globin 
gene, as a result of differences in the promoter region (Steinberg and Adams, 
1991). The low transcription rate and the lack of apparent physiological 
significance of Hb A2 may indicate that the delta globin gene is destined to 
become another pseudogene. The delta globin chain differs from the beta chain by 
just ten residues between positions 22 and 115.  
Haemoglobin A2 is found in apes and New World monkeys, as well as Man; the 
delta globin gene is found in Old World monkeys, although not expressed. Other 
animals are known to have more than one normal Hb type in adulthood, e.g. 
horses have two, present in equal amounts, and salmon have two with different 
physiological attributes, which may reflect the salmon’s occupation of both fresh 
and saltwater environments (Lehmann and Huntsman, 1974).  
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Figure 1.4 Change in the proportions of different haemoglobin types in embryonic 
life and infancy 
 
Adapted from: Haemoglobinopathy Diagnosis (Bain, 2006) 
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1.4 The molecular basis of the haemoglobinopathies 
In 1910, J B Herrick observed the presence of 'peculiar elongated and sickle 
shaped' red cells in a medical student of Caribbean origin suffering from anaemia 
(Herrick, 1910). More cases of sickle cells were reported in African-Americans 
following Herrick's initial observations (Washburn, 1911; Cook, 1915; Mason, 
1922) and studies in subsequent decades showed that there were two types of 
sickle cells: those present in the untreated blood of individuals with severe 
anaemia and those that could only be induced by the in vitro treatment of blood 
from asymptomatic relatives of the patients with the anaemia. The asymptomatic 
condition was called sickle cell trait and it was suggested that the anaemia and the 
trait were the homozygous and heterozygous state of the same condition (Beet, 
1947; Neel 1947; Neel, 1949). Linus Pauling (Pauling, 1949) discovered that the 
blood of sickle cell carriers contained two Hbs of different electrophoretic mobility, 
Hb A and Hb S, whereas blood from individuals with sickle cell anaemia contained 
Hb S but no Hb A. 
Mutations in the globin genes may arise as point mutations of the genetic code or 
from the deletion of a part of the gene. The known Hb variants and thalassaemia 
mutations are listed on the HbVar database, on the Globin Gene server (Hardison, 
1998; Hardison, 2002; Patrinos, 2004; Giardine, 2007).  
Globin gene mutations can be grouped into the following main categories: 
1.4.1 Mutations in the coding part of the gene that result in 
structurally abnormal Hb variants. More than one thousand 
structural Hb variants have been described. The clinical significance 
of the mutation depends upon the nature of the amino-acid 
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substitution and its location. The majority have no impact; however, 
substitutions in the haem pocket, substitutions affecting the 
secondary or tertiary folding of the chain, substitutions affecting the 
quaternary interaction of the globin chains and substitutions affecting 
the molecule’s solubility may have serious consequences on the 
molecule’s physiological function. 
1.4.2 Mutations in the non-coding part of the globin gene causing 
defective gene expression and failure to synthesise the globin 
chain in normal quantities, resulting in a group of conditions known 
collectively as the thalassaemia disorders. More than four hundred 
mutations have been described, most affecting the beta globin and 
alpha globin genes. Mutations of the gamma or delta globin genes 
have also been described but are of less clinical significance. 
1.4.3 Mutations that result in the production of a hybrid globin gene, 
e.g. a hybrid delta- beta globin gene, as a result of crossing over of 
the genes. The resulting gene may be defective, with reduced 
expression and / or a structurally abnormal output. 
1.4.4 Mutations that cause a failure of the normal switch from Hb F to 
Hb A in the neonatal period, causing a diverse group of conditions 
characterised by an increased Hb F synthesis in the adult, known 
collectively as Hereditary Persistence of Fetal Haemoglobin (HPFH). 
Although a small number of dominant mutations exist, globin gene mutations are 
generally recessive and asymptomatic in the heterozygote. The disease state 
occurs in the homozygous or compound heterozygous condition and then only if 
the mutation is of clinical significance.  
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1.5. Clinically significant structural haemoglobin variants 
The majority of structural Hb variants have no impact on the molecule’s 
physicochemical characteristics, i.e. its solubility, stability or oxygen affinity (Wild 
and Bain, 2004). The most frequently encountered, clinically significant, structural 
Hb variants are Hb S, Hb C, Hb DPunjab, Hb E and Hb OArab, all of which affect the 
non-alpha globin chain, and Hb Lepore, which arises from a cross-over between 
the beta and delta globin genes. Haemoglobin S in the homozygous state or in 
combination with Hb C, Hb DPunjab or Hb OArab, and to a lesser extent Hb E or Hb 
Lepore, results in the sickling disorders, characterised by severe anaemia and 
varying pathophysiology depending on the exact genotype and other ameliorating 
factors. A severe sickling disorder (Hb S-beta thalassaemia) also occurs when Hb 
S is co-inherited with a beta thalassaemia mutation, which reduces or abrogates 
the production of any structurally normal beta globin.  
Some structural mutations reduce the output from the gene and are described as a 
‘thalassaemic haemoglobinopathy’. The most common example is Hb E, which 
results from the substitution of glutamic acid for lysine at position twenty-six of the 
beta globin chain. As well as being structurally abnormal, the mutation provides an 
alternative splicing site, resulting in reduced output from the mutated globin gene. 
Another is Hb Constant Spring, an alpha globin mutation of the termination codon 
of the alpha-2 globin genes, producing an elongated and unstable alpha globin 
chain (Clegg, 1971). 
1.6. The thalassaemia disorders 
The thalassaemias are a group of disorders characterised by a reduction in the 
output of the affected globin gene because of a deletional mutation or a mutation 
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affecting gene transcription or the stability of the messenger RNA (mRNA). The 
severity of the thalassaemia mutation depends on the globin gene affected, the 
extent to which the gene output is reduced and, in the case of the alpha 
thalassaemia mutations, the number of genes affected. 
Thalassaemia conditions may be described in terms of the clinical phenotype, a 
practice that arose initially because the molecular basis of the disease was 
unknown. The carrier or heterozygous state for thalassaemia may be described as 
thalassaemia minor, often qualified by which globin gene is affected, a largely 
asymptomatic condition only detectable by laboratory testing. The term 
thalassaemia minor is no longer widely used but would equate to a thalassemia 
carrier individual. Thalassaemia intermedia describes a condition associated with 
a range of genotypes that are symptomatic but not transfusion- dependent, except 
perhaps in conditions of physiological stress such as pregnancy. Thalassaemia 
major describes a severe, transfusion dependent condition, usually arising from 
homozygosity or compound heterozygosity for severe beta thalassaemia 
mutations. Each of these descriptions is broad and covers a spectrum of clinical 
conditions (Oliveri and Weatherall, 2001; Weatherall and Clegg, 2001). 
1.7. Globin gene mutations and the burden of disease 
The impact of a globin gene mutation on the burden of human disease depends on 
its clinical significance and the frequency of the mutation in a population. Clinically 
significant mutations that are restricted to members of the same family or an 
isolated geographical location may be diagnostically and therapeutically 
challenging but do not pose a significant public health risk. 
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Despite the severity of the disorders of Hb structure or synthesis in the 
homozygous or compound heterozygous disease states, they provide protection 
against Plasmodium falciparum malaria infection in carriers, hence the frequency 
of the most clinically significant mutations is highest in people of differing ethnic 
backgrounds originating from areas of the world where malaria either is or was 
endemic (Lehmann and Huntsman, 1974; Clegg and Weatherall, 1999; Williams, 
2002; Williams, 2005a; Williams, 2005b; Piel, 2010; Weatherall, 2018). 
Within Europe, the Hb disorders have an overall frequency of less than one per 
two thousand individuals, which classifies them as ‘rare’ diseases according to the 
European Union regulations (Regulation (EC) 141/2000); however, this 
classification reflects the low incidence of Hb disorders in the indigenous Northern 
European population. The distribution differs by region within Europe and is 
changing as a consequence of migration both within and from outside the 
continent (Modell 2008, Gulbis 2010; Piel, 2016). Rund (2005) estimated that 
1.67% of the world's population overall carries a gene for thalassaemia. The 
prevalence of thalassaemia is highly variable by region with the highest carrier 
frequency seen in Cyprus (fourteen to eighteen percent); in India the frequency 
overall is approximately three percent but may be up to forty percent in some 
locations (Bain, 2006). The Thalassaemia International Federation (TIF) estimates 
that there may be 200,000 transfusion dependent thalassaemia sufferers 
worldwide with up to 20,000 in Europe (Capellini, 2008; Galanello, 2003; 
Galanello, 2010). Twenty-three thousand new beta thalassaemia major infants are 
estimated to be born each year (Weatherall, 2010). 
Migration from ‘thalassaemic’ regions means that non-endemic countries, such as 
the UK, now recognise thalassaemia as a public health problem (Zeuner, 1999: 
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Davies, 2000; Weatherall, 2010; Piel, 2016). Henderson (Henderson 2009) noted 
that sixty-eight different thalassaemia mutations had been reported in the UK and 
that there are more beta and alpha thalassaemia mutations in the UK than in sixty 
other countries with published data in this area, reflecting the racially 
heterogeneous UK population. Some beta thalassaemia mutations are found in 
the native UK population but these are infrequent (Hall 1992).  
1.8. Population screening for the haemoglobin disorders 
Population screening and definitive diagnosis for the Hb disorders are different 
(Streetly and Holland, 2009). Screening requires high throughput, reliable and cost 
effective procedures to identify a defined range of disorders. Screening is not 
designed to detect every disorder and only provides a presumptive diagnosis to 
enable appropriate intervention.  
Population screening for the Hb disorders may be undertaken at several 
opportune stages in life (Giordano, 2009; Streetly and Holland, 2009): at birth, 
during mandatory schooling, pre-marriage (pre-conception) and in early 
pregnancy, as well as upon request. Screening may cause unnecessary anxiety 
and should only be implemented where there is an identified benefit to the health 
of the individual or the population as a whole through the implementation of an 
effective medical or social intervention (Wald and Leck, 2000).  
In the UK, the Standing Medical Advisory Committee advised in 1993 that 
universal newborn and antenatal screening was provided in those areas where 
more than 15% of the local population was of an ethnic background at risk of a 
severe haemoglobinopathy, with selective screening on the basis of ethnicity in 
other areas. It was recognised that the provision of screening was patchy and the 
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concept of a linked newborn and antenatal screening programme, offering 
universal screening for all newborn infants at birth and all pregnant women in early 
pregnancy, was proposed with the establishment of the National Health Service 
Sickle and Thalassaemia Screening Programme (NHS STP) (Streetly, 2000). 
Universal newborn screening for clinically significant haemoglobins using dried 
blood spots is undertaken at thirteen specialist laboratories in England (Streetly, 
2009), with similar services in the other UK home nations. Although the aim of 
newborn screening is the detection of infants with sickling disorders, the NHS STP 
has proposed that 1.5% or less of Hb A should be considered indicative of 
possible beta thalassaemia major and referred for follow up (NHS STP Newborn 
Laboratory Handbook, 2017). Antenatal screening is done at district general 
hospital level, differing in approach according to whether the area is classified as 
low or high prevalence for haemoglobin disorders. In low prevalence areas, 
screening is offered on the basis of the full blood count (FBC) and a family origin 
questionnaire and further testing is only undertaken if either of these indicates a 
risk. In high prevalence areas, all women are offered laboratory testing. The NHS 
STP aim is that all women receive effective, high quality, antenatal screening for 
the haemoglobinopathies, regardless of the expertise of their local hospital. The 
NHS STP publishes standards and protocols and offers advice and training for 
laboratory staff and other healthcare professionals. The NHS STP Antenatal 
Laboratory Handbook (2017) includes an algorithm for antenatal screening, with a 
Hb A2 concentration of 3.5% or above set as the action point for the diagnosis of a 
beta thalassaemia carrier individual. This cut-off was selected on the basis of 
advice of a panel of expert advisors to the NHS STP and conforms to the author’s 
personal laboratory experience that the majority of ‘normal’ individuals will have a 
17 
Hb A2 value less than 3.4% and the majority of beta thalassaemia carriers a value 
greater than 3.7% with very few results in the intermediate zone. This does not 
mean that a result in the borderline zone is of no significance (Old, 2012). 
The provision of screening programmes in other countries is variable. Some 
Southern European countries have offered antenatal screening for some time 
(Giordano, 2009) and pre-marital screening has been mandatory in Cyprus since 
1973 (Angastiniotis, 1981). Turkish Cyprus introduced pre-marital screening by 
law in 1980 (Bozkurt, 2007) and Iran in 1991 (Najmabadi, 2006). When first 
introduced in Iran, the purpose of screening was to avoid marriage between two 
affected individuals; this was amended to include the option of termination of 
pregnancy for beta thalassemia major in 1997. In non-endemic countries, a 
national antenatal screening programme is only offered in the UK, Greece and The 
Netherlands (Giordano, 2009, Martinez 2014) at the time of writing, although is 
available on request or as part of a local programme elsewhere (Cousens, 2010). 
Newborn screening is universal only in the UK, Greece, The Netherlands and the 
USA amongst non-endemic countries at the time of writing (Streetly 2009, 
Giordano 2009, Hoppe 2009, Martinez 2014). In France it is offered on a targeted 
basis (Bardakdjian-Michau, 2009; Thuret, 2010). 
The NHS STP requires laboratories to participate in an accredited EQA scheme 
and to demonstrate satisfactory performance against the criteria set by the EQA 
provider and the professions (NHS STP Antenatal Laboratory Handbook, 2017). 
The NHS STP has also established minimum standards for EQA schemes: these 
include a requirement for a transparent and robust scoring system for participant 
performance assessment (NHS STP Antenatal Laboratory Handbook, 2017).  
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1.9. Laboratory diagnosis of the haemoglobin disorders 
Carriers of Hb disorders are usually asymptomatic and can only be identified by 
laboratory testing. Although disease sufferers have clinical symptoms, laboratory 
testing is required to confirm the precise nature of the disease. The range of 
disorders seen in an ethnically diverse population requires expert screening and 
referral laboratory diagnostic services and is the subject of a number of published 
guidelines (Streetly and Holland, 2009; ICSH, 1978; Ryan, 2010; Traeger-
Synodios, 2015). 
The laboratory identification of carriers of inherited Hb disorders is presumptive 
and these are one of the few categories of genetic disorders that can be 
diagnosed largely on the basis of clinical background and protein chemistry, rather 
than molecular techniques. Depending on the condition and the reasons for 
diagnosis, the following information may be used to make a definitive diagnosis 
(Clarke and Higgins, 2000; Weatherall and Clegg, 2001; Old, 2003; Bain, 2006; 
Bain 2010; Old 2012; Traeger-Synodios 2015): 
 The patient's ethnic background and clinical presentation. 
 General laboratory tests, in particular the FBC (especially the Hb 
concentration, red blood count and mean cell haemoglobin), 
reticulocyte count, peripheral blood film morphology and iron status. 
 Haemoglobin pattern analysis, using tests based on the altered 
electrical charge of the Hb molecule. 
 Quantification of normal and abnormal Hb fractions, which may be 
undertaken by the same methods or as part of the Hb pattern 
analysis. 
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 Demonstration of red cell inclusion bodies. 
 Demonstration of the distribution of Hb F within the red cells. 
 Functional investigations of the Hb molecule, e.g. demonstration of 
altered solubility, stability or O2 affinity. 
 Relative rates of globin chain synthesis (mainly historical, rarely 
used at the time of writing). 
 Molecular techniques, including both mass spectrometry and 
mutational analysis of DNA. 
The range and complexity of the laboratory methods used require specialised 
equipment and a skilled workforce. It is not cost effective to offer the full range of 
investigations in all testing centres, requiring the establishment of laboratory 
networks to ensure the provision of high quality services. The establishment of 
expert networks for the diagnosis and treatment of the rare and congenital 
anaemias is strongly supported by the European Network for Rare and Congenital 
Anaemias (ENERCA) (Vives-Corrons, 2014). The referral of patients to expert 
secondary or tertiary testing centres, sometimes across national borders 
(European Directive 2011/24/EU on patients’ rights in cross border healthcare), 
requires harmonised laboratory procedures and a clear demonstration of 
competency by the service provider. 
1.10. Laboratory aspects of Haemoglobin A2 measurement 
Shortly after its discovery, Hb A2 was reported to be raised in the parents of 
children suffering from Cooley's anaemia, later known as beta thalassaemia major 
(Kunkel, 1957) and the demonstration of a raised Hb A2 is the cornerstone of the 
laboratory identification of the beta thalassaemia carrier (ICSH, 1978: Globin Gene 
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Disorder Working Party of the British Committee for Standardisation in 
Haematology General Haematology Task Force, 1994; Bain, 1988; Ryan, 2010). 
The increased Hb A2 level in beta thalassaemia carriers is due to an absolute 
increase in the synthesis of delta globin chains rather than a relative increase in 
Hb A2 due to the reduction in beta globin synthesis (Olivieri and Weatherall, 2001). 
The observed increase in Hb A2 in the beta thalassaemia carrier is variable, 
depending upon the severity of the beta thalassaemia mutation (Huisman, 1997) 
but is rarely outside the range of 3.5 to 7.0% with the pathological range for most 
common beta thalassaemia mutations between 4.0 to 6.0% (Stephens, 2012). The 
normal reference interval is rarely outside 2.0 to 3.5%. Mild (beta plus) mutations 
may have Hb A2 levels close to or overlapping the normal range but are clinically 
significant as they have been shown to result in severe, transfusion-dependent 
conditions in the homozygous or compound heterozygous state (Angastiniotis, 
2013; Old, 2012). The small difference in Hb A2 between the unaffected individual 
and the beta thalassaemia carrier demands that the method of measurement of 
Hb A2 is both accurate and precise. 
The methods currently available and recommended for Hb A2 quantification 
depend on the separation of Hb A2 from Hb A on the basis of charge (Ryan, 2010; 
Stephens, 2012). The most commonly available automated methods for Hb A2 
quantitation are high performance liquid chromatography (HPLC) (Wild and 
Stephens, 1997; Van Delft 2009) and automated capillary zone electrophoresis 
(CZE) (Cotton, 1999; Gulbis, 2003). Earlier manual methods (ICSH, 1978) using 
anion exchange microcolumns (Efremov 1977) and electrophoresis on cellulose 
acetate followed by elution (Marengo-Rowe, 1965) remain the recommended 
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reference methods but are not widely used in screening or diagnostic laboratories 
because they are labour intensive and require considerable technical expertise.  
Electrospray tandem mass spectrometry (TMS) is a method that has been 
demonstrated to be suitable for definitive identification of haemoglobin variants 
(Wild 2001; Wild, 2004) and, more recently, Hb A2 quantification (Daniel 2007). It 
has been shown to be effective for use in newborn screening (Moat 2014). 
An increased Hb A2 may also be associated with hyperthyroidism (Kendall, 1981), 
human immunodeficiency virus (HIV) infection treated with anti-retroviral therapy 
(Routy, 1993) and megaloblastic anaemia (Mehta, 1983). Haemoglobin A2 
measurement is misleading in the presence of Hb S when measured by some 
HPLC methods due to the co-elution of glycated Hb S fractions with Hb A2 (Suh, 
1996; Head, 2004). Haemoglobin A2 measurement is also unreliable in the 
presence of Hb variants that co-elute with Hb A2 on HPLC, such as Hb E, some 
Hb D variants and Hb Lepore. Haemoglobin A2 may be reduced in certain 
haemoglobinopathies, e.g. delta-beta thalassaemia, some HPFH conditions, alpha 
thalassaemia, Hb H disease and delta thalassaemia. Both structural and 
thalassaemic mutations of the delta globin gene have been identified (Bain, 2006); 
these are of no clinical significance but their coinheritance with a beta 
thalassaemia mutation may result in a ‘split’ Hb A2 peak and the apparent 
reduction of a pathological Hb A2 concentration to the normal reference range, 
possibly confounding diagnosis. Severe iron deficiency accompanied by severe 
anaemia is known to reduce the Hb A2 value (Galanello, 1981), although the 
significance of this has been debated (Passarello, 2012). Severe iron deficiency 
may depress the Hb A2 of an individual with a mild beta thalassaemia and a 
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borderline Hb A2 into the normal range, resulting in misdiagnosis (Stephens, 
2012). 
An early study in the UK examined the ability of laboratories to diagnose beta 
thalassaemia using Hb A2 quantitation and found that half of the laboratories 
incorrectly reported a specimen from a beta thalassaemia carrier as normal, 
reflecting the lack of expertise and a lack of awareness of factors affecting 
laboratory performance (White and Lewis, 1973).  
Evaluation of Hb A2 data from EQA surveys in the UK NEQAS Haematology 
scheme between 2006 and 2008 (Batterbee 2010) demonstrated a bias between 
the most popular HPLC systems in use, although the study was not peer-
reviewed. Paleari (2007) undertook a pilot EQA exercise for Hb A2 measurement 
using three fresh blood specimens, anti-coagulated with 
ethylenediaminetetraacetic acid (EDTA) and with normal, borderline and raised Hb 
A2 levels, sent to forty-eight Italian laboratories using HPLC machines from the 
same manufacturer (Bio-Rad Laboratories). This study reported an overall 
interlaboratory coefficient of variation (CV%) of between 6 to 8% for the three 
pools, with up to 32% of laboratories reporting results outside the allowable total 
error (TE) set by the authors. The study did not examine the bias between 
manufacturers but the authors noted that results varied according to which model 
of Bio-Rad instrument was used. The numbers in each individual model group 
were small and the results may not be statistically valid. All laboratories that took 
part in this exercise correctly differentiated the normal from the beta thalassaemia 
carrier.  
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In 2011, UK NEQAS Haematology data showed similar range of geometric CV% 
(GCV%) to that reported by Paleari in the results of ten EQA samples (all methods 
Hb A2 values between 1.9% and 3.6% and GCV values of 6.0 to 11.2%) 
distributed to more than 270 laboratories (UK NEQAS Haematology Annual 
Report, 2011). Note that the GCV% is used by UK NEQAS Haematology because 
the data are log transformed before analysis. 
Paleari also gathered information on reference intervals used by the laboratories in 
the study and reported that there was an overlap between the upper reference 
interval limit for normal patients (3.0 to 3.5%) and the lower reference interval for 
beta thalassaemia carrier patients (3.1 to 3.7%) (Paleari, 2007). A variation in 
normal reference intervals used, even by users of the same instrument type, was 
also reported in the evaluation of UK NEQAS Haematology data (Batterbee 2010). 
In a later study, Paleari evaluated five HPLC analysers (Bio-Rad Classic running 
the beta thalassaemia short programme, Bio-Rad Variant II using the dual kit 
programme, Menarini Diagnostics HA8160, Tosoh G7 and Tosoh G8) and three 
CZE systems (Sebia Capillarys 2, Beckman Coulter P/ACE MDQ with Analis 
CEofix™-Hb A2 kit and Proteome PA 800 with Analis CEofix™-Hb A2 kit) (Paleari 
2012). The instruments were based in two expert thalassaemia centres and a total 
of eighty EDTA samples were analysed, from healthy individuals (n=40), beta 
thalassaemia carriers (n=29) and individuals with low Hb A2 (n=11). There was 
good agreement between the HPLC and CZE methods, and good correlation 
between the different HPLC methods: however, a bias was observed between the 
HPLC methods. This study reported better reproducibility than seen previously 
with CV% values between 0.5% and 4.4% for the HPLC analysers; however, this 
is expected since a single analyser of each type was used. The CV% would be 
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expected to be better on a single instrument than on a number of instruments in 
different locations (De la Salle, 2012a). 
There are few published acceptable performance specifications (APS) for Hb A2. 
Mosca has published analytical goals for the measurement, giving different values 
for total error depending on whether it is derived from biological variation (TE = 
4.5%), expert opinion (TE >9.0%) or clinical need (TE = 7.0%) (Mosca, 2009; 
Mosca, 2013) and has suggested a limit of ±0.25% of total Hb A2 as an APS for a 
borderline Hb A2 value of 3.6%. The rationale stated for this was to avoid a Hb A2 
value of 3.6% being misclassified as normal, i.e. less than 3.35%, or a beta 
thalassaemia carrier, i.e. greater than 3.85%. Throughout this thesis, a single APS 
of ±0.25% of total Hb A2 is used as a guide to acceptable EQA performance; which 
conforms to the clinical need TE of 7.0% at the critical borderline Hb A2 value of 
3.6%. The clinical need TE was chosen to conform to the aspiration of determining 
APS according to clinical outcome (Sandberg, 2015). Where dealing with actual 
UK NEQAS data reported to one decimal place (as is the norm for Hb A2 
measurement), this limit was rounded up to 0.3%. This was a pragmatic decision 
based on the author’s experience of the state-of-the-art of performance in Hb A2 
EQA that predicted rounding down to 0.2%, would prove too strict a specification 
for inter-laboratory assessment. Stephens advised that in the critical borderline Hb 
A2 area of 3.0 and 4.0%, a standard deviation (SD) of 0.05 is achievable for Hb A2, 
with duplicate estimations within 0.2% of the numerical Hb A2 result (Stephens, 
2012); however, this specification related to within rather than between-analyser 
performance. 
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1.14.4 To examine the current 1.11. External quality assessment as 
part of total quality management 
The concept of using statistical analysis for quality control as part of the production 
process was developed in the decades between the first and second world wars 
(Shewhart, 1931; Pearson, 1935) with the introduction of mass production 
methods in industry. The objective was to interact with the production process to 
ensure a consistent, high quality output of mass-produced, manufactured goods 
from factory settings with a relatively unskilled workforce. Quality management 
became integral to the high throughput workplace, where the workload precludes 
individual attention for each production item. Similar requirements exist in the 
provision of diagnostic laboratory services, where quality is monitored and 
maintained through total quality management (TQM) of the testing process rather 
than the attention of a skilled analyst to each individual result. The importance of 
TQM in the laboratory is enshrined in the international standard ISO15189 (ISO 
15189:2012). The quality of the laboratory’s output is demonstrated by the use of 
internal quality control (IQC) to monitor batch-to-batch or day-to-day quality and 
EQA to monitor interlaboratory and intermethod quality, amongst other key 
performance indicators. 
EQA, also known as proficiency testing (PT), was introduced in the UK in the late 
1960s following studies on interlaboratory performance (Lewis and Burgess, 1969; 
Whitehead, 1973). EQA schemes vary in design but all entail the distribution of 
assay material of known but undisclosed content to the participating laboratories, 
who test the material as a standard test item and report their results back to the 
EQA provider. The EQA provider analyses the results against agreed performance 
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criteria, providing an assessment of the quality of the laboratory's output against 
that of its peers. 
EQA is available to some degree in all developed healthcare systems and the 
World Health Organisation (WHO) provides a manual to support the establishment 
of national EQA services (Urassa, 2016). ISO 15189:2012 requires the medical 
laboratory to undertake interlaboratory comparison for all diagnostic procedures in 
its repertoire and to take part in EQA where this is available. Selection of the EQA 
scheme is the responsibility of the participating laboratory (James, 2014) but the 
scheme should be accredited against the international standard ISO 17043 (ISO 
17043:2010) where possible. Depending on national and local regulations, EQA 
participation may be voluntary, a prerequisite for laboratory accreditation as in the 
UK, or mandatory for licensing, e.g. as in France and the USA. In the USA, the 
requirement for EQA (or PT) is stipulated in the Clinical Laboratory Improvement 
Amendments (CLIA) regulations of 1988. 
The international standard ISO 17043:2010 (ISO 17043, 2010) requires an 
element of performance evaluation in the EQA scheme design and EQA providers 
have devised a number of performance assessment systems (Sandberg, 2015; 
Jones, 2017b). For participants to derive the greatest benefit from participation 
and for the EQA provider to manage the data returned effectively, a statistically 
derived performance score against a target value or model answer is the most 
commonly used performance assessment mechanism. The ISO standard ISO 
13528:2015, provides guidance on the correct use of statistical methods in EQA 
as does the informative Annex B of ISO 17043 (ISO 13528:2015; ISO 
17043:2010)  
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The EQA target value for a quantitative test may be determined in a number of 
ways, including the use of known values (determined from manufacture or 
dilution), certified reference values (determined from a definitive measurement 
method), reference values (determined by analysis of the assay material against a 
reference material or standard), consensus values from expert participants (for 
example reference laboratories) and consensus values from all participants (ISO 
17043:2010, Thompson, 2006). The use of the consensus value from all 
participants is the method associated with the greatest degree of measurement 
uncertainty; however, in the absence of a certified reference material (CRM) or 
method, it may be the only option. Performance assessment in qualitative or 
interpretive schemes may be against an expected result or model answer, expert 
opinion or a reference method test result. For the scheme to be credible with 
participants, the EQA provider must demonstrate the quality of the survey material 
through the uncertainty of measurement of the target and the degree of consensus 
of the participants’ results with the target. 
External quality assessment is uniquely placed to gather data on the 'state of the 
art' in laboratory methodology and may be used to identify technical problems with 
in-vitro diagnostic devices, although the conditions for this are rigorous in terms of 
the commutability of survey material (BS EN 14136:2004). International standards 
applicable to EQA require assay material to be as close to patients’ samples as 
possible, traceable to a CRM, where available, and commutable in the event that 
the EQA scheme is to be used for inter-method comparison (ISO 17043:2010; BS 
EN 14136:2004). 
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1.12. The standardisation Haemoglobin A2 measurement 
Metrological traceability is the means by which laboratory results can be made 
comparable even where different calibration materials or methods of measurement 
are used, through the use of a CRM or measurement methods/procedures to 
which the values of other standards, calibrators or controls can be traced through 
an unbroken chain of calibrations. A CRM is a substance used for calibration, 
method development or traceability that is certified as meeting the requirements of 
the measure in terms of homogeneity, stability and characterisation as specified in 
the relevant ISO standards. CRMs are listed in the catalogues published by the 
Joint Research Centre of the European Union, the European Reference Material 
co-operation and the National Institute for Standards and Technology in the United 
States of America for materials they produce. The Joint Committee on Traceability 
in Laboratory Medicine provides a searchable database of higher order reference 
materials. 
The only Hb A2 reference material available at the time of writing is the first WHO 
Reference Material (89/666) developed in 1989, available from the National 
Institute for Biological Standards and Controls in the UK. This reference material 
has an assigned Hb A2 value of 5.3% and was validated for use with the manual 
Hb A2 methods in use at the time of its development. The International Federation 
of Clinical Chemistry (IFCC) established a working party to develop a commutable 
standard for Hb A2 in 2004. Initial work has been reported on a suitable candidate 
material (Paleari, 2010) but at the time of writing this requires further extensive 
validation before it is available for use. 
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1.13. UK NEQAS Haematology external quality assessment 
provision for the haemoglobinopathies 
UK NEQAS Haematology offers a comprehensive programme for the EQA of 
laboratory performance in the haemoglobinopathies. It is one of the major 
schemes available worldwide with numbers equivalent to those registered in the 
College of American Pathologists (CAP) PT programme and the Royal College of 
Pathologists in Australasia Quality Assessment Programme (RCPAQAP). It is the 
most comprehensive scheme available in Europe, in terms of the range of 
investigations covered and the number of specimens distributed annually (Vives-
Corrons, 2014). Three individual programmes are available: 
1.13.1 The Newborn Sickle Screening programme, which monitors the 
performance of laboratories screening for clinically significant 
haemoglobinopathies using dried blood spot (DBS) samples. At the time of 
writing, twelve distributions of three specimens each are made annually. 
The numbers registered are relatively small (approximately 30 at 
December 2015 with six outside the UK) (UK NEQAS Haematology Annual 
Report, 2015). 
1.13.2 The Abnormal Haemoglobins programme, which monitors the 
performance of laboratories undertaking the screening and diagnostic 
investigation of adult patients in the haemoglobinopathies using non-
molecular techniques. There are several registration options in the 
scheme: emergency sickle solubility testing (three whole blood specimens 
distributed six times per year), full participation for Hb fraction identification, 
quantitation and the interpretation of the results (six distributions of three 
30 
whole blood specimens annually) and specimens that simulate capillary 
blood samples from a newborn infant for laboratories (approximately thirty 
in the UK) that undertake clinician-directed newborn testing for 
haemoglobinopathies (six distributions of two specimens annually). At 
December 2015, there were 317 laboratories registered for full 
participation, 170 of which were outside the UK (UK NEQAS Haematology 
Annual Report, 2015).  
1.13.3 The DNA Diagnostics for Haemoglobinopathies programme, which 
monitors the performance of laboratories undertaking alpha and beta 
globin mutational analysis for the haemoglobinopathies. This is an 
internationally operated programme with the majority of participating 
laboratories outside the UK. At December 2015 there were forty-eight 
laboratories registered, thirty-eight outside the UK (UK NEQAS 
Haematology Annual Report 2015). 
An example report for the Abnormal Haemoglobins scheme is shown in Appendix 
1  
UK NEQAS Haematology uses a harmonised method for the calculation of 
performance scores across all its quantitative assay schemes. The system was 
developed in 1996 for the evaluation of performance in the automated counting 
schemes (FBC, Automated Differential Count and Reticulocyte Count) and, 
although ratified by the UK NEQAS Steering Committee and the oversight body, 
the National Quality Assurance Advisory Panel, in a discussion paper (England 
1995), it was not published in a peer-reviewed journal. The system is based on the 
principle of scoring long-term, retrospective performance (UK NEQAS 
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Haematology Participants’ Manual, 2017), taking between four to six months for 
persistent unsatisfactory performance in Hb A2 quantitation to become evident. 
The length of time taken to detect a laboratory with unsatisfactory performance 
has been noted as a source of concern by the NHS STP since the unsatisfactory 
laboratory could screen a large number of antenatal patients in the intervening 
period. One-off errors that could constitute misdiagnosis if they occurred with a 
patient's sample are not monitored by the current scoring system. 
The NHS STP does not have a formal screening programme for the detection of 
infants with beta thalassaemia major but has suggested a concentration of less 
than 1.5 % Hb A may be an indicator of the condition (NHS STP Newborn 
Laboratory Handbook, 2017). There is no EQA data on how sensitive the 
screening methods are at this Hb A concentration.  
The majority of errors in laboratory medicine occur outside the analytical phase 
(Plebani 2014) and the performance assessment of the interpretation of results is 
an increasingly important feature of EQA performance. The provision of an 
unambiguous interpretation of haemoglobinopathy results is essential to ensure 
the correct follow up actions are taken. Interpretation is not scored in the Abnormal 
Haemoglobins scheme and may be a challenge given the large international 
participant base. For any scoring method in EQA to be effective and credible with 
participants, the source of errors must be understood and steps taken to eliminate 
confounding factors that result from the scheme design. 
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1.14. Project aims 
1.14.1 To review the current state of the art Hb A2 measurement using 
historical UK NEQAS data, to assess the bias between instrument 
types and the impact that this might have on the laboratory diagnosis 
of beta thalassaemia carriers. 
1.14.2 To explore the suitability of the currently used EQA survey material 
for the assessment of laboratory performance in the quantitation of 
Hb A2 in comparison to fresh blood.  
1.14.3 To examine the sensitivity of current methods for newborn 
haemoglobinopathy testing for the quantitation of Hb A in dried blood 
spot specimens, as a means to detect infants with beta thalassaemia 
major.  
performance scoring methods for Hb A2 quantitation for their effectiveness 
in detecting laboratories with unsatisfactory performance and how 
these methods might be improved to allow the earlier identification of 
problems.  
1.14.5 To explore national and international barriers to the extension of 
performance assessment to Hb fraction identification and case 
interpretation in the Abnormal Haemoglobins scheme and how these 
may be overcome 
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1.15 Declaration 
Two sources of data have been used in this thesis: historical EQA data from UK 
NEQAS exercises, which has been mined and further analysed for performance 
trends and the modelling of amendments to performance assessment methods, 
and experimental data gathered as a result of practical exercises. 
Raw historical EQA data (participants’ results and target values) that had been 
gathered and calculated as part of routine UK NEQAS exercises were extracted 
from the UK NEQAS database; statistics calculated in this way are identified as 
those produced using the bespoke EQA software supplied by KPMD Ltd 
(Sheffield, UK). All further analysis and data modelling was undertaken by the 
author. None of the data analyses presented form part of the current data reported 
in UK NEQAS Haematology exercises.  
An initial analysis of performance trends for Hb A2 data gathered between 2006 
and 2008 was commissioned by the National Sickle and Thalassaemia Screening 
Programme and undertaken by Hannah Batterbee (Batterbee, 2010): this data is 
referred to for comparison purposes and some of the same raw data is included in 
the further analysis where it falls into the time periods described in this document. 
.
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Chapter 2: Review of Historical 
UK NEQAS Haematology Haemoglobin A2 Data for 
Trends in Performance 
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2.1. Aim 
To review the current state of the art in laboratory performance in the 
measurement of Hb A2 using historical UK NEQAS external quality assessment 
data. 
2.2. Introduction 
Haemoglobin A2 (Hb A2) was identified in 1955 as a minor, normal Hb fraction in 
adults, found at a concentration of approximately 3% (Kunkel and Wallenius, 
1955). The percentage of Hb A2 was later shown to be increased in carriers of 
beta thalassaemia (Kunkel, 1957) and the laboratory demonstration of an 
increased Hb A2, together with characteristic changes in red cell indices, is the 
standard biomarker used in population screening for adult beta thalassaemia 
carriers. 
Suitable protein chemistry methods for the quantitation of Hb A2 as a percentage 
of total Hb are based the charge difference between Hb A2, a tetramer of two 
alpha and two delta globin chains (22), and the other haemoglobin fractions 
found in the normal adult, i.e. Hb A (22) and Hb F (2). A number of manual 
methods have been used historically, based on the separation of Hb A2 from other 
Hb fractions by electrophoresis or chromatography. The modern medical 
laboratory requires population screening methods that are cost effective and high 
throughput, as well as of clinical utility, and the most widely used automated and 
semi-automated methods for Hb A2 measurement in use at the time of writing are 
analysers utilising high performance liquid chromatography (HPLC) or capillary 
zone electrophoresis (CZE). The use of DNA diagnostic methods is not a cost-
effective means of population screening for beta thalassaemia at the time of 
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writing, even in well-developed health economies, and is used only when a 
definitive diagnosis is required. 
The difference in Hb A2% between the normal and the beta thalassaemia 
heterozygote individual is small (less than 0.5% in some cases) and variable, 
dependent upon the nature of the beta globin gene mutation inherited (Weatherall 
and Clegg, 2001; Old, 2012). A wide range of beta thalassaemia mutations is seen 
in the UK, reflecting the diverse ethnic backgrounds of the population, and is 
greater than may be seen in the regions of the world from which people may have 
migrated (Henderson, 2009). The NHS Sickle and Thalassaemia Screening 
Programme's (NHS STP) laboratory screening algorithm includes a cut-off Hb A2 
value of 3.5% or above, in conjunction with a MCH of less than 27 pg, as indicative 
beta thalassaemia carrier status in an antenatal woman, recommending the 
screening of the fetus’ biological father to assess whether the fetus is at risk of a 
major haemoglobinopathy. The small difference between the normal and beta 
thalassaemia carrier state and the use of a fixed cut-off requires methods of 
measurement that are both accurate and precise. 
The UK NEQAS Haematology scheme for Abnormal Haemoglobins was 
established in 1975 (unpublished UK NEQAS Haematology Steering Committee 
papers and annual reports). At the time of writing, the scheme makes six 
distributions annually, each comprising three adult, whole blood specimens for the 
identification of variant haemoglobin fractions and the quantitation of Hb A2, Hb S 
and Hb F, as appropriate to the case. The general pattern of specimens distributed 
results in one to two specimens for Hb A2 quantitation per survey; on occasion 
none or all three may require Hb A2 measurement (UK NEQAS Haematology 
Annual Report, 2015). 
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The UK NEQAS Haematology Abnormal Haemoglobins scheme provides a unique 
resource of historical data that can be mined to understand better the differences 
between different methods and to monitor trends in performance over time. The 
strength of the historical data is that it has been gathered from numerous models 
of the most commonly used analysers, based in routine diagnostic laboratories 
and testing aliquots of the same, homogeneous pools of survey material. This 
gives a good representation of inter-laboratory and inter-method variability in 
performance over time, assuming that the survey material is commutable. The 
weakness of using historical data is that it is by its nature retrospective and will 
always be out-of-date; however, as long as this is borne in mind, historical data 
provides an important tool for understanding the principles of the potential sources 
of error in laboratory testing. The use of historical EQA data may be confounded 
by changes in the method of survey material preparation; however, this is not the 
case for the preparation of UK NEQAS Haematology Abnormal Haemoglobins 
material, the preparation of which is described below. 
2.3. Preparation of survey material 
UK NEQAS Haematology Abnormal Haemoglobins survey material is prepared 
from whole blood in citrate phosphate dextrose (CPD) anticoagulant, supplied by 
the National Health Service Blood and Transplant (NHSBT) service. The use of 
donor blood for quality assessment purposes is approved by NHSBT and donors 
agree to this use as part of their general consent to blood donation. Each pool of 
survey material is prepared from a minimum of one unit of whole blood 
(approximately 450 mL) or concentrated red cells made up to volume with ABO 
group compatible fresh frozen plasma. Blood is screened by NHSBT as negative 
for anti-HIV antibodies, anti-hepatitis C virus (anti-HCV) antibodies, HbsAg and 
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syphilis and is seventy-two hours old upon receipt by UK NEQAS. The blood is not 
stabilised for use as EQA material but broad spectrum antibiotics are added to 
maintain sterility (benzyl penicillin BP reconstituted with sterile 0.9% sodium 
chloride infusion BP, at a final concentration of 5 g penicillin per mL of blood; 
gentamicin sulphate injectable solution at a final concentration of 50g gentamicin 
per mL of blood). Specimens are dispensed into 2 mL, plain glass tubes using a 
bespoke mixing and dispensing system. On occasion, ABO-compatible units of 
blood may be pooled to increase the volume of the survey material available or to 
create a specimen with an ‘intermediate’ Hb A2 value at or around 3.5% by mixing 
blood from a beta thalassaemia carrier and a normal donor. The finished EQA 
specimens are seven to ten days old at distribution, which is by first-class post in 
the UK and door-to-door courier service to participating laboratories outside the 
UK. Participants are allowed ten days from the date of despatch to analyse the 
samples and return their results for analysis.  
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2.4 Manual methods of Haemoglobin A2 measurement 
2.4.1 Densitometry 
Haemoglobin A2 is separated from Hb A by electrophoresis at alkaline pH on 
paper, starch gel or cellulose acetate. It is possible to quantitate the resulting 
peaks by scanning the stained electrophoretic strip and integrating the peak area 
of the Hb fractions present; however, this has been shown to be inaccurate for the 
measurement of Hb A2 and the identification of beta thalassaemia carriers, the 
major technical challenge being the large difference between the density of the 
Hb A and Hb A2 bands and the consequent variance in the Hb A2 measurement 
(Schneider, 1974; Schmidt, 1975; Ueda, 1975; Sreedharanunni, 2015).  
2.4.2 Cellulose acetate electrophoresis followed by elution 
Haemoglobin A and Hb A2 in a haemolysate are separated on 25x120mm 
cellulose acetate electrophoresis strips in a Tris-EDTA-borate buffer system at pH 
8.9 (Marengo-Rowe, 1965; Old, 2012). The resulting Hb A and Hb A2 bands are 
cut out and the haemoglobins eluted in 20 mL and 4.0 mL respectively of the Tris-
EDTA-borate buffer (or similar volumes in the same proportion). The Hb A2 
concentration is calculated from the optical density of the eluates at 413 nm, using 
the formula shown in Equation 2.1. 
       
           
(               )             
       
Equation 2.1 Calculation of Hb A2 concentration 
This method is time-consuming and requires a high level of technical skill; 
however, it is reproducible and sufficiently accurate for the laboratory diagnosis of 
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beta thalassaemia carriers (ICSH 1978; Weatherall and Clegg, 2001; Stephens 
2012). 
2.4.3 Microcolumn chromatography 
Haemoglobin A and Hb A2 in a haemolysate are separated by microcolumn 
chromatography using a mobile buffer phase and a stationary diethylaminoethyl 
(DEAE) cellulose anion-exchange resin. In the original method of Efremov 
(Efremov 1974) haemolysate is applied to a DEAE cellulose column equilibrated 
with Tris buffer at pH 8.5, at which all the Hb fractions bind to the column; the Hb 
A2 fraction is eluted with a fixed volume of ‘developer’ buffer at pH 8.3 and the 
eluted Hb A2 fraction collected into a container of suitable, accurate and known 
volume (e.g. a 5 mL volumetric flask). The remaining Hb is eluted using a larger 
volume of Tris buffer at neutral pH and collected into a second container of 
suitable, known volume (e.g. a 25 mL volumetric flask). The eluates are made up 
to volume with deionised water, their absorbance read spectrophotometrically at 
413 nm and used to calculate the Hb A2 concentration as described for the 
electrophoresis and elution method. This method and variations thereof, including 
commercially-produced, single-use columns, have been shown to perform well for 
Hb A2 quantitation (Brosious 1978; Galanello 1977) but again the method 
demands a high level of technical skill and is labour intensive. 
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2.5 Automated and semi-automated methods of Haemoglobin 
A2 measurement 
2.5.1 High performance liquid chromatography 
High performance liquid chromatography has emerged as the predominant 
method for Hb A2 measurement in recent decades, as the method allows the 
simultaneous separation and quantitation of the normal Hb fractions and common, 
clinically significant abnormal Hb variants. The method separates Hb variants 
according to their different mobilities in a mobile, phosphate buffer phase and a 
stationary, cation exchange resin phase held in a temperature controlled cartridge. 
After initial binding of all Hb fractions to the column, the analyser delivers a pre-
programmed buffer gradient of increasing pH and ionic strength, eluting the Hb 
fractions on the basis of their charge. The separated fractions pass through a flow 
cell where they are putatively identified by their relative retention time on the 
column and quantitated on the basis of their absorbance. 
Automation of HPLC with sample loaders, computer-driven analysis and 
interfacing with the laboratory information system has made the method relatively 
high throughput and ‘walk-away', incorporated into commercially produced 
analysers. Although this method demands less technical skill than the earlier 
manual methods, the set-up, quality management and diagnostic interpretation of 
the chromatographic output requires expertise. Haemoglobin A2 quantitation by 
HPLC is sufficiently accurate to distinguish most beta thalassaemia carriers for the 
purposes of screening (Tan, 1993: Wild 1997; Van Delft 2009). 
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2.5.2 Capillary zone electrophoresis 
Capillary zone electrophoresis separates Hb fractions in narrow (25 to 100 mm 
diameter), buffer-filled capillary tubes on the basis of their charge. The capillary 
walls are coated with silanol molecules, which dissociate to give the surface a 
positive charge, binding negatively charged molecules present in the mobile 
phase. The application of a potential across the capillary causes the cations in the 
mobile phase to migrate towards the cathode, producing an electro-osmotic flow of 
the bulk solution through the capillary. Haemoglobin fractions are separated 
according to the degree of negative charge on the molecule and the strength of 
their interaction with the positively charged capillary wall. As with HPLC, the 
separated fractions are quantitated from their absorbance as they pass through a 
flow cell and putatively identified from their retention time in the capillary. 
Commercially produced CZE analysers have a number of capillaries operating in 
parallel and the method is a viable alternative to HPLC for Hb A2 quantitation 
(Mario, 1997; Cotton, 1999; van Delft, 2009; Sangkitporn, 2011). 
2.5.3 Electrospray tandem mass spectrometry 
Electrospray tandem mass spectrometry (TMS) is a method that has been 
demonstrated to be suitable for definitive identification of haemoglobin variants 
(Wild, 2001) and, more recently, Hb A2 quantification (Daniel, 2007), separating 
ionised globin peptides on the basis of their charge to weight ratio.  
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2.6. Materials and methods 
2.6.1 Statistical analysis 
Statistical analysis was undertaken using either STATA 14 (Stata Corp, Texas, 
USA) or Microsoft Excel 97 2003 (Microsoft Corp, WA, USA) with the downloaded 
analysis Toolpak, unless the UK NEQAS all laboratory trimmed mean (ALTM) or 
method trimmed mean (MTM) target value is quoted, which had been calculated 
as described in section 2.6.3. 
The Hb A2 data returned by UK NEQAS participants cannot be assumed to be 
normally distributed since the data sets may include spurious or outlier results 
(e.g. as a result of specimen transposition or data entry errors, as well as 
analytical problems) and these will skew the distribution. The outliers are removed 
by trimming in the calculation of the standard all lalaboratory trimmed mean 
(ALTM) and method trimmed mean (MTM) target values; however, for some 
instrument groups, the numbers of participants registered are too few (fewer than 
ten) for the use of standard trimming. For these reasons, robust, non-parametric 
statistical methods were used to calculate the non-ALTM and non-MTM 
descriptive statistics used in this study, i.e. the median, interquartile range (IQR), 
estimated standard deviation (est. SD) and estimated coefficient of variation (est. 
CV) (Tukey 1977). 
The est. SD was calculated using the interquartile range (IQR) as shown in 
Equation 2.2. 
              
   
     
 
Equation 2.2 Calculation of the estimated standard deviation 
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The est. CV% was calculated by dividing the est. SD by the median and 
expressing the result as a percentage.  
The pattern of bias can highlight performance problems in the results returned by 
individual participants in successive EQA distributions and performance trends in 
different methods. The percent bias (D%) of the EQA result from the target value 
was calculated as shown in Equation 2.3, where    is the test result and     is the 
target or assigned value. 
     (  )  
      
   
       
Equation 2.3 Calculation of percent bias 
The Kruskal-Wallis equality of rank test, a non-parametric analysis of variance 
(ANOVA) test was used to assess the statistical significance of differences 
between the data from different analyser groups. The Kruskal-Wallis test is a one-
way analysis of variance test suitable for use where the data is not normally 
distributed (Altman 1992, Bland 2015). 
2.6.2 Box and whisker plots 
Box and whisker plots illustrate the distribution of data and whether the data is 
skewed. Box and whisker plots show a rectangular ‘box’ equivalent to the IQR with 
the median marked. The ‘whiskers’ show the range of 1.5 times the upper or lower 
quartile rolled back to the closest data point, representing the distribution of the 
data excluding outliers, which are shown as individual data points beyond the 
whiskers as illustrated in Figure 2.1. 
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Figure 2.1. Diagram of the ‘box and whisker’ plot layout 
 
2.6.3 Calculation of the All Laboratory, Method and Sub-method Trimmed 
Mean values 
UK NEQAS target values are generated from a consensus of participants’ data 
using bespoke EQA software (KPMD Ltd, Sheffield, UK). Data is trimmed 
symmetrically to remove outliers that might otherwise affect the mean value: 10% 
of data points (5% from the top and 5% from the bottom of the distribution) are 
removed and data is log-transformed prior to the calculation of the consensus 
target mean. A robust estimate of the standard deviation (SD) is calculated (Healy 
1979). The All Laboratory Trimmed Mean (ALTM) includes data from all 
participants returning data for the distribution. The Method Laboratory Trimmed 
Mean (MTM) is calculated for each Hb A2 method principle, provided there are 
more than twenty participants registered for the method. At the time of writing, the 
MTM is calculated for HPLC and CZE method groups.  
The appropriate MTM is used in UK NEQAS Abnormal Haemoglobin surveys as 
the target value (    or mean for proficiency testing) for the performance 
Median Outlier Whisker = 1.5 x upper or 
lower quartile 
Interquartile Range 
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assessment of Hb A2 estimation for HPLC and CZE; other method principles with 
smaller numbers are assessed against the ALTM for statistical robustness. The 
use of the MTM where there are sufficient numbers registered is largely historical, 
from the period when manual methods were in use. The separation of HPLC and 
CZE methods for performance assessment is not evidence-based. The Sub-
Method Trimmed Mean (SMTM), e.g. for different HPLC methods, is calculated for 
information where there are sufficient instruments registered (usually more than 
twenty) as it provides state-of-the-art performance information by instrument 
model for manufacturers and participants. 
2.6.4 Analysis of changes in methodology (2001 to 2015) 
The number of methods used for for Hb A2 quantitation in December of each year 
was analysed by method principle from 2001 to 2015. Instruments or methods 
registered from which results were not returned were excluded since they may no 
longer have been in use, as were laboratories using methods that are not 
recommended for Hb A2 quantitation (Ryan, 2010; Stephens, 2012). 
2.6.5 Analysis of trends in Haemoglobin A2 performance (2001 to 2016) 
The est. CV% by HPLC was calculated for each survey material pool distributed 
between 2001 and 2016 and the change in est. CV% during the period examined, 
grouping the results according to the ALTM Hb A2 (2.0% or less, 2.1 to 2.5%, 2.6 
to 3.2% and 3.6% or greater; note that there were no specimens with ALTM values 
between 3.3% and 3.5%). 
2.6.6 Evaluation of Haemoglobin A2 performance data (2006 to 2008) 
UK NEQAS Haematology undertook a review of historical Hb A2 data from the UK 
NEQAS Abnormal Haemoglobins scheme between 2006 and 2008. This work was 
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commissioned by the NHS STP and undertaken in collaboration with the Sheffield 
Teaching Hospitals NHS Trust. This work was not published in a peer-reviewed 
journal but was made publicly available as a UK NEQAS Haematology report 
(Batterbee 2010). The 2006 to 2008 study examined the results of twenty-seven 
specimens issued for the assessment of Hb A2%, analysed by the most commonly 
used Hb A2 quantitation methods in use at the time. The conclusions were that 
there was an observed difference in the performance of different analysers, with a 
‘significant negative bias’ or a ‘significant positive bias’ noted with particular 
analyser models. However, the bias was only documented graphically and did not 
include statistical analysis. 
To evaluate the performance of the different analytical methods further, the bias of 
the SMTM against the ALTM was calculated in this study for the same twenty-
seven specimens distributed between 2006 and 2008 and compared to an 
‘acceptable EQA performance range’ of the ALTM ±0.25% of Hb A2 for each 
specimen, established using published performance limits (Mosca, 2013). 
2.6.7 Evaluation of Haemoglobin A2 performance data (2013 to 2016) 
UK NEQAS Hb A2 data for thirty-four survey material pools (distributions 1304AH 
to 1603AH) distributed between August 2013 and June 2016 was examined for 
inter-method variation, comparing the SMTM for each instrument method with the 
trimmed ALTM. For each specimen, only methods with more than ten results were 
included, resulting in the exclusion of all manual methods but the inclusion of 
newer HPLC and CZE analysers in comparison to the 2006 to 2008 study. The 
results from seven HPLC methods (Bio-Rad D10 using the dual kit programme, 
Bio-Rad Variant II using the beta thalassaemia short programme, Bio-Rad Variant 
II using the dual kit programme, Menarini HA8160, Primus Ultra, Tosoh G7 and 
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Tosoh G8) and three CZE methods (Sebia Capillarys, Sebia Capillarys 2 and 
Sebia Minicap) were included. For two methods (the Tosoh G7 and the Sebia 
Minicap), there were fewer than ten results returned for some specimens (one 
specimen for the Tosoh G7 and ten for the Sebia Minicap) and these specimens 
were excluded from the evaluation for these analysers where individual analyser 
groups were used. For some parts of the evaluation, all CZE instruments 
manufactured by Sebia were grouped together to give a more statistically robust 
data set, as the performance of the three analyser models was sufficiently similar 
(see later analysis). Miscellaneous HPLC or CZE instrument types or those where 
no analyser model was quoted were excluded from instrument group or sub-
method analysis but were included in the method principle (HPLC or CZE) and all 
methods analyses. 
The variance between the results returned for each of the thirty-four specimens 
distributed was examined to assess whether the observed differences in the 
means returned were significant statistically, using the non-parametric Kruskal-
Wallis test. The null hypothesis for the analysis was that there was no difference 
between the different analyser groups, i.e. that any differences observed were the 
result of sampling. 
2.6.8 ‘Borderline Hb A2 specimens (2006 to 2011) 
Three ‘borderline’ Hb A2 specimens with Hb A2 values of 3.6 to 3.7% (0604AH4, 
Hb A2 3.7%; 0902AH1, Hb A2 3.7% and 1105AH3, Hb A2 3.6%, distributed in the 
five years between 2006 to 2011) were examined to assess the possible impact of 
the use of different methods of Hb A2 measurement on the correct diagnosis of 
beta thalassaemia carrier status in patients with Hb A2 results at or around the 
3.5% cut-off value. 
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2.6.9 Reported Haemoglobin A2 reference intervals 
The reference intervals reported for the 1604AH distribution from June 2016 were 
collated and the most commonly reported minimum and maximum reference 
values identified for instrument groups with more than ten analysers.  
2.6.10  European Network for Congenital and Rare Anaemias exercise 
(2010) 
In a separate practical exercise in 2010, two specimens, from a beta thalassaemia 
carrier and a normal donor, were prepared according to standard UK NEQAS 
methods for Hb A2 survey material pools and distributed to 243 laboratories in the 
UK and Europe as part of an EQA study in collaboration with ENERCA. The 
results were returned within the standard ten days for usual UK NEQAS exercise.  
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2.7 Results 
2.7.1 Change in methodology (2001 to 2015) 
The number of laboratories returning Hb A2 results in December each year rose 
from 238 in 2001 to 324 in 2015, an increase of 36%. There was a significant 
change in the methodology used during the period, with a decline in the use of 
manual methods (microcolumn chromatography and electrophoresis and elution) 
from 60% of participants in 2001 (144/238) to just 3% in 2015 (10/324) and a 
corresponding increase in automated methods from 39% (94/238) of participants 
in 2001 to 97% (314/324) in 2015. The predominant automated method used 
during the period was HPLC, rising from 34% (94/238) in 2001 to a peak of 90% 
(253/280) in 2009. From 2009, the proportion of results returned from HPLC 
analysers declined to 79% (256/324) in 2015, although the absolute numbers of 
results returned from HPLC analysers increased. During the same period, the 
results returned from automated CZE instruments increased from nil to 18% 
(58/324) (see Figure 2.2). 
In December 2015 there were 328 HPLC and CZE methods registered for Hb A2 
quantitation, from 31 different countries. The largest numbers of instruments were 
in the UK (160), Belgium (36), Turkey (24), Portugal (18), Italy (18) and Israel (12) 
(see Table 2.1). Twenty-two countries had five or fewer instruments registered. 
Note that the number of instruments registered is greater than the number results 
returned. Since not all participants return results for all distributions, the exact 
numbers and range of analysers reporting data for any individual distribution 
described in this study may vary slightly from the numbers registered. 
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Figure 2.2. Change in method principles used for Haemoglobin A2 measurement in UK NEQAS Haematology from 2001 to 2015, 
data showing the methods stated for results returned in December of each year. 
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Country 
Bio-Rad Menarini HA Primus TOSOH HPLC 
Other 
Sebia Capillarys CZE 
Other 
TOTAL 
D10 CL V2 B V2 DK 8160 8180T  G7 G8 CE CE2 Mini 
UK 15 2 47 18 16 5 4 6 32 3 6 4 2 0 160 
Belgium 0 1 0 0 3 0 0 3 3 1 11 7 6 1 36 
Turkey 1 0 0 0 0 3 15 0 2 2 0 0 0 1 24 
Italy 2 0 2 6 1 0 0 0 4 0 1 2 0 0 18 
Portugal 3 2 3 0 6 0 0 1 1 0 1 1 0 0 18 
Israel 3 0 2 0 0 0 0 1 0 0 4 2 0 0 12 
RoI 1 0 2 0 0 0 1 1 1 0 1 1 0 0 8 
Kuwait 1 0 2 0 0 0 0 0 0 3 0 0 0 0 6 
Norway 0 0 3 0 0 0 0 0 1 0 1 1 0 0 6 
Switzerland 1 0 1 2 0 0 0 0 0 1 0 0 0 0 5 
France 1 0 0 0 0 0 0 1 0 0 0 1 1 0 4 
Austria 0 0 1 0 2 0 0 0 0 0 0 0 0 0 3 
Germany 0 0 0 0 0 0 0 0 0 1 0 2 0 0 3 
Table 2.1. Location of HPLC or CZE instruments registered in UK NEQAS Haematology for Haemoglobin A2 quantitation  
in December 2015 
Continued on next page 
 53 
 
 
Country 
Bio-Rad Menarini HA 
Primus 
TOSOH HPLC 
Other 
Sebia Capillarys 
CZE 
Other 
TOTAL 
D10 CL V2 B V2 DK 8160 8180T G7 G8 CE CE2 Mini 
Sweden 0 0 2 0 0 0 0 0 0 1 0 0 0 0 3 
UAE 0 0 1 0 0 0 1 0 0 1 0 0 0 0 3 
Greece 0 0 0 1 0 0 0 1 0 0 0 0 0 0 2 
Luxembourg 0 0 0 1 0 0 0 0 0 0 0 0 1 0 2 
Oman 0 0 2 0 0 0 0 0 0 0 0 0 0 0 2 
Australia 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 
Bulgaria 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
Cyprus 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
Czech 
Republic 0 0 0 0 0 0 0 0 0 0 0 0 1 0 
1 
Table 2.1. continued 
Continued on next page   
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Country 
Bio-Rad HA Primus TOSOH HPLC 
Other 
Sebia Capillarys CZE 
Other 
TOTAL 
D10 CL V2 B V2 DK 8160 8180T  G7 G8 CE CE2 Mini 
Denmark 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 
Finland 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 
India 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
Kenya 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 
Malta 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 
Netherlands 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
NL Antilles 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 
South Africa 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 
Spain 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 
TOTAL 28 7 70 28 28 8 21 15 45 15 26 22 13 2 328 
 
Table 2.1. continued 
Continued on next page 
  
 55 
Legend to Table 2.1: 
Bio-Rad D10: Bio-Rad D10 HPLC analyser 
Bio-Rad CL:  Bio-Rad Classic HPLC analyser 
Bio-Rad V2 B: Bio-Rad Variant II HPLC analyser with the beta thalassaemia short programme 
Bio-Rad V2 DK: Bio-Rad Variant II HPLC analyser with the Dual Kit programme 
HA8160/8180T: Menarini HA8160 and 8180T HPLC analysers 
Primus:  Primus Ultra 2 HPLC analyser 
Tosoh G7/G8: Tosoh G7 and G8 HPLC analysers 
HPLC Other:  Miscellaneous HPLC instruments or method not stated 
Sebia Capillarys: CE, CE 2 and Minicap CZE analysers 
CZE Other:  Miscellaneous CZE instruments or method not stated 
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2.7.2 Range of specimens distributed (2001 to 2016) 
Between 2001 and 2016 a total of 144 specimens were distributed with Hb A2 
values ranging from 1.5% to 5.0%. 14/144 (9.7%) were in the low/normal 
Hb A2 range of 1.5 to 2.0%, 114/144 (79.2%) in the mid-normal range of 2.1 
to 3.2%, 3/144 (2.1%) in the borderline range of 3.3 to 3.8% and 13/144 
(9.0%) in the beta thalassaemia range of greater than 3.9%. Figure 2.3 
shows the distribution of the Hb A2 values distributed by year. 
2.7.3 Analysis of estimated CV% trends in Haemoglobin A2 
performance (2001 to 2016) 
The coefficient of variation (CV%) is a measure of the variation in a data set 
relative to the mean and can be used to observe the trends in performance 
over time. The est. CV% values for Hb A2 by HPLC were analysed for trends 
in performance and are shown in Figure 2.4.  
For specimens of all values of Hb A2 there has been a downward trend in est. 
CV% in the time period reviewed from an average of 14.25% in 2001 to 
8.87% in 2016. A similar trend is seen at all Hb A2 levels, although there is an 
inverse relationship between the est. CV% and the measurand value.  
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Figure 2.3. The range of Haemoglobin A2 % values distributed by UK NEQAS Haematology between 2001 and 2016. The 
Haemoglobin A2 cut-off of 3.5% for the identification of beta thalassaemia carriers is shown by the solid line. 
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Figure 2.4. Trends in CV% values for HPLC Haemoglobin A2 method performance in UK NEQAS Haematology 
from 2001 to 2016, by Hb A2 value 
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2.7.4 Evaluation of Haemoglobin A2 performance data (2006 to 2008) 
The six most commonly used Hb A2 quantitation methods in use by the 
participants during the period 2006 to 2008 were manual ion exchange 
microcolumn chromatography, three HPLC systems from Bio-Rad 
Laboratories (the Variant Classic with the beta thalassaemia short 
programme, the Variant II with the beta thalassaemia short programme and 
the Variant II with the dual kit programme), the Menarini Diagnostics HA8160 
HPLC analyser and the Tosoh Biosciences G7 HPLC analyser. Figure 2.5 
shows a box and whisker plot for the biases observed for each of the six sub-
method (analyser) groups in the 2006 to 2008 study, in comparison to the 
‘acceptable EQA performance range’ of ± 0.25% of Hb A2.  
 
Figure 2.5. Distribution of the bias of sub-method trimmed mean values 
compared to the all method trimmed mean for Hb A2 in UK NEQAS surveys 
from 2006 to 2008. The solid lines show ±0.25% performance limits. 
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Legend to Figure 2.5: 
BRV2BT:  Bio-Rad Variant II HPLC analyser with the beta thalassaemia 
short programme 
BRV2DK:  Bio-Rad Variant II HPLC analyser with the dual kit programme 
BRVCL:  Bio-Rad Variant Classic HPLC analyser 
CC:   Microcolumn chromatography 
G7:   Tosoh G7 HPLC analyser 
HA8160:  Menarini HA8160 HPLC analyser 
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The box and whisker plot shows a variation in the results of the different 
methods, although the median of each sub-method group and the distribution 
of the data for five out of six of the sub-method groups, excluding outliers, 
were within the ±0.25% performance range. For Bio-Rad HPLC analysers, 
the Bio-Rad Variant II analyser running the dual kit programme gave lower 
Hb A2 SMTM values than the other two Bio-Rad methods. The Tosoh G7 
sub-method group returned four of the twenty-seven sub-method mean 
results as outliers, all with a positive bias. The distribution of the means for 
the HA8160 sub-method group was negatively skewed in comparison to the 
acceptable EQA performance range, with the bottom whisker and one outlier 
mean result extending beyond the lower limit of –0.25% of Hb A2. 
2.7.5 Evaluation of Haemoglobin A2 performance data (2013 to 2016) 
During the time period studied (August 2013 to June 2016), thirty-four 
specimen pools with ALTM Hb A2 values ranging from 1.47 to 5.02% were 
distributed. The data used for the study is shown in Table 2.2. 
In total, 329 SMTMs were evaluated from ten analyser groups. The SMTM 
was only calculated where there were more than ten results by analyser 
group. The bias of the SMTM values against the ALTM by method group is 
shown in the box and whisker plot in Figure 2.6, using an ‘acceptable EQA 
performance range’ of ALTM ± 0.25% of Hb A2.
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Distribution 1304 1305 1306 1401 1402 1403 1404 1405 1406 
Specimen AH1 AH2 AH3 AH1 AH2 AH1 AH3 AH1 AH3 AH1 AH2 AH2 AH3 AH1 AH2 AH1 AH2 AH3 
ALTM Hb A2 % 4.28 2.86 2.15 2.71 2.28 2.81 2.40 2.57 3.99 2.35 1.97 2.66 2.35 4.31 1.47 2.31 2.31 2.13 
HPLC MTM Hb A2 % 4.26 2.84 2.15 2.71 2.25 2.80 2.39 2.57 3.97 2.34 1.97 2.65 2.36 4.30 1.48 2.32 2.33 2.13 
CE MTM Hb A2 % 4.37 2.90 2.17 2.71 2.41 2.88 2.44 2.61 4.06 2.40 1.97 2.67 2.35 4.27 1.42 2.26 2.24 2.11 
Analysers Number of results returned by specimen pool 
BRD10 29 29 29 27 27 29 29 27 27 29 29 27 27 29 29 29 29 29 
BRV2 DK 20 20 19 20 20 19 19 20 20 21 20 22 21 24 24 24 24 24 
BRV2 BTHAL 58 58 58 62 62 63 63 68 68 67 66 66 65 64 64 65 65 65 
HA8160 41 41 42 42 42 40 40 43 43 41 42 39 39 37 36 34 34 34 
PRIMUS 11 11 13 12 13 13 13 14 14 17 17 18 18 21 21 22 22 22 
TOSOH G7 35 36 31 32 32 29 29 28 28 26 26 24 24 22 22 19 19 19 
TOSOH G8 23 23 25 25 25 26 26 30 30 31 31 36 36 38 38 39 39 39 
CE 22 22 24 23 23 24 24 24 24 24 24 23 23 25 25 24 24 24 
CE 2 10 10 12 12 12 14 14 15 15 13 13 15 16 16 16 16 16 16 
CE MINI ~ ~ ~ 10 10 11 11 12 12 12 12 11 11 ~ ~ ~ ~ ~ 
Total 249 250 253 265 266 268 268 281 281 281 280 281 280 276 275 272 272 272 
  Sub-method trimmed mean Hb A2 % (SMTM) by specimen pool 
BRD10 4.40 2.93 2.13 2.77 2.25 2.84 2.33 2.55 3.97 2.39 1.88 2.78 2.48 4.36 1.52 2.43 2.41 2.17 
BRV2 DK 4.25 2.76 1.97 2.63 2.14 2.73 2.24 2.47 3.97 2.30 1.84 2.60 2.31 4.37 1.39 2.30 2.28 2.05 
BRV2 BTHAL 4.10 2.84 2.25 2.68 2.29 2.81 2.51 2.59 3.86 2.37 2.13 2.65 2.39 4.16 1.68 2.38 2.40 2.28 
HA8160 4.03 2.82 2.09 2.71 2.24 2.68 2.22 2.53 3.77 2.38 1.79 2.66 2.38 4.08 1.44 2.34 2.30 2.06 
PRIMUS 4.09 2.71 2.07 2.56 2.16 2.70 2.34 2.44 3.90 2.22 1.90 2.45 2.15 4.20 1.39 2.10 2.16 2.02 
TOSOH G7 4.78 2.98 2.19 2.89 2.33 3.02 2.57 2.65 4.43 2.36 2.11 2.82 2.37 4.93 1.41 2.38 2.43 2.19 
TOSOH G8 4.67 2.90 2.09 2.79 2.19 2.82 2.36 2.59 4.33 2.24 1.85 2.59 2.25 4.63 1.25 2.22 2.25 1.98 
CE 4.33 2.88 2.16 2.70 2.41 2.87 2.44 2.59 4.05 2.42 1.96 2.68 2.35 4.26 1.41 2.25 2.23 2.11 
CE 2 4.39 2.92 2.17 2.67 2.39 2.87 2.45 2.57 3.98 2.35 1.94 2.65 2.34 4.26 1.41 2.23 2.21 2.05 
CE MINI ~ ~ ~ 2.75 2.40 2.89 2.47 2.69 4.15 2.41 2.01 2.70 2.38 ~ ~ ~ ~ ~ 
Table 2.2 Analysers and trimmed mean values for specimen pools 1304AH to 1603AH  
(continued on next page) 
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Distribution 1501 1502 1503 1504 1505 1506 1601 1602 1603 
Specimen AH1 AH1 AH2 AH3 AH1 AH1 AH2 AH2 AH3 AH2 AH3 AH1 AH2 AH1 AH3 AH2 
ALTM Hb A2 % 2.71 5.02 2.08 1.58 2.59 2.78 2.24 2.48 1.98 2.45 2.52 2.45 2.39 2.37 1.94 2.45 
HPLC MTM Hb A2 
% 
2.74 5.04 2.10 1.60 2.59 2.78 2.24 2.48 2.00 2.46 2.52 2.45 2.40 2.38 1.96 2.47 
CE MTM Hb A2 % 2.63 4.90 1.97 1.52 2.58 2.77 2.24 2.48 1.94 2.40 2.51 2.43 2.34 2.31 1.90 2.39 
Analysers Number in each distribution 
BRD10 28 28 28 28 27 26 26 27 27 27 27 26 26 27 26 28 
BRV2 DK 25 27 27 27 28 28 28 28 28 27 27 28 28 25 25 27 
BRV2 BTHAL 64 68 68 68 68 66 66 69 69 70 68 70 70 73 73 74 
HA8160 34 28 28 28 28 26 26 28 28 27 27 29 29 30 28 29 
PRIMUS 20 17 17 17 17 19 19 19 19 20 20 23 23 26 26 25 
TOSOH G7 22 18 18 18 16 14 14 15 14 15 15 12 12 10 10 ~ 
TOSOH G8 40 44 44 44 44 44 44 43 43 44 44 45 45 46 46 47 
CE 23 21 21 21 23 25 25 25 25 24 23 25 25 24 24 23 
CE 2 19 18 18 18 19 18 18 20 19 21 21 29 29 31 30 27 
CE MINI ~ 10 10 10 ~ 10 10 10 10 11 11 12 12 12 12 13 
Total 275 279 279 279 270 276 276 284 282 286 283 299 299 304 300 293 
 
Sub-method trimmed mean Hb A2 % (SMTM) 
BRD10 2.87 5.31 2.30 1.66 2.67 2.89 2.30 2.59 2.05 2.62 2.69 2.64 2.50 2.56 2.07 2.75 
BRV2 DK 2.73 5.03 1.99 1.37 2.56 2.75 2.12 2.44 1.85 2.38 2.46 2.40 2.30 2.31 1.78 2.75 
BRV2 BTHAL 2.73 4.84 2.22 1.80 2.63 2.81 2.30 2.59 2.05 2.62 2.69 2.64 2.50 2.56 2.07 2.75 
HA8160 2.73 4.67 2.14 1.46 2.58 2.70 2.11 2.49 1.91 2.44 2.54 2.43 2.33 2.35 1.79 2.51 
PRIMUS 2.55 4.80 1.77 1.48 2.43 2.64 2.18 2.42 1.91 2.34 2.35 2.29 2.30 2.18 1.92 2.26 
TOSOH G7 2.86 6.01 2.02 1.72 2.66 2.99 2.31 2.71 2.08 2.61 2.64 2.51 2.52 2.37 2.14 ~ 
TOSOH G8 2.69 5.53 1.95 1.39 2.51 2.74 2.08 2.42 1.81 2.30 2.36 2.31 2.26 2.19 1.77 2.29 
CE 2.62 4.88 1.97 1.52 2.58 2.77 2.23 2.47 1.92 2.41 2.51 2.42 2.34 2.30 1.89 2.40 
CE 2 2.62 4.91 1.95 1.51 2.56 2.78 2.24 2.48 1.94 2.38 2.49 2.41 2.33 2.31 1.90 2.38 
CE MINI ~ 4.94 1.99 1.56 ~ 2.74 2.26 2.52 1.96 2.41 2.53 2.49 2.34 2.33 1.95 2.42 
Table 2.2 Analysers and trimmed mean values for specimen pools 1304AH to 1603AH (continued from previous page)  
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Legend to Table 2.2  
BRD10:  Bio-Rad D10 HPLC analyser 
BRV2 DK:  Bio-Rad Variant II HPLC analyser running the Dual Kit programme 
BRV2 BTHAL: Bio-Rad Variant II HPLC analyser running the Beta Thalassaemia Short programme 
HA8160:  Menarini HA8160 HPLC analyser 
PRIMUS:  Primus Ultra 2 HPLC analyser 
TOSOH G7:  Tosoh G7 HPLC analyser 
TOSOH G8:  Tosoh G8 HPLC analyser 
CE:   Sebia Capillarys CZE analyser 
CE2:   Sebia Capillarys 2 CZE analyser 
CE MINI:  Sebia Minicap CZE analyser 
ALTM:  All laboratory trimmed mean 
MTM:  Method trimmed mean 
SMTM:  Sub-method trimmed mean 
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Figure 2.6. Distribution of the bias of sub-method trimmed mean values compared 
to the all method trimmed mean for Hb A2 in UK NEQAS surveys from 2013 to 
2016. The broken lines show the ±0.2% performance limits and the solid lines 
±0.25% performance limits. 
Legend to Figure 2.6: 
BRD10:  Bio-Rad D10 HPLC analyser 
BRV2 DK: Bio-Rad Variant II HPLC analyser running the dual kit 
programme 
BRV2 BTHAL: Bio-Rad Variant II HPLC analyser running the beta 
thalassaemia short programme 
HA8160: Menarini HA8160 HPLC analyser 
PRIMUS: Primus Ultra 2 HPLC analyser 
TOSOH G7: Tosoh G7 HPLC analyser 
TOSOH G8:  Tosoh G8 HPLC analyser 
CE: Sebia Capillarys CZE analyser 
CE2: Sebia Capillarys 2 CZE analyser 
CE MINI:  Sebia Minicap CZE analyser 
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For all ten sub-methods, the median and IQRs of the SMTMs were within the 
± 0.25% acceptable performance limits. There were a small number of outliers: 
most notably both the Tosoh G7 and G8 analysers produced four SMTMs that 
were high outliers. Further examination of the data showed that for both sub-
methods, the outliers were specimen pools with raised Hb A2 values (1304AH1, 
Hb A2 ALTM = 4.3%; 1402AH1, Hb A2 ALTM = 4.0%; 1405AH3, Hb A2 ALTM = 
4.3% and 1502AH1, ALTM Hb A2 = 5.0%), suggesting a lack of linearity with high 
Hb A2 values for the instruments. The HA8160 analysers had a single low outlier, 
with specimen pool 1502AH1. The Primus sub-method group had a single outlier 
SMTM (specimen pool 1502AH2, ALTM Hb A2 = 2.1%) as did the Bio-Rad 
analysers, all with specimen pool 1603AH2, ALTM Hb A2 = 2.5%.  
The evaluation of the bias of the median results returned by method group takes 
no account of the range of the results within each sub-method. The potential 
impact of the variation in the results from one instrument to another of the same 
model is illustrated in Figures 2.7 and 2.8, where the results for the same survey 
material pools tested on different analysers of the same type showed a range of 
up to 2.0% of Hb A2 for some instrument groups. This would be sufficient to alter 
the clinical outcome at or around the 3.0 to 4.0% Hb A2 range. Figures 2.7 and 
2.8, which were samples sent out in the same distribution suggest that for some 
instruments the bias against the ALTM may differ depending upon the Hb A2 %. 
For example, there was a far greater proportion of the results from the Tosoh G7 
and G8 groups outwith the acceptable performance limits for specimen 1502AH1 
(ALTM Hb A2 = 5.1%, Figure 2.7) than for specimen 1502AH2 (ALTM Hb A2 = 
2.1%, Figure 2.8). 
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Linear regression analysis of the SMTM (i.e. the analyser group values) against 
the MTM values (i.e. the ‘expected’ target results against which performance 
assessment is undertaken) was performed for the seven HPLC analyser groups 
and three Sebia CZE analysers (see Figures 2.9, 2.10 for HPLC methods and 2.11 
for CZE methods). The linear regression for the HPLC methods confirms that there 
is lack of alignment between particular instruments and that this varies according 
to measurand concentration in some cases, e.g. for the Bio-Rad Variant II with the 
beta thalassaemia short programme (linear regression y = 0.87x + 0.383), the 
slope is lower but the intercept higher than for the other Bio-Rad instruments 
predicting that the results for raised Hb A2 values will be lower and results at low 
Hb A2 values higher with that model (Figure 2.9). For the Tosoh HPLC analysers 
(Figure 2.10), the slope is higher but the intercept is lower than for other HPLC 
analysers, predicting that raised Hb A2 values will be higher and low Hb A2 values 
will be lower than for other HPLC analysers. The results for the three Sebia CZE 
analysers are very closely aligned (Figure 2.11). The CZE analysers all show 
linear regression equations with a slope close to 1.0 with a very small intercept, 
indicating a close relationship between the observed SMTM and the target MTM 
and very comparable results from the three instrument models. For this reason, 
the results from the three Sebia CZE analysers (the Capillarys, Capillarys 2 and 
the Mini cap) have been consolidated for many of the remaining analyses in this 
and later chapters. 
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Figure 2.7 Distribution of Haemoglobin A2 results by instrument group for UK 
NEQAS specimen 1502AH1 (All methods trimmed mean Hb A2 value = 5.1%). 
Legend to Figure 2.7: 
BRCL: Bio-Rad Classic HPLC analyser 
BRD10: Bio-Rad D10 HPLC analyser 
BRV2Bth: Bio-Rad Variant II HPLC analyser running the beta thalassaemia 
short programme 
BRV2DK: Bio-Rad Variant II HPLC analyser running the dual kit programme 
CE:  Sebia CZE analysers 
G7:  Tosoh G7 HPLC analyser 
G8:   Tosoh G8 HPLC analyser 
HA8160: Menarini HA8160 HPLC analyser 
HA8180T: Menarini HA8180T HPLC analyser 
PRIMUS: Primus Ultra 2 HPLC analyser 
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Figure 2.8 Distribution of Haemoglobin A2 results by instrument group for UK 
NEQAS specimen 1502AH2 (All methods trimmed mean Hb A2 value = 2.1%). 
Legend to Figure 2.8: 
BRCL: Bio-Rad Classic HPLC analyser 
BRD10: Bio-Rad D10 HPLC analyser 
BRV2BTh: Bio-Rad Variant II HPLC analyser running the beta thalassaemia 
short programme 
BRV2DK: Bio-Rad Variant II HPLC analyser running the dual kit programme 
CE:  Sebia CZE analysers 
G7:  Tosoh G7 HPLC analyser 
G8:   Tosoh G8 HPLC analyser 
HA8160: Menarini HA8160 HPLC analyser 
HA8180T: Menarini HA8180T HPLC analyser 
PRIMUS: Primus Ultra 2 HPLC analyser 
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Figure 2.9 Linear regression of the SMTM values for Bio-Rad HPLC analysers against  
the HPLC MTM Haemoglobin A2% target value for specimens 1304AH to 1603AH 
BRD10  y = 1.0273x + 0.0186
R² = 0.9895
BRV2BTH  y = 0.8729x + 0.383
R² = 0.997
BRV2DK y = 1.0504x - 0.205
R² = 0.997
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Figure 2.10 Linear regression of the SMTM values for non-Bio-Rad HPLC analysers against  
the HPLC MTM Haemoglobin A2% target value for specimens 1304AH to 1603AH 
HA8160 y = 0.9208x + 0.1363
R² = 0.9882
PRIMUS y = 0.9786x - 0.0812
R² = 0.9929
G7 y = 1.2432x - 0.4638
R² = 0.9917
G8  y = 1.2234x - 0.6203
R² = 0.9959
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Figure 2.11 Linear regression of the SMTM values for Sebia capillary electrophoresis analysers against  
the capillary electrophoresis MTM Haemoglobin A2% target value for specimens 1304AH to 1603AH 
CE y = 0.9947x + 0.0069
R² = 0.9999
CE2  y = 1.002x - 0.0207
R² = 0.9992
CE mini  y = 1.0023x + 0.0248
R² = 0.998
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The Kruskal-Wallis test was used to test whether the differences between analyser 
groups was due to sampling alone. Table 2.3 shows the results of the Kruskal-
Wallis (KW) test for all thirty-four specimen pools distributed between 2013 
(1304AH) to 2016 (1603AH). The table gives the number of analysers in each 
group, the non-parametric statistics (median and IQR), the Chi-squared (2) 
values, with the degrees of freedom. For every specimen pool, the KW test gave a 
probability (p value) of 0.0001 that the null hypothesis, i.e. that the differences 
observed were due to sampling only, would be true in 1/1000 instances. This 
indicates that the difference between the different analyser groups is statistically 
significant. The KW test does not specify which of the groups is/are different.
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Specimen 
Results by instrument group 
2
 with ties with 7 
degrees of freedom 
Probability 
(p)  BRD10 BRV2 Beta BRV2 DK CZE HA8160 Primus G7 G8 
1304AH1 
N 29 58 20 41 41 11 35 23 
133.81 0.0001 Median 4.4 4.1 4.2 4.4 4.1 4.1 4.8 4.8 
IQR 0.2 0.2 0.25 0.1 0.4 0.3 0.4 0.4 
1304AH2 
N 29 58 20 41 41 11 36 23 
38.19 0.0001 Median 3.0 2.85 2.8 2.9 2.8 2.7 3.0 2.9 
IQR 0.3 0.1 0.2 0.0 0.3 0.0 0.35 0.2 
1305AH3 
N 29 58 19 45 42 13 31 25 
38.51 0.0001 Median 2.2 2.25 2.0 2.2 2.1 2.1 2.3 2.1 
IQR 0.3 0.1 0.3 0.1 0.4 0.1 0.4 0.2 
1306AH1 
N 27 62 20 45 42 12 32 25 
45.88 0.0001 Median 2.8 2.7 2.6 2.7 2.7 2.55 2.9 2.8 
IQR 0.3 0.1 0.25 0.2 0.3 0.1 0.3 0.3 
1306AH2 
N 27 62 20 45 42 13 32 25 
51.45 0.0001 Median 2.3 2.3 2.1 2.4 2.3 2.2 2.4 2.2 
IQR 0.3 0.0 0.3 0.2 0.2 0.1 0.3 0.2 
1401AH1 
N 29 63 19 49 40 13 29 26 
56.42 0.0001 Median 2.8 2.8 2.7 2.9 2.7 2.7 3.1 2.8 
IQR 0.3 0.1 0.2 0.1 0.3 0.0 0.3 0.2 
1401AH3 
N 29 63 19 49 40 13 29 26 
86.13 0.0001 Median 2.3 2.5 2.2 2.5 2.3 2.4 2.5 2.35 
IQR 0.3 0.2 0.3 0.1 0.3 0.1 0.2 0.3 
Table 2.3 Kruskal-Wallis equality of rank test results for specimens 1304AH1 to 1603AH2 (continued on next page) 
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Specimen 
Results by instrument group 
2
 with ties with 7 
degrees of freedom 
Probability 
(p)  BRD10 BRV2 Beta BRV2 DK CZE HA8160 Primus G7 G8 
1402AH1 
N 27 68 20 51 43 14 28 30 
33.42 0.0001 Median 2.6 2.6 2.5 2.6 2.5 2.5 2.7 2.55 
IQR 0.1 0.15 0.2 0.2 0.3 0.1 0.3 0.2 
1402AH3 
N 27 68 20 51 43 14 28 30 
133.26 0.0001 Median 4.0 3.9 4.0 4.0 3.7 3.9 4.5 4.3 
IQR 0.4 0.1 0.25 0.2 0.3 0.2 0.4 0.3 
1403AH1 
N 29 67 21 49 41 17 26 31 
35.99 0.0001 Median 2.4 2.4 2.3 2.4 2.4 2.2 2.35 2.3 
IQR 0.2 0.1 0.2 0.1 0.3 0.1 0.3 0.2 
1403AH2 
N 29 66 20 49 42 17 26 31 
107.58 0.0001 Median 1.9 2.15 1.8 2.0 1.9 1.9 2.1 1.9 
IQR 0.2 0.1 0.3 0.1 0.3 0.1 0.3 0.1 
1404AH2 
N 27 66 22 49 39 18 24 36 
60.45 0.0001 Median 2.8 2.65 2.6 2.7 2.7 2.45 2.8 2.6 
IQR 0.2 0.1 0.2 0.1 0.4 0.1 0.25 0.2 
1404AH3 
N 27 65 21 50 39 18 24 36 
60.56 0.0001 Median 2.5 2.4 2.4 2.35 2.4 2.2 2.3 2.3 
IQR 0.1 0.1 0.2 0.1 0.4 0.1 0.4 0.3 
1405AH1 
N 29 64 24 49 37 21 22 38 
131.53 0.0001 Median 4.4 4.1 4.4 4.3 4.1 4.2 5.0 4.6 
IQR 0.3 0.1 0.3 0.1 0.4 0.2 0.5 0.3 
Table 2.3 (continued) 
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Specimen 
Results by instrument group 
2
 with ties with 7 
degrees of freedom 
Probability 
(p)  BRD10 BRV2 Beta BRV2 DK CZE HA8160 Primus G7 G8 
1405AH2 
N 29 64 24 49 36 21 22 38 
138.69 0.0001 Median 1.5 1.7 1.4 1.4 1.5 1.4 1.4 1.2 
IQR 0.1 0.1 0.15 0.1 0.3 0.0 0.1 0.1 
1406AH1 
N 29 65 24 49 34 22 19 39 
75.04 0.0001 Median 2.4 2.4 2.35 2.2 2.4 2.1 2.4 2.2 
IQR 0.2 0.1 0.2 0.1 0.3 0.2 0.3 0.3 
1406AH2 
N 29 65 24 49 34 22 19 39 
71.92 0.0001 Median 2.4 2.4 2.3 2.2 2.35 2.2 2.4 2.2 
IQR 0.2 0.2 0.2 0.1 0.3 0.1 0.3 0.3 
1406AH3 
N 29 65 24 49 34 22 19 39 
91.64 0.0001 Median 2.2 2.3 2.1 2.1 2.05 2.0 2.2 2.0 
IQR 0.1 0.1 0.3 0.0 0.3 0.1 0.2 0.2 
1501AH1 
N 28 64 25 49 34 20 22 40 
69.53 0.0001 Median 2.9 2.7 2.7 2.6 2.8 2.55 2.9 2.7 
IQR 0.15 0.1 0.2 0.1 0.4 0.1 0.3 0.26 
1502AH1 
N 28 68 27 49 28 17 18 44 
159.46 0.0001 Median 5.3 4.8 5.0 4.9 4.8 4.8 6.0 5.6 
IQR 0.4 0.25 0.3 0.2 0.5 0,.1 0.5 0.4 
1502AH2 
N 28 68 27 49 28 17 18 44 
127.29 0.0001 Median 2.3 2.2 2.0 2.0 2.2 1.8 2.0 2.0 
IQR 0.2 0.15 0.2 0.1 0.5 0.2 0.3 0.2 
Table 2.3 (continued) 
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Specimen 
Results by instrument group 
2
 with ties with 7 
degrees of freedom 
Probability 
(p)  BRD10 BRV2 Beta BRV2 DK CZE HA8160 Primus G7 G8 
1502AH3 
N 28 68 27 49 28 17 18 44 
136.02 0.0001 Median 1.65 2.2 1.4 1.5 1.55 1.5 1.8 1.4 
IQR 0.1 0.15 0.3 0.1 0.45 0.2 0.2 0.2 
1503AH1 
N 27 68 28 51 28 17 16 44 
55.31 0.0001 Median 2.7 2.6 2.6 2.6 2.6 2.4 2.65 2.55 
IQR 0.2 0.1 0.15 0.1 0.25 0.1 0.15 0.3 
1504AH1 
N 26 66 28 53 26 19 14 44 
50.51 0.0001 Median 2.9 2.8 2.8 2.8 2.8 2.6 2.95 2.7 
IQR 0.2 0.1 0.25 0.1 0.4 0.1 0.4 0.35 
1504AH2 
N 26 66 28 53 26 19 14 44 
95.40 0.0001 Median 2.3 2.4 2.1 2.2 2.2 2.2 2.3 2.1 
IQR 0.2 0.1 0.2 0.1 0.4 0.1 0.4 0.3 
1505AH2 
N 27 69 28 55 28 19 15 43 
69.90 0.0001 Median 2.6 2.6 2.4 2.5 2.5 2.4 2.7 2.5 
IQR 0.2 0.2 0.1 0.1 0.3 0.2 0.3 0.2 
1505AH3 
N 27 69 28 54 28 19 14 43 
117.03 0.0001 Median 2.1 2.2 1.85 1.9 1.9 1.9 2.1 1.9 
IQR 0.3 0.1 0.1 0.1 0.3 0.0 0.4 0.2 
1506AH2 
N 27 70 27 56 27 20 15 44 
69.19 0.0001 Median 2.6 2.5 2.4 2.4 2.5 2.4 2.6 2.3 
IQR 0.2 0.1 0.2 0.0 0.3 0.1 0.3 0.35 
Table 2.3 (continued) 
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Specimen 
Results by instrument group 
2
 with ties with 7 
degrees of freedom 
Probability 
(p)  BRD10 BRV2 Beta BRV2 DK CZE HA8160 Primus G7 G8 
1506AH3 
N 27 68 27 55 27 20 15 44 
84.99 0.0001 Median 2.7 2.6 2.5 2.5 2.6 2.35 2.6 2.4 
IQR 0.2 0.1 0.3 0.0 0.3 0.1 0.3 0.35 
1601AH1 
N 26 70 28 66 29 23 12 45 
95.36 0.0001 Median 2.7 2.5 2.45 2.4 2.4 2.3 2.5 2.3 
IQR 0.3 0.1 0.2 0.1 0.4 0.2 0.3 0.2 
1601AH2 
N 26 70 28 66 29 23 12 45 
108.20 0.0001 Median 2.5 2.5 2.3 2.3 2.4 2.3 2.5 2.3 
IQR 0.2 0.1 0.2 0.1 0.3 0.2 0.4 0.2 
1602AH1 
N 27 73 25 67 30 26 10 46 
145.97 0.0001 Median 2.6 2.5 2.3 2.3 2.35 2.1 2.3 2.2 
IQR 0.1 0.1 0.2 0.1 0.3 0.2 0.2 0.2 
1602AH3 
N 26 73 25 66 28 26 10 46 
144.34 0.0001 Median 2.1 2.1 1.8 1.9 1.8 1.9 2.2 1.8 
IQR 0.2 0.1 0.2 0.0 0.35 0.1 0.5 0.2 
1603AH2 
N 28 74 27 63 29 25 10 46 
143.59 0.0001 Median 2.8 2.6 2.4 2.4 2.5 2.3 2.6 2.3 
IQR 0.3 0.1 0.2 0.0 0.3 0.1 0.5 0.2 
Table 2.3 (continued) 
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Legend to Table 2.3 
BRD10: Bio-Rad D10 with the dual kit programme 
BRV2 Beta: Bio-Rad Variant 2 with the beta thalassaemia short programme 
BRV2 DK: Bio-Rad Variant 2 with the dual kit programme 
CZE:  Sebia CZE analysers 
HA8160: Menarini HA8160 
PRIMUS: Primus Ultra 2 
G7:  Tosoh G7 
G8:  Tosoh G8
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2.7.6 Borderline Haemoglobin A2 specimens 
The NHS STP’s laboratory screening algorithm sets a Hb A2 value of 3.5% or 
above with a MCH of less than 27 pg for the identification of beta thalassaemia 
carriers in antenatal screening. Although it is recognised that haemoglobinopathy 
screening will not detect 100% of cases, the misdiagnosis of an antenatal woman 
with a borderline Hb A2 result, e.g. as a result of her being a ‘silent’ beta 
thalassaemia carrier, will result in her partner not being invited for screening and 
may result in the unexpected birth of an infant with a severe haemoglobinopathy if 
co-inherited with another beta thalassaemia mutation or clinically significant Hb 
variant (Weatherall and Clegg, 2001). If there is overestimation, unnecessary 
additional investigation or partner testing may be undertaken, increasing anxiety in 
the patient and costs to the laboratory service. Even if the results of all screening 
methods were aligned, the normal dispersion of results around a statistical mean 
value of 3.5% will result in 50% of the results falling below the cut-off and 50% 
above; the concern is that the risk of misdiagnosis may be increased depending 
on the analysis method used.  
The distributions of the data returned for each of three specimens with an ALTM 
Hb A2 of 3.6 to 3.7% are shown in the box-and-whisker plots in Figures 2.12 
(0604AH4, Hb A2 3.7%), 2.13 (0902AH1, Hb A2 3.7%) and 2.14 (1105AH3, Hb A2 
3.6%) for the six main HPLC instrument groups, with twelve to fifty-two 
instruments in each group. Each plot shows the ‘acceptable performance limits' of 
the expected result ±0.25% of Hb A2. The distribution of results varies by 
instrument type in median result, IQR and bias against the MTM value for the 
specimen. Examination of the actual data returned demonstrated that the 
proportion of results that would have been identified as ‘normal’ varied by 
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instrument. Using a cut-off Hb A2 value of 3.5%, 16/28 (57%) participants using 
the Menarini HA8160 would have reported 0604AH4 as normal on the basis of the 
Hb A2 result alone, for the other specimens the proportion was 31/43 (72%) for 
0902AH1 and 36/52 (69%) for 1105AH3. By comparison, for users of the Bio-Rad 
Variant II analyser with the beta thalassaemia short programme, the proportions 
were 6/37 (16%) (0604AH4), 4/46 (9%) (0902AH1) and 28/51 (55%) (1105AH3) 
and the Tosoh G7 group 2/21 (10%) (0604AH4), 2/29 (7%) (0902AH1) and 2/32 
(6%) (1105AH3). The results for all the analyser groups are shown in Table 2.4. 
 
  
 82 
 
Figure 2.12 Distribution of Haemoglobin A2 results by analyser type for  
specimen 0604AH4, MTM Hb A2 3.7%.  
The broken lines show the ±0.25% performance limits. 
 
Legend to Figure 2.12 
BRD10: Bio-Rad D10 with the dual kit programme 
BRV2BTH: Bio-Rad Variant II with the beta thalassaemia short programme 
BRV2DK: Bio-Rad Variant II with the dual kit programme 
HA8160: Menarini HA8160 
PRIMUS: Primus 
TOSG7: Tosoh G7 
TOSG8: Tosoh G8 
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Figure2.13 Distribution of Haemoglobin A2 results by analyser type for  
specimen 0902AH1, MTM Hb A2 3.7%.  
The broken lines show the ±0.25% performance limits. 
Legend to Figure 2.13 
BRD10: Bio-Rad D10 with the dual kit programme 
BRV2BTH: Bio-Rad Variant II with the beta thalassaemia short programme 
BRV2DK: Bio-Rad Variant II with the dual kit programme 
HA8160: Menarini HA8160 
PRIMUS: Primus Utra 2 
TOSG7: Tosoh G7 
TOSG8: Tosoh G8 
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Figure 2.14 Distribution of Haemoglobin A2 results by analyser type for  
specimen 1105AH3, MTM Hb A2 3.6%.  
The broken lines show the ±0.25% performance limits. 
Legend to Figure 2.14 
BRD10: Bio-Rad D10 with the dual kit programme 
BRV2BTH: Bio-Rad Variant II with the beta thalassaemia short programme 
BRV2DK: Bio-Rad Variant II with the dual kit programme 
HA8160: Menarini HA8160 
PRIMUS: Primus 
TOSG7: Tosoh G7 
TOSG8: Tosoh G8 
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Specimen 
MTM Hb 
A2 % 
Method 
No. labs 
(total) 
"Normal" Hb A2 ≤3.5% 
N % 
0604AH4 3.7 BRD10 13 2 15% 
    BRV2BTH 37 6 16% 
    BRV2DK 12 1 8% 
    HA8160 28 16 57% 
    TOSG7 21 2 10% 
    TOSG8 12 3 25% 
          
 0902AH1 3.7 BRD10 19 4 21% 
    BRV2BTH 46 4 9% 
    BRV2DK 17 1 6% 
    HA8160 43 31 72% 
    TOSG7 29 2 7% 
    TOSG8 13 3 23% 
          
 1105AH3 3.6 BRD10 27 12 44% 
    BRV2BTH 51 28 55% 
    BRV2DK 19 6 32% 
    HA8160 52 36 69% 
    TOSG7 32 2 6% 
    TOSG8 17 2 12% 
 
Table 2.4. The numbers of results returned as normal by HPLC  
for three borderline Haemoglobin A2 specimens. 
Legend to Table 2.4 
BRD10: Bio-Rad D10 with the dual kit programme 
BRV2BT: Bio-Rad Variant II with the beta thalassaemia short programme 
BRV2DK: Bio-Rad Variant II with the dual kit programme 
HA8160: Menarini HA8160 
TOSG7: Tosoh G7 
TOSG8: Tosoh G8  
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2.7.7 Haemoglobin A2 reference intervals in use 
In the absence of a fixed action point or cut-off for a measurand, laboratories and 
manufacturers may set or recommend a reference interval peculiar to the 
instrument or method, acknowledging the difference between methodologies. This 
approach may cause confusion amongst service users, especially where patients 
are tested by different hospitals or diagnostic testing providers. The Pathology 
Harmony project attempted to standardise reference intervals for common 
measurands in clinical chemistry (Berg and Lane, 2011), although the 
Haematology Harmony Project only managed to agree nomenclature and units of 
measurement for the extended FBC (De la Salle, 2012b).  
UK NEQAS Haematology requests the reference interval for Hb A2 used by 
participants for a normal adult male at each distribution of the Abnormal 
Haemoglobins scheme as this can be of use when assessing the interpretation of 
results returned. 
Figure 2.15 shows the overall range of reference values reported as in use by 
participants at the 1603AH distribution in June 2016. The minimum reported 
reference value by any participant was zero per cent Hb A2 and the maximum was 
4.0%. The mode (most commonly occurring) values for the lower and upper limits 
of the reference intervals quoted are shown in Table 2.5, the range overall is from 
1.5% to 3.5% although there is some variation by instrument type, especially at the 
lower limit where the mode was 2.0% and 2.2% for some instruments. Only CZE 
instrument users did not have a mode value of 3.5% for the upper reference 
interval limit, with a value of 3.2%. 
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Figure 2.15. Haemoglobin A2 reference intervals for a normal adult male reported as in use by participants in June 2016 
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METHOD 
Hb A2% reference interval 
Min Max 
ALL 1.5 3.5 
BRD10 2.2 3.5 
BRV2 BTH 2.0 3.5 
BRV2 DK 1.7 3.5 
HA8160 1.5 3.5 
HA8180 1.5 3.5 
PRIMUS 1.5 3.5 
TOSG7 2.0 3.5 
TOSG8 2.0 3.5 
CE 1.5 3.5 
CE MINI 2.2 3.2 
CE2 2.2 3.2 
 
Table 2.5. The most commonly used minimum and maximum values of 
Haemoglobin A2 % reference intervals by instrument type,  
as reported to UK NEQAS Haematology in June 2016 
Legend to Table 2.5: 
BRD10: Bio-Rad D10 HPLC analyser 
BRV2 BTH: Bio-Rad Variant II HPLC analyser running the beta thalassaemia s 
BRV2 DK: Bio-Rad Variant II HPLC analyser running the dual kit programme 
HA8160: Menarini HA8160 HPLC analyser 
HA8180: Menarini HA8180T HPLC analyser 
PRIMUS: Primus Ultra 2 HPLC analyser 
TOSG7: Tosoh G7 HPLC analyser 
TOSG8:  Tosoh G8 HPLC analyser 
CE:  Sebia Capillarys CZE analyser 
CE2:  Sebia Capillarys 2 CZE analyser 
CE MINI: Sebia Minicap CZE analyser 
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2.7.8 European Network for Congenital and Rare Anaemias exercise (2010) 
The median Hb A2 results were 4.7% and 2.3% for the beta thalassaemia carrier 
and the normal donor specimen respectively. The results showed 95% confidence 
limits of 3.96 to 5.44% for the beta thalassaemia specimen and 2.00 to 2.60% for 
the normal specimen; two laboratories reported results below 3.5% for the beta 
thalassaemia specimen and no laboratory reported a raised Hb A2 result for the 
normal specimen. The observed bias compared to the median for the major 
instrument types ranged from –8.4% to +17.4% for the beta thalassaemia 
specimen with 4/7 instrument types showing a bias of more than 5%, with the 
same pattern of bias by instrument type as shown in the historical UK NEQAS 
data. The bias shown by individual laboratories was greater, ranging from –30% to 
+36% across both specimens, reinforcing the need for standardisation of Hb A2 
measurement. The study was part of a presentation at the Thalassaemia 
International Federation meeting in 2012, the proceedings of which were published 
(see Publications). 
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2.8 Discussion  
In the UK, population screening for beta thalassaemia carriers is offered in early 
pregnancy to allow couples an informed reproductive choice. A total of 14,0731 
antenatal women in England had a positive screening result for a significant 
haemoglobinopathy or thalassaemia in 2015/16, of which 3,755 were identified as 
beta thalassaemia carriers (NHS STP Data Report 2015/16). Although the 
newborn screening programme is not designed to detect babies with beta 
thalassaemia major, there were thirty infants detected with Hb F only at birth in the 
UK during 2015/16, which are likely to be cases of beta thalassaemia major or 
intermedia (NHS STP Data Report 2015/16). Although these numbers are 
relatively small, beta thalassaemia is a disease requiring lifelong transfusion 
support with life-changing and life-limiting complications (Galanello and Origa, 
2010). Beta thalassemia mutations are also significant in the compound 
heterozygous state with other structural haemoglobin variants, e.g. Hb S and 
Hb E.  
Molecular techniques are recommended for the definitive diagnosis of beta 
thalassaemia and to confirm an at-risk pregnancy: however, the large number of 
patients screened initially requires a continued reliance on protein chemistry 
methods. On a global perspective, the majority of births affected by thalassaemia 
disorders occur in low-income countries where diagnosis depends upon non-
molecular techniques (Piel, 2016). The necessity for simple screening techniques 
is illustrated by the development of a non-quantitative, one tube osmotic fragility 
test for thalassaemia screening, utilising the increased resistance to lysis of 
                                                          
1
 These figures are likely to be a slight underestimate because of gaps in data reporting by some 
laboratories (NHS Sickle and Thalassaemia Programme Data Report 2015/16) 
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thalassaemic red cells in a buffered 0.36% salt solution, as a cost effective method 
for population screening in resource limited countries (Chow, 2005; Fucharoen 
and Winichagoon, 2012). 
UK NEQAS historical Hb A2 data has shown a near total adoption of automated 
Hb A2 analysis methods since 2001. Improvement was seen in the performance of 
Hb A2 measurement as measured by a reduction in est. CV% in UK NEQAS 
results in the predominant automated method (HPLC) in the period. The average 
HPLC method group est. CV% fell from 14.25% in 2001 to 8.87% in 2016, a value 
comparable to the CV% of between 6.0 to 9.6% reported in a comparison of three 
HPLC models from the same manufacturer (Paleari 2007). Since only HPLC 
methods were included in the analysis, the improvement is not the result of a 
transfer from manual to automated techniques, although the removal of older, less 
reliable HPLC systems may have had an influence. Other reasons for the 
improvement in overall performance may include a greater awareness of quality 
management and sources of error amongst both participants and instrument 
manufacturers as a result of the educational and oversight role of organisations 
such as the NHS STP and the European Network for Rare and Congenital 
Anaemias (ENERCA) project. These initiatives have set standards for screening 
services, published educational information (the NHS STP Antenatal Laboratory 
Handbook, 2017; Vives-Corrons, 2014) and offered training. The importance of 
quality management and accreditation has been promoted by the introduction of 
the international accreditation standard ISO 15189 for medical laboratories (ISO 
15189:2012). 
Healthcare science professionals must understand inter-method variation to 
ensure equity of diagnostic outcome for patients. The study has shown significant 
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differences when the same specimen is analysed by different Hb A2 measurement 
methods, sufficient to produce a different clinical outcome in the borderline Hb A2 
region. The lack of an international standard to which Hb A2 results are traceable 
has been recognised as a barrier to quality improvement since it is not possible to 
say which method gives the ‘correct’ result. At the time of writing, the only 
reference material available is the WHO International Reference Reagent for 
Hb A2 (WHO 89/666), which was issued in 1989 prior to the widespread 
introduction of automated methods of Hb A2 measurement. The IFCC has 
undertaken preliminary work on the development of a new standard (Paleari, 
2010). 
Despite the recommendation of a cut-off value for Hb A2 of 3.5% for the 
identification of adult beta thalassaemia carriers, a number of laboratories still 
quote reference intervals with differing upper limits. This may reflect a varied 
approach to establishment of reference intervals (Barth, 2009; Sinclair, 2014), 
including a failure to update reference intervals as methods change. Of the twenty 
laboratories in the study who quoted an upper Hb A2 reference interval limit of 
greater than 3.5%, ten were located in the UK or Republic of Ireland. Just three 
were within the oversight of the NHS STP in England, suggesting that most 
laboratories within the NHS STP’s remit were using an upper reference interval 
that conformed to (or was less than) the 3.5% cut-off Hb A2 value for screening for 
beta thalassaemia carriers. 
Historical EQA data is a substantial resource that can be mined for trends in 
performance and variability between methods.  
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Interlaboratory comparison of performance through EQA can offer support to 
oversight bodies and national screening programme initiatives, monitoring trends 
in performance of both methods and individual laboratories. However, variability in 
the EQA scheme design may confound the interpretation of trends in performance 
(Miller 2011). 
The first challenge in EQA is the nature and quality of the survey material 
distributed. The ideal is a material that is commutable across all instruments, 
stable in transit and for the period of the EQA distribution, homogeneous, 
traceable to an international standard and in a format that is comparable to 
patients’ material (Miller, 2006; De la Salle, 2017). The EQA provider should also 
provide cases that test the participating laboratories at the limits of clinical decision 
making, reporting the results with background educational content where needed 
to enhance the educational aspects of the scheme. To provide a long-term, 
retrospective assessment of performance, the scheme must adopt a sensitive, fair 
and statistically robust performance scoring method that supports the needs of 
participating laboratories and other stakeholders (Coucke, 2017). Subsequent 
chapters will examine how well aspects of the services provided by UK NEQAS 
Haematology for the performance assessment of Hb A2 measurement meet these 
ideals in terms of the nature of the survey material provided and the Hb A2 scoring 
methods.
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Chapter 3: Survey material for the performance 
assessment of Haemoglobin A2 measurement
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3.1 Aim 
To assess the impact of the anticoagulant used and the age of survey material on 
the performance assessment of Hb A2 measurement. 
3.2 Introduction 
The specimen of choice for Hb A2 measurement is whole blood anti-coagulated 
with the potassium or sodium salts of ethylenediaminetetraacetic acid (EDTA), 
although any anticoagulant can be used (Bain 2006, Stephens 2012, Mosca 
2009). Shokrani (Shokrani 2000) used heparin or EDTA-anticoagulated samples in 
a study of Hb A2 measurement by HPLC and Maharini (Maharini 2014) used 
citrate phosphate dextrose (CPD) anticoagulated donor blood to assess frequency 
of Hb variant and thalassaemia carriers amongst blood donors. The use of EDTA 
for Hb A2 measurement is largely one of convenience since it is the anticoagulant 
used for FBC samples in the haematology laboratory (Banfi 2007) and its use for 
Hb A2 measurement allows utilisation of the same specimen, reducing the number 
of samples taken and facilitating reflex testing when a beta thalassaemia carrier is 
suspected from the FBC results. EDTA is also the anticoagulant recommended for 
Hb A1c measurement by HPLC by the IFCC (Jeppsson 2002); therefore, the use of 
the same specimen type for Hb A2 quantitation simplifies the use of analysers with 
dual Hb A1c and haemoglobinopathy functionality. 
EDTA anticoagulated blood is not a practical solution for haematology EQA in 
general (Urassa 2016, De la Salle 2017). Patients' samples in EDTA are available 
in relatively small specimen volumes and pooling of specimens to provide 
sufficient blood for an EQA exercise would require a large number of specimens 
from patients with the same clinical condition and compatible ABO blood groups. 
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Although EDTA blood is the best anticoagulant for the preservation of blood cell 
parameters and morphology for diagnostic purposes, CPD (as used for donor 
blood for transfusion) is a better option for stabilisation of red cells for periods of 
several weeks (Beutler 1983). For an EQA scheme with a substantial number of 
participants in a range of geographical locations, the practical option for the 
preparation of whole blood survey material is CPD blood from volunteer donors 
(De la Salle 2017, Lewis 1995). With more than three hundred participants 
registered for Hb A2 measurement, UK NEQAS Haematology requires up to 500 
mL of blood per survey material pool in order to provide each laboratory with 1.0 to 
1.5 mL of blood for testing with sufficient additional specimens for in-house 
homogeneity and stability testing and repeat samples. Non-clinical issue blood is 
collected through NHSBT from anonymised, consented donors and screened for 
known blood-borne infectious agents prior to issue. A single donor unit is of 
sufficient volume for one survey material pool. UK NEQAS Haematology uses 
donations either from donors with no known haemoglobin variant or thalassaemia 
or from a selected panel of donors known to be beta thalassaemia or Hb variant 
carriers. 
The NHS STP advises that the results of antenatal haemoglobinopathy screening 
should be available at least as an interim report within three days of receipt of the 
sample by the laboratory (NHS STP Antenatal Laboratory Handbook, 2017). This 
turnaround is dictated by the clinical need for the timely review of results and 
arrangement of testing of the baby's father, if indicated. Although analysis should 
be undertaken as soon as possible after collection, EDTA-anticoagulated blood 
specimens for Hb A2 measurement have been reported to be stable for up to 21 
days post venesection if stored at 2 to 8 °C (Tietz 1990). The blood used for the 
  
97 
preparation of UK NEQAS Hb A2 survey material is seventy-two hours old when 
issued by NHSBT. The procedure for bottling, packing and shipping of the EQA 
survey material means that specimens are fourteen days post venesection when 
distributed as EQA material and twenty-four days old on survey closing day. 
A major challenge in EQA is to provide survey specimens that behave in a similar 
fashion to patients’ clinical material and are commutable across all testing 
platforms and methods (Miller, 2003; Ceriotti, 2014). The purpose of the study 
described in this chapter was to investigate whether the anticoagulant used and 
the age of the sample when analysed have an impact on the Hb A2 results 
obtained, which might affect the performance of participants in the EQA surveys 
compared to their testing of clinical material. 
The study described in this chapter was undertaken by the author at the 
commencement of the evaluation of Hb A2 performance and was approximately 
ten years old at the time of writing. It was derived only from manual and HPLC 
methods in use by participating laboratories at the time. This neither compromises 
the comparison of the UK NEQAS survey material with fresh EDTA blood nor the 
demonstration of the stability of survey material over time, since it would be a 
reasonable experimental design to undertake the work with a single testing 
method. The only question that might arise is the commutability of the survey 
material with new methods as they come to market, which is a constant challenge 
in any EQA programme and is discussed later in the chapter. 
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3.3 Materials and methods 
3.3.1 Survey material 
A consented, volunteer male donor was venesected under medical supervision in 
a Haematology clinic for a total of 400 mL of blood: the first 200 mL of the donation 
was taken into sterile di-potassium ethylenediaminetetraacetic acid (K2EDTA) 
solution in 0.9% w/v sodium chloride intravenous infusion BP solution at a final 
concentration of 1.5 to 2.0 mg EDTA per mL of blood; the second 200 mL of the 
donation was taken into CPD in a standard blood donor pack with 50% of the CPD 
anticoagulant removed. The blood was not tested for blood-borne infectious 
agents as the donor had been tested prior to venesection for HIV and hepatitis B, 
thus removing any delay to the distribution of the exercise. 
3.3.2. Phase One: EDTA specimen preparation and distribution 
This phase of the exercise was designed to assess performance of Hb A2 
measurement with a survey material as similar to a patient's EDTA sample as 
possible. The EDTA-anticoagulated blood was dispensed without further treatment 
in 1 mL aliquots into 2 mL volume, plain glass specimen vials (no anticoagulant), 
labelled with a unique survey identifier and despatched by first class post within 
twenty-four hours of venesection to 160 UK laboratories registered for Hb A2 
quantitation. 
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3.3.3 Phase Two: CPD specimen preparation and distribution 
This phase of the exercise was designed to replicate the usual survey material for 
Hb A2 measurement with blood taken from the same donor and at the same time 
as in phase one but prepared by the same procedures and in the same timeframe 
as a standard UK NEQAS Abnormal Haemoglobins sample. The CPD 
anticoagulated blood was stored for seventy-two hours at 2 to 8 °C immediately 
post-venesection, so that it was the same age when preparation started as the 
whole blood received from NHSBT for routine survey material pools. At seventy-
two hours, the blood was thoroughly mixed by inversion and transferred to a 
sterile, 500 mL Duran® bottle. Antibiotics were added (0.1 mL per 500 mL of 
whole blood of 200 mg/mL benzyl penicillin sodium BP reconstituted in 0.9% w/v 
sterile sodium chloride intravenous infusion BP solution; 0.625 mL per 500 mL of 
whole blood of 40 mg/mL Genticin injectable solution) (Reardon, 1991) and the 
blood was mixed for ten minutes on a roller mixer before being dispensed in 1 mL 
aliquots into 2 mL volume, plain glass (no anticoagulant) specimen vials. The 
specimens were labelled with a unique exercise identifier and returned to storage 
at 2 to 8 °C for a further ten days, to simulate the usual time taken for the 
preparation and packing of a UK NEQAS survey distribution, after which the 
specimens were dispatched by first class post to the same 160 participants as in 
phase one. 
3.3.4 Survey material analysis schedule 
Participants were instructed to test both phase one (EDTA-anticoagulated) and 
phase two (CPD-anticoagulated) specimens by their standard Hb A2 method and 
to record both the date of receipt and testing. To ensure that results were returned 
in a timely fashion, a closing date of ten days post-distribution was given for each 
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phase of the exercise. This is the same 'survey open' period used for UK NEQAS 
Abnormal Haemoglobins exercises. Allowing for twenty-four to forty-eight hours in 
the post and twenty-four hours for receipt and processing of the samples in the 
participant's laboratory, it was anticipated that the majority of phase one 
specimens would be three days and the majority of phase two specimens sixteen 
days post venesection when tested. Drawing from previous experience of the 
pattern of testing in regular UK NEQAS exercises, it was anticipated that 25 to 
50% of samples would be tested later than the predicted date, ranging up to the 
closing date of the exercise. 
3.3.5 Statistical analysis 
Statistical analysis was undertaken using STATA 14 statistical software or 
Microsoft Excel. Because some of the instrument groups contained fewer than 
twenty results, non-parametric methods (median, est.SD and est. CV) were used 
for the calculation of descriptive statistics. Where there were five results or fewer 
for an instrument, the results were included in the ‘all methods’ group. 
One-sample t-tests were calculated as shown in Equation 3.1 where   is the mean 
of the differences between the phase one and phase two results, 
 
 is the 
hypothesised mean,   is the standard deviation and   is the number of 
observations. The value for 
 
 (the hypothesised mean) was set at zero, i.e. the 
null hypothesis is that there is no difference between the phase one (EDTA) and 
phase two (CPD) specimens. 
    
    
 
   ⁄
 
Equation 3.1 Calculation of one-sample t-tests  
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3.4 Results 
3.4.1 Numbers of results returned by analyser / method 
Results were received for each phase of the experiment from 144/160 laboratories 
(90%) and for both phases from 138/160 laboratories (86%). The Hb A2 methods 
used by participants are shown in Table 3.1. Results were returned from manual, 
microcolumn chromatography and HPLC methods, which were representative of 
the methods in use at the time. 
3.4.2 Analysis of Haemoglobin A2 results by anticoagulant and specimen age 
The summary statistics for phases one and two are shown in Table 3.2. Median 
and est. SD results were calculated because some of the method groups 
contained fewer than ten results. Individual method group statistics were not 
calculated for instruments where there were five or fewer results available. 
Two results returned in phase one were excluded from the data analysis as the 
samples were tested at fifteen days post-venesection, i.e. after the exercise 
closing date, giving 142 results included in the data analysis for phase one. One 
result was excluded from the phase two data analysis as the sample was tested at 
thirty-one days post-venesection, giving 143 results in phase two.  
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Method Phase 1 Phase 2 
Column Chromatography 60 61 
Bio-Rad Variant Classic HPLC 13 14 
Bio-Rad Variant II / Dual programme HPLC 9 8 
Bio-Rad Variant II / Beta Thalassaemia Short 
Programme HPLC 
32 32 
Bio-Rad D10 HPLC 2 2 
Menarini HA8160 HPLC 12 11 
Primus HPLC 5 5 
TOSOH G7 HPLC 11 11 
ALL METHODS 144 144 
 
Table 3.1. Numbers of results returned by analyser or method type for 
Haemoglobin A2 measurement in phases one and two 
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Phase 1 Method N 
Hb A2 Results 
Median IQR Est SD Est CV% Min Max 
 
CC 59 2.7 0.5 0.3706 13.73 1.9 3.3 
 
BRD10 2 ~ ~ ~ ~ 2.3 2.7 
 
BRV2Bth 31 2.6 0.2 0.1483 5.70 2 3 
 
BRV2DK 9 2.4 0.3 0.2224 9.27 2.1 2.5 
 
BRVClass 13 2.6 0.1 0.0741 2.85 2.2 2.7 
 
HA8160 12 2.25 0.25 0.1853 8.24 2.1 2.7 
 
Primus 5 ~ ~ ~ ~ 2.2 2.4 
 
Tosoh G7 11 2.7 0.4 0.2965 10.98 2.1 3.2 
 
ALL METHODS 142 2.6 0.4 0.2965 11.40 1.9 3.3 
Phase 2 Method N 
Hb A2 Results 
Median IQR Est SD Est CV% Min Max 
 
CC 61 2.7 0.3 0.2224 8.24 2.2 3.3 
 
BRD10 2 ~ ~ ~ ~ 2.7 2.9 
 
BRV2Bth 32 2.6 0.2 0.1483 5.70 2.2 3.1 
 
BRV2DK 8 2.3 0.15 0.1112 4.83 2.2 2.6 
 
BRVClass 13 2.5 0.1 0.0741 2.97 2.4 2.7 
 
HA8160 11 2.2 0.4 0.2965 13.48 2 2.8 
 
Primus 5 ~ ~ ~ ~ 2.1 2.3 
 
Tosoh G7 11 2.7 0.5 0.3706 13.73 2.2 3 
 
ALL METHODS 143 2.6 0.4 0.2965 11.40 2.0 3.3 
 
Table 3.2. Summary statistics for Haemoglobin A2 results returned in phases one and two 
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Legend to Table 3.2: 
   
CC: Microcolumn chromatography  
BRD10: Bio-Rad D10 HPLC analyser 
BRVBTh: Bio-Rad Variant II HPLC analyser, using the beta thalassaemia short programme  
BRV2DK: Bio-Rad Variant II HPLC analyser, using the dual programme kit 
BRVClass: Bio-Rad Variant Classic HPLC analyser 
HA8160: Menarini HA8160 HPLC analyser 
Primus385: Primus HPLC analyser 
TOSG7: Tosoh G7 HPLC analyser 
IQR: Interquartile range 
Est. SD: Estimated standard deviation 
Est. CV%: Estimated coefficient of variation 
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The all methods summary statistics for both phases were identical, with a median 
Hb A2 result of 2.6% and an est. CV% of 11.4%. The range of Hb A2 results was 
1.9 to 3.3% (phase one) and 2.0% to 3.3% (phase two). The median Hb A2 values 
for the phase one specimens by instrument group ranged from 2.25% (Menarini 
HA8160 group) to 2.7% (microcolumn chromatography and Tosoh G7 groups). For 
the phase two specimens the median Hb A2 values ranged from 2.2% (Menarini 
HA8160 group) to to 2.7% (microcolumn chromatography and Tosoh G7 groups). 
The CV% for most of the individual method groups was less than the overall value 
of 11.4%; for phase one only the microcolumn chromatography and the Tosoh G7 
groups both had an est. CV% greater than 10%, for phase two only the Menarini 
HA8160 and the Tosoh G7 method groups had an est. CV% greater than 10%. 
3.4.3 Effect of specimen age on Haemoglobin A2 results 
In phase one the specimens were between two and ten days old when tested, with 
two other results returned on specimens at fifteen days post venesection. The 
mode for the age of the specimens on testing was three days (37/144 specimens, 
26%). A total of 68/144 (47%) were three days old or less, 105/144 (73%) were 
seven days old or less and 142/144 (98.6%) were ten days old or less. Figure 3.1 
shows the results returned by specimen age and by instrument group in phase 
one. The results of the two EDTA specimens tested fifteen days post venesection 
were in consensus with the other results but were excluded from the data analysis 
as outliers as the specimens had been tested after the closing date for the 
exercise. The outlier results are included Figure 3.1 for information. 
In phase two, specimens were between fourteen and twenty-three days post 
venesection when tested, with one other result returned on a specimen tested on 
day thirty-one. The mode for the age of the specimens at testing was sixteen days 
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(39/144 specimens, 27.1%). A total of 72/144 (50.0%) were sixteen days old or 
less, 125/144 (86.8%) were twenty-one days old or less and 143/144 (99.3%) 
were twenty-three days old or less. Figure 3.2 shows the results returned by 
specimen age and by instrument or method in phase two. The specimen tested 
thirty-one days post venesection was excluded from data analysis as an outlier as 
the specimen had been tested after the exercise closing date. The outlier result is 
shown in Figure 3.2 for information. 
Figure 3.3 shows the box and whisker plots by day of testing for both phase one 
and phase two specimens. The mean Hb A2 result for all specimens was 2.58%, 
with a ± 0.25% acceptable performance range of 2.33 to 2.83%. The median result 
returned for each day that specimens were reported fell within this range except 
for specimens tested on day nine in phase one (EDTA specimens), which returned 
a median Hb A2 result of 2.3%. The box and whisker plots do not suggest a trend 
in the results with specimen age when specimens are tested within the survey 
closing date. Overall there were more results returned that were less than the 
mean ± 0.25% Hb A2 range (68/284, 24%) than greater than the mean ± 0.25% Hb 
A2 range (46/284, 16%) but this distribution was observed across the full range of 
testing dates. The proportion of results falling outside the mean ± 0.25% 
performance range of 2.33% to 2.83% by specimen age at testing for both phases 
is shown in Figure 3.4.  
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Figure 3.1. Distributional plot showing the Haemoglobin A2 result returned by 
specimen age and method for EDTA anticoagulated specimens distributed in 
phase 1. The reference line shows the median result for each method group. 
Legend to Figure 3.1: 
CC: Ion exchange microcolumn chromatography 
BRD10: Bio-Rad D10 HPLC analyser 
BRVBTh: Bio-Rad Variant II HPLC analyser, using the beta 
thalassaemia short programme 
BRV2DK: Bio-Rad Variant II HPLC analyser, using the dual kit 
programme 
BRVClass: Bio-Rad Variant Classic HPLC analyser 
HA8160: Menarini HA8160 HPLC analyser 
Primus385: Primus 385 HPLC analyser 
TOSG7: Tosoh G7 HPLC analyser 
Total: All methods results 
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Figure 3.2. Distributional plot showing the Haemoglobin A2 result returned by 
specimen age and method for CPD anticoagulated specimens distributed  
in phase 2. The reference line shows the median result for each method group. 
Legend to Figure 3.2:   
CC: Ion exchange microcolumn chromatography 
BRD10: Bio-Rad D10 HPLC analyser 
BRVBTh: Bio-Rad Variant II HPLC analyser, using the beta 
thalassaemia short programme 
BRV2DK: Bio-Rad Variant II HPLC analyser, using the dual kit 
programme 
BRVClass: Bio-Rad Variant Classic HPLC analyser 
HA8160: Menarini HA8160 HPLC analyser 
Primus385: Primus 385 HPLC analyser 
TOSG7: Tosoh G7 HPLC analyser 
Total: All methods results 
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Figure 3.3. Box and whisker plots of Haemoglobin A2 result returned by specimen 
age in days. Specimen ages shown in purple are phase 1 (EDTA) specimens 
(days two to fourteen), those in black are phase 2 (CPD) specimens (days 
fourteen to twenty-three). The mean result for all specimens is 2.58% with a ± 
0.25% performance range of 2.33% to 2.83%, all shown by solid reference lines. 
The 95% confidence limits (mean ± 2SD) are shown by broken reference lines. 
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Figure 3.4. Proportion of results returned by specimen age at testing that were less than, within or greater  
than the mean ± 0.25% performance range of 2.33% to 2.83%. Phase one (EDTA) specimens  
are those tested at fourteen days or less, phase two (CPD) specimens at fifteen days or more 
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3.4.4 Effect of anticoagulant on Haemoglobin A2 performance 
T-tests were calculated where results were returned for both phases by the same 
participants to examine whether the difference between the results returned for 
phase one (EDTA anticoagulated) and phase two (CPD anticoagulated) 
specimens was significantly different from zero. Participants who had returned 
results that were identified as outliers because of the age of the specimens (two 
participants who had tested the phase one specimen at fifteen days and one 
participant who had tested the phase two specimen at thirty-one days post 
venesection) were excluded from the analysis, giving 136 sets of data. T-tests 
were calculated for the all methods group, by method principle and by sub-method 
(analyser type) where there were more than five results in the sub-method group. 
The results of the t-tests are shown in Table 3.3. Using a probability value of p 
≤0.05 as significant, there was no significant difference between the results 
returned for phase one and phase two for all methods results, by method principle 
or by the major HPLC sub-methods. 
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Method 
EDTA 
mean HbA2 
CPD 
mean Hb A2 
Mean 
Difference 
SD N DF T value t-critical P(T≤t) 
CC 2.6614 2.7000 -0.0386 0.3288 57 56 -0.8862 2.0032 0.38 
HPLC (All) 2.4975 2.5089 -0.0114 0.2088 79 78 -0.4850 1.9904 0.63 
BRVClass 2.5750 2.5500 0.0250 0.1357 12 11 0.6383 2.2010 0.54 
BRV2BTh 2.5567 2.6133 -0.0567 0.2373 30 29 -1.3077 2.0452 0.20 
BRV2DK 2.3250 2.3625 -0.0375 0.1302 8 7 -0.8143 2.3646 0.44 
HA8160 2.3091 2.2818 0.0273 0.1348 11 10 0.6708 2.2282 0.52 
TOSG7 2.6545 2.6000 0.0545 0.2622 11 10 0.6901 2.2282 0.51 
All Methods 2.5662 2.5890 -0.0228 0.2650 136 135 -1.0032 1.9777 0.32 
 
Table 3.3. One sample t-test to test the difference between the Phase One (EDTA) and Phase Two (CPD) specimens 
Legend to Table 3.3: 
CC: Ion exchange microcolumn chromatography 
BRVClass: Bio-Rad Variant Classic HPLC analyser  
BRVBTh: Bio-Rad Variant II HPLC analyser, using the beta thalassaemia short programme 
BRV2DK: Bio-Rad Variant II HPLC analyser, using the dual kit programme 
HA8160: Menarini HA8160 HPLC analyser 
TOSG7: Tosoh G7 HPLC analyser 
All Methods: All methods results 
SD:  Standard deviation of the mean difference between EDTA and CPD results 
N:  Number of results 
DF:  Degrees of freedom (N-1) 
T:  Calculated t-test results 
t-critical:  limit of t-test result for the given the degrees of freedom and the chosen confidence limit (95%) 
  
113 
3.5 Discussion 
In this study blood from the same donor was distributed to 160 UK NEQAS 
participating laboratories as a fresh, EDTA-anticoagulated specimen and after 
collection into CPD and processing according to the standard protocols for the 
preparation of survey material for the UK NEQAS Abnormal Haemoglobins 
scheme. 
Although the ideal EQA material is one that is as similar to patients' clinical 
material as possible, there has to be a compromise in EQA between comparability 
with clinical material and the logistics of distributing an EQA service to a number of 
participants in diverse locations. The options for EQA survey material for Hb A2 
measurement for a large, international EQA scheme include whole blood in CPD, 
as used by UK NEQAS; 'stabilised' blood, as used by the College of American 
Pathologists (CAP) PT Programme; and lyophilised haemolysate, as used by the 
Royal College of Pathologists in Australia Quality Assessment Programme 
(RCPAQAP) at the time of writing. Lyophilised haemolysate was used for the 
preparation of the WHO Hb A2 International Reference Reagent and more 
recently, Pornprasert (2016) and Paleari (2010) described the use of lyophilisation 
for the production of materials for the control of haemoglobin variant typing and Hb 
A2 quantitation. Lyophilised materials offer many advantages for EQA in terms of 
batch manufacture, long term storage and the stability of material in transit; 
however, lyophilised materials require reconstitution before use, which may 
introduce an additional source of error not found with clinical specimens. 
Lyophilised haemolysate is not suitable for sickle solubility testing, which is still 
widely used in Hb variant identification and is part of the UK NEQAS Abnormal 
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Haemoglobins scheme design, as the sickle solubility test requires intact red blood 
cells. 
Oxidation of Hb to methaemoglobin (MetHb) causes deterioration in the quality of 
the separation of Hb fractions with additional minor peaks and a poor baseline that 
confound the accurate quantitation of Hb A2 (Stephens 2012). MetHb is formed 
physiologically at a rate of two to three percent of total Hb per day but this is 
reduced, primarily by NADH-linked MetHb reductase in the red cell (Mansouri, 
1993; Çimen, 2008). Storage of red cells leads to the exhaustion of the metabolic 
pathways and a subsequent increase in MetHb, which can be slowed by exclusion 
of atmospheric oxygen as far as possible and storage of the sample at 2 to 8 °C 
(Tietz, 1990). Clinical samples in EDTA are stable for up to twenty-one days for Hb 
A2 if kept under these conditions (Tietz 1990) and this timeframe is approximately 
the same as a UK NEQAS Hb A2 ‘survey open’ period. Louahabi (2006) stored 
specimens for up to four weeks for the evaluation of the Sebia Capillarys CZE 
analyser and reported the samples stable for Hb A2 measurement during that time.  
UK NEQAS Haematology survey packages are shipped at ambient temperature to 
most destinations. The international profile of the scheme means that 45% of 
participants overall are outside the UK at the time of writing and this proportion is 
even higher for participants registered for full participation in the Abnormal 
Haemoglobins programme, with 168/328 (51.2%) of laboratories registered for Hb 
A2 measurement located outside the UK at the end of 2015. Of the non-UK 
participants registered at December 2015, fifty-two (15.8% of the total 
registrations) are outside Europe, with most non-European participants being 
located in Turkey, Israel and the Middle East. Delivery outside the British Isles is 
by courier to maintain the integrity of the specimens and the average transit time 
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by courier is four days. It is a requirement for accreditation to ISO 17043:2010 
(ISO 17043:2010) for the EQA provider to demonstrate that the survey specimens 
are fit for purpose wherever they are tested.  
UK NEQAS Haematology undertakes stability studies routinely on each batch of 
Hb A2 survey material produced, testing the material on preparation, despatch and 
closing day with specimens stored at 2 to 8 °C. This exercise gave the opportunity 
to examine UK NEQAS survey material during the course of a simulated Abnormal 
Haemoglobins survey. Both the EDTA specimens distributed in phase one and the 
CPD specimens distributed in phase two showed no deterioration during the 
exercise as indicated by the Hb A2 results returned. 
Deterioration of specimens for Hb A2 measurement is accelerated at high ambient 
temperatures and daytime temperatures of 50 °C are commonly encountered in 
some of the locations to which UK NEQAS services are sent. The quality of the 
results returned from all participants is a matter of concern not just because of the 
potentially adverse impact on the individual laboratory’s performance but also to 
ensure the reliability of the statistics against which the performance of all 
participants is monitored. UK NEQAS Haematology uses temperature trackers to 
monitor the temperatures to which packages are exposed in international transit to 
selected participants and uses this information to make adjustments to the 
shipping conditions for future shipments where necessary. To avoid an increase in 
shipping costs due to the use of unnecessary additional cold-chain packaging, 
stability studies were undertaken to ascertain the stability of the Hb A2 survey 
material at different temperatures in an experiment that was not part of this study 
but was undertaken under the direction of the author to demonstrate ISO 17043 
compliance for accreditation purposes. Fifteen specimens from each of ten 
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batches of survey material distributed over the course of ten months for Hb A2 
measurement were taken on despatch day. Five were kept at ambient temperature 
in an air-conditioned laboratory (air temperature ranging from 20 to 25 °C), five 
were kept at 30 °C and five at 37 °C for up to four days to simulate the average 
length of time specimens spend in transit. One specimen from each temperature 
batch was analysed each day in triplicate for Hb A2 using a Bio-Rad Variant II 
analyser with the beta thalassaemia short programme. Overall specimens kept for 
four days at ambient temperature showed a negative bias of 1.2% (range from -
12.0% to zero) against the control specimen kept at 2 to 8 °C (note that this is the 
percent bias and not the change in absolute Hb A2 result). At 30 °C a negative 
bias of 0.04% was seen at four days (range -0.2% to 0.11%) and a negative bias 
of 4.3% (range -14.0% to 0.31%) for specimens kept at 37 °C. These figures 
indicate that the UK NEQAS survey material is very stable at temperatures of up to 
30 °C for four days in transit and that short exposure to temperatures up to 37 °C 
should not cause the specimens to deteriorate to such an extent that participants 
incur an unsatisfactory performance score. 
The second question asked in this study concerned the impact of the 
anticoagulant used by UK NEQAS Haematology on the commutability of the 
survey material. Commutability is the ability of the EQA survey material to give the 
same result when tested across all platforms. It is essential that both the EQA 
provider and the participating laboratory understand the limits of commutability 
when evaluating EQA performance (James, 2014; ISO 17043:2010; BS EN 
14136:2004). Where there is a single cut-off Hb A2 value for the identification of a 
beta thalassaemia carrier, as in the antenatal screening algorithm of the NHS 
STP, the ideal is that the EQA performance of all instruments can be assessed in 
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the same group to reflect ‘real-life’ practice. On the basis of the findings from this 
exercise, there is no statistical significance in the difference of the results obtained 
from material prepared according to standard UK NEQAS procedures (distributed 
in phase two) and fresh EDTA material from the same donor (distributed in phase 
one) supporting the conclusion that the UK NEQAS Haematology Abnormal 
Haemoglobins material is commutable for the measurement of A2. Commutability 
of the survey material makes the current practice of scoring performance against 
the MTM questionable, since the only justification for grouping instruments for 
performance assessment is a lack of commutability. The separate performance 
assessment of HPLC and CZE methods is for historical reasons dating from the 
use of manual methods and this should be re-evaluated as it is not evidence-
based. 
Although a representative range of HPLC methods together with microcolumn 
chromatography were included in this exercise, the changes in methodology of 
recent years mean that a number of current analysers and methods, including 
CZE and TMS, were not included in the study. The evaluation of the suitability of 
EQA material for new techniques and platforms is a constant requirement in all 
areas of EQA provision. A full study of this nature, with the venesection of a 
volunteer donor is not a practical means of undertaking this validation on a regular 
basis; however, the study has demonstrated that in principle the UK NEQAS Hb A2 
survey material performs in a comparable fashion to fresh EDTA blood. 
Verification of this assumption is possible using comparison studies as new 
instruments are introduced and the regular data mining of participants’ results on a 
survey by survey basis.  
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Chapter 4: The quantitation of Hb A in dried blood spot 
specimens as a means for screening newborn infants for 
beta thalassaemia major
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4.1. Aim 
To assess the measurement of Hb A% as a means to screen newborn infants for 
beta thalassaemia using dried blood spot cards. 
4.2 Introduction 
The benefit of early intervention on the course of certain inherited disorders was 
recognised in the 1950s when the implementation of a modified diet in very young 
children with phenylketonuria (PKU), an inborn error of amino acid metabolism 
was found to be beneficial in their management (Horst 1954). Newborn screening 
for PKU was introduced approximately ten years later and there are now up to fifty 
disorders that are screened for in the neonatal period (Wilcken, 2008; Sahai, 2009; 
Mak, 2013). At the time of writing, newborn screening is offered for nine inherited 
conditions in England using a dried blood spot (DBS) sample taken five to eight 
days after birth. The conditions are sickle cell disease, cystic fibrosis, congenital 
hypothyroidism and the inherited metabolic diseases PKU, medium-chain acyl-
CoA dehydrogenase deficiency (MCADD), maple syrup urine disease, isovaleric 
acidaemia, glutaric aciduria type 1 and pyridoxine unresponsive homocystinuria 
(NHS Newborn Blood Spot Screening Programme Standards, 2017). Of the 
conditions screened for, sickle cell disease is the most frequently encountered, 
estimated to affect one in two thousand babies in the UK. Early diagnosis of sickle 
cell disease and the implementation of penicillin prophylaxis have been shown to 
be beneficial in reducing mortality in sickling disorders (Rogers, 1978a; Rogers, 
1978b; Gaston, 1986).  
The main Hb present in the fetus is fetal haemoglobin, Hb F, which is replaced by 
adult Hb (Hb A), starting in late fetal life with a switch from the production of the 
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gamma globin chains of Hb F to the production of the beta globin chains of Hb A. 
The inheritance of a beta thalassaemia mutation results in reduced or absent 
globin chain synthesis; if both beta globin genes are affected as in beta 
thalassaemia major, Hb A is absent or severely reduced. The synthesis of gamma 
globin chains is not affected by the presence of a beta thalassaemia mutation, and 
the clinical symptoms of beta thalassaemia only become evident as the production 
of Hb F declines in the neonatal period. Thus an infant with beta thalassaemia 
major undiagnosed at birth typically presents in the first one to two years of life, 
with symptoms of severe anaemia, haemolysis and ineffective erythropoiesis 
(Bain, 2006; Weatherall and Clegg, 2001). An early knowledge of the inheritance 
of beta thalassaemia major permits diagnostic testing to determine the mutation(s) 
present and ensures that the infant is referred promptly for appropriate clinical 
care (Hoppe, 2009). Early identification of the unexpected birth of a beta 
thalassaemia major infant will also facilitate the prompt investigation of any 
possible failure in an associated antenatal screening programme where these are 
linked services. 
Universal newborn screening for sickle haemoglobin and other clinically significant 
haemoglobinopathies using DBS specimens was implemented in 2006 in England 
(Streetly, 2009b), the same year as it was mandated in all states in America 
(Benson, 2010). The NHS STP for newborn sickle screening in England requires 
the identification of infants with sickle cell anaemia (HbSS or homozygous for Hb 
S) and other sickling conditions resulting from co-inheritance of Hb S with HbC, 
beta thalassaemia, Hb DPunjab, Hb E, Hb OArab, Hereditary Persistence of Fetal 
Haemoglobin (HPFH) or with any other structural Hb variant (NHS STP Newborn 
Laboratory Handbook, 2017). Over seven million newborn infants were screened 
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in England in the ten years to 2016, of which 3,600 were found to be positive for 
significant haemoglobinopathies (NHS STP Data Report 2015/16: trends and 
performance analysis, 2017). Although it is not one of the aims of the programme, 
newborn screening will detect infants with an absence of Hb A or an Hb A% that is 
low for gestational age, which may be indicative of beta thalassaemia major or 
thalassaemia intermedia. In the first ten years of newborn screening in England, 
268 ‘Hb F only’ infants were identified. 
Mantikou (Mantikou, 2009) published evidence that beta thalassaemia carriers 
could be detected at birth using a cut-off value for Hb A of less than 15%, 
demonstrating a quantitative relationship between Hb A% at birth and reduced 
output from the beta globin gene(s). The proportion of Hb A at birth is highly 
variable, even in full-term infants, and an effective screening programme requires 
a cut-off that reliably identifies the majority of affected infants but with relatively 
few false positives. A major retrospective analysis of newborn blood spot 
screening data from 2,288,008 infants born in England in the period 2005 to 2012 
has been undertaken to identify the relationship between Hb A% at birth and beta 
thalassaemia major. The data demonstrated that the adoption of a 1.5% cut-off for 
Hb A in infants of more than thirty-two weeks’ gestation has a good positive 
predictive value, specificity and sensitivity, better than that demonstrated for 
newborn screening for MCADD deficiency (Streetly, 2013). Of the 2,288,008 
infants reviewed, 170 were identified as having beta thalassaemia major or beta 
thalassaemia intermedia using a cut-off of 1.5% Hb A. 119 / 170 were identified 
prospectively from their Hb A% at birth and 51 / 170 were identified retrospectively 
in a look-back exercise. Seven of the prospectively identified infants were lost to 
follow up and fifteen were subsequently found to be false positives (eleven were 
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premature infants of less than thirty-two weeks’ gestation, one a beta 
thalassaemia carrier and one a compound heterozygote for beta thalassaemia and 
HPFH). Of the remainder, ninety were confirmed as beta thalassaemia major and 
seven as beta thalassaemia intermedia. Although there were no ‘missed’ cases 
reported from the screening centres involved in the study, one infant would have 
been a false negative (Hb A = 1.9%) but for the fact that it was followed up as a 
result of parental results. The NHS STP Newborn Laboratory Handbook for 
Newborn Screening Laboratories recommends a cut-off of 1.5% Hb A at birth for 
the identification of infants with beta thalassaemia major. 
Newborn screening for haemoglobinopathies requires the initial or primary 
screening of the DBS and the confirmation of any positive result by a secondary 
method. Amongst the laboratories registered in the UK NEQAS Haematology 
Newborn Sickle Screening scheme in December 2016, the primary screening 
methods were HPLC (the Bio-Rad VARIANT™ newborn screening (Vnbs) 
analyser, running the sickle cell short programme), CZE (the Sebia Capillarys 
Neonat Haemoglobin FAST™ CZE system) and electrospray TMS. Confirmatory 
methods used were from the same range of methods plus isoelectric focusing 
(IEF). The statements of intended use for both Vnbs and the Neonat Fast 
instruments are that the instruments are intended for the qualitative detection of 
the presence of haemoglobins F, A, S, C, D and E (Bio-Rad Vnbs) in neonatal 
blood and the separation of the normal Hb F and Hb A in human newborns and for 
the detection of the variant Hbs S, C, E, D and Barts (Sebia Neonat Hb Fast) 
(Substantial equivalence determination decision summaries K051072 and 
K091283, US Food and Drug Administration agency; Bio-Rad VARIANT™ nbs 
Sickle Cell Programme instruction manual; Sebia Capillarys Neonat Hb FAST™ kit 
  
123  
insert Ref 2006). No limit of detection (LOD) has been determined for the Sebia 
Capillarys Neonat Hb FAST™ but an equivalent performance of 1.1% for Hb S, 
2.3% for Hb C and 1.1% for Hb E in comparison with the reference Bio-Rad Vnbs 
HPLC system is given in a sensitivity study. By comparison, a LOD of 1% is given 
for the Bio-Rad Vnbs analyser for the detection of Hb S, D, C and E, although no 
LOD is given for Hb A (Substantial equivalence determination decision summary 
K051072 and K091283, US Food and Drug Administration agency). 
The purpose of the experiments described in this chapter was to review the 
performance of the main methods of newborn haemoglobinopathy screening (Bio-
Rad Vnbs and Sebia Capillarys Neonat Hb kit) for the quantitation of low 
concentrations of Hb A, as recommended for the detection of infants with beta 
thalassaemia major by the NHS STP. Although both instruments provide a 
quantitative result for all Hb fractions detected, the limitations of this quantitation 
must be understood since the systems are not marketed as quantitative devices. 
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4.3 Materials and methods 
4.3.1 Dried blood spot card preparation 
Twelve mL of EDTA-anticoagulated blood was collected with informed consent 
from a female, adult patient with homozygous delta-beta thalassaemia, who was 
managed clinically as thalassaemia intermedia. Blood collected for the purpose of 
quality assurance and instrument or method validation is exempt from the Human 
Tissue Act regulations (Human Tissue Act, 2004). The patient’s 
haemoglobinopathy screen showed Hb F (82.6%) and Hb A2 (1.4%) but no Hb A 
and no abnormal Hb variant present when tested using a Bio-Rad Variant Classic 
HPLC analyser with the sickle cell short programme (see Figure 4.1a).  
One unit of waste umbilical cord blood was obtained from NHSBT. The unit was 
unsuitable for therapeutic use and the mother had consented for its use for quality 
assurance and/or validation purposes. The haemoglobinopathy screen of the 
umbilical cord blood showed Hb F (73.8%) and Hb A (11.2%), no Hb A2 and no 
abnormal Hb variant when tested using a Bio-Rad Variant Classic HPLC analyser 
with the sickle cell short programme (see Figure 4.1b). 
The adult and cord red blood cells (RBC) were washed separately three times in 
0.9% w/v phosphate buffered saline (PBS), using a ratio of approximately 10:1 
PBS: RBC each time in 10 mL plastic, conical centrifuge tubes, centrifuging at 
3000 rpm in a Heraeus Megafuge centrifuge at 20 °C at each wash. The 
supernatant saline was removed between washes using a water operated Venturi 
pump, taking care not to disturb the RBC layer. After three washes, the RBCs 
were resuspended in PBS to give a cell suspension of approximately 50%.  
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The haematocrit (Hct) of each cell suspension was measured using a Sysmex 
XE2100 FBC analyser and adjusted to a value in the range 0.45 to 0.55, to 
simulate a typical Hct for a newborn infant. The actual final Hct of both the adult 
and cord RBC suspensions was 0.49 L/L. The cell suspensions were adjusted to 
the same Hct to allow the calculation of the proportions of adult and cord cells 
required to make a range of Hb A% without having to take account of the Hct of 
the cell suspensions. 
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Figure 4.1. HPLC chromatograms of the adult and cord blood samples used for 
preparation of the red cell suspensions. 
(Note the poor quality of these scans is due to the  
thermal paper output of the instrument). 
  
a) Adult sample b) Cord sample 
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The washed, resuspended adult and cord RBCs were mixed to make eight red cell 
suspensions with a range of Hb A% concentrations calculated to be between 0.5% 
and 10%. The actual Hb A% of each RBC suspension was measured ten times 
using a Bio-Rad Vnbs HPLC analyser with the sickle cell short programme, 
preparing a separate dilution (5 L cell suspension to 1 mL deionised water) for 
each, and the mean Hb A% of the ten measurements calculated. 
Forty dried blood spot (DBS) cards (Perkin-Elmer Health Sciences, SC, USA) 
were prepared from each of the eight mixtures with a single spot of 25 l of RBC 
suspension per card, applied using a 100 l air displacement pipette. The cards 
were checked to ensure that the RBC suspension had penetrated through the filter 
paper to the back of the card and left to air-dry for thirty minutes. Once dried, a 
test card was taken from each batch and tested using a Bio-Rad Vnbs HPLC 
analyser, as a reference for the comparison of the quality of the baseline and the 
peak separation for the DBS during the different stages of the study. 
Table 4.1 shows the volumes of adult and cord blood cells used to prepare the 
mixtures and the Hb A% of both the RBC suspensions and the DBS cards 
immediately after preparation. 
Once dried, the cards were labelled with the survey material batch number (one to 
eight) and packed into individual glassine envelopes, supplied with the cards. 
Each batch of cards was wrapped tightly as a bundle in aluminium foil and then 
plastic wrapping film and stored at -40 °C for a total of twelve months until all parts 
of the experiment had been completed. UK NEQAS Haematology experience of 
storing DBS for use as EQA material has demonstrated that DBS are stable for 
this period, providing they are kept at -40 °C and tightly wrapped to exclude 
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moisture (unpublished pre-acceptance testing evidence from ten years of the UK 
NEQAS Haematology Newborn Sickle Screening EQA programme operation). 
When the DBS were removed from storage, the bundle of cards was opened and 
the required number removed. The remaining cards were rewrapped promptly and 
returned to storage at -40 °C. Once removed from storage, the cards were laid in a 
single layer on a clean bench and allowed to equilibrate at ambient temperature 
(20 to 24 °C in an air-conditioned laboratory) before being packaged for 
distribution or tested in-house. 
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Card 
batch 
number 
Calculated 
Hb A% 
Volume of 
adult cells 
(L) 
Volume of 
cord cells 
(L) 
Mean Hb A% of 
the mixed RBC 
suspension 
Hb A% DBS 
immediately 
after 
preparation 
1 0.5 1145 55 0.6 0.3 
2 1.0 1090 110 1.0 0.7 
3 1.5 1040 160 1.5 1.2 
4 2.0 990 215 2.0 1.6 
5 3.0 880 320 3.1 2.7 
6 5.0 665 540 5.0 4.5 
7 7.0 450 750 7.0 6.6 
8 10.0 100 1100 10.9 10.6 
 
Table 4.1. Preparation of dried blood spot cards with a range of Hb A%. The adult 
cells were a suspension of RBC from a patient with beta thalassaemia intermedia 
(Hb F and Hb A2 only); the cord cells were a suspension of RBC from a unit of 
umbilical cord blood (Hb F and Hb A). Both adult and cord cell suspensions had a 
haematocrit of 0.49 L/L. 
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4.3.2 Bio-Rad VARIANT™ nbs HPLC analyser specimen preparation and 
analysis  
A 3 mm blood spot was punched from each DBS using a hand-held DBS card 
punch into a labelled 1.5 mL clear microtube and 250 L deionised water added. 
The tube was capped and left to stand for ten minutes at room temperature and 
then agitated gently to encourage elution of the dried blood from the filter paper 
and to mix the eluate. Three to five drops of eluate were transferred using a 
pastette to a well in a ninety-six well microtitre plate, which was loaded onto the 
Bio-Rad Vnbs analyser for analysis together with blank (deionised water), FAES 
and FADC retention time markers (Bio-Rad Laboratories, CA). The plates were 
held at 9 ± 2 ⁰C in the analysis chamber. The samples were injected automatically 
in sequence into the HPLC cartridge on the analyser and the Hb fractions present 
in the eluate separated by cation exchange chromatography using a pre-
programmed buffer gradient. The separated fractions were detected by their 
absorbance as they passed through a flow cell in a spectrophotometer monitored 
at 415 and 690 nm and identified by the retention time window into which they fell. 
The percentage of each fraction as a part of the whole was calculated 
automatically by the integration of the area under the absorbance peak. 
Samples of liquid blood or RBC suspension were prepared by diluting 5 L of 
mixed, whole blood or RBC suspension in 1 mL of deionised water in a 1.5 mL 
clear microtube and mixed by inversion before being analysed in the same way as 
the eluate from a DBS. 
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4.3.3 Distribution of dried blood spot cards for the assessment of 
Haemoglobin A% quantitation 
The DBS cards were distributed for testing on two occasions to fourteen UK 
Newborn Screening Laboratories registered in the UK NEQAS Newborn Sickle 
Screening scheme. Both exercises (identified as 1301NHEX and 1401NHEX) took 
place within a year of preparation of the DBS cards. The timing was selected for 
logistical purposes. A set of cards was tested in the UK NEQAS Haematology 
laboratory at the same time, giving a total of fifteen sets of results for each 
distribution. 
At each distribution, fifteen cards were withdrawn from storage from each of the 
eight batches. One card was tested within twenty-four hours of removal from 
storage using the Bio-Rad Vnbs HPLC analyser in the UK NEQAS Haematology 
laboratory and the quality of the chromatogram and the quantitation of the Hb 
peaks reviewed against the original results of the card tested prior to storage. The 
cards were packed into fifteen sets with one card from each batch in each set and 
a set of eight cards was dispatched by first class post to each of fourteen UK 
newborn screening laboratories. The laboratories were asked to test the cards by 
their routine primary method for newborn sickle upon receipt in the order one to 
eight, i.e. from the lowest to the highest Hb A% and to return their results using a 
proforma result sheet. An example instruction sheet and proforma results sheet 
are shown in Appendix 2. 
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4.3.4 Precision of low Haemoglobin A% measurements 
Precision is the agreement between replicate analyses of the same specimen and 
is an essential component of the uncertainty of a measurement. It is not the same 
as accuracy. Two cards from each batch were withdrawn from storage. The DBS 
from each card was cut out in its entirety using a clean pair of scissors and left to 
stand for ten minutes in 3 mL of deionised water in a plastic test tube to elute the 
Hb from the DBS. The tube was covered with Parafilm™ and mixed by gentle 
agitation. The resulting eluate was tested using a Bio-Rad Vnbs analyser and its 
concentration adjusted with deionised water to give the correct concentration for 
accurate analysis. The eluate from each card was used to make ten replicate 
analyses of Hb A% using the Bio-Rad Vnbs analyser at UK NEQAS Haematology, 
i.e. twenty results in total. Two cards from each batch were sent to two volunteer 
newborn screening laboratories using the Bio-Rad Vnbs analyser (identified as 
sites X and Y), where the experiment was repeated. The results were analysed 
using one-way analysis of variance (ANOVA) to examine the variance in the 
results between different DBS cards and between sites for the same Hb A%. 
4.3.5 Carryover of Haemoglobin A 
Carryover is the degree of contamination of a specimen by the one immediately 
preceding it (Broughton 1974) and is of particular relevance when samples of very 
low analyte concentration may be analysed in a batch of samples with 'normal' 
analyte concentrations. 
One card from each batch was withdrawn from storage and an eluate was 
prepared from each for analysis on the Bio-Rad vNBS analyser. An umbilical cord 
blood with a normal Hb variant pattern (Hb F + Hb A) and a Hb A concentration of 
approximately 25% was selected and 25 L of cord blood diluted in 5 mL of 
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deionised water to represent an eluate from a DBS card from an infant with a 
‘normal’ Hb A%. Carryover studies were run with each of the low Hb A% DBS by 
running three replicate analyses of the normal eluate (designated H1 to H3) 
followed by three replicate analyses of the low Hb A% DBS (designated L1 to L3 
for each DBS batch). The carryover was calculated using the formula shown in 
Equation 4.1 (Briggs, 2014). 
            
(     )
(     )
       
Equation 4.1. Calculation of carry over 
 
4.3.6 Statistical analysis 
Statistical analyses were undertaken using STATA 14 (Stata Corp, Texas, USA) or 
Microsoft Excel 97 2003 (Microsoft Corp, WA, USA) with the downloaded analysis 
Toolpak. 
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4.4 Results 
4.4.1 Accuracy of low Haemoglobin A% measurements from different testing 
sites and methods 
Dried blood spot (DBS) cards prepared from RBC suspensions with Hb A 
concentrations ranging from 0.6% to 10.9% were distributed to fourteen UK 
Newborn Screening Laboratories on two occasions for testing by their primary 
newborn sickle screening method. The DBS cards were also tested by UK NEQAS 
Haematology. On both occasions, results were returned from two Sebia Capillarys 
Neonat Hb Fast CZE analysers, one Bio-Rad Variant II HPLC analyser using the 
beta thalassaemia short programme and twelve Bio-Rad Variant Newborn Sickle 
screening (Vnbs) HPLC analysers, which included one located at UK NEQAS 
Haematology. The one Bio-Rad Variant II analyser used was part of the secondary 
screening methodology used by the one UK Newborn Screening Laboratory that 
used TMS as its primary method of newborn sickle screening. This laboratory 
operates a screening protocol that is designed to detect only sickle cell disease. 
The results returned on both duplicate studies are shown in Table 4.2 and the 
descriptive statistics (mean, SD, CV and range) in Table 4.3 for all methods and 
separately for the largest instrument group (Vnbs analysers). The results are 
shown graphically against the 'expected' values as determined from the original 
RBC suspensions from which the DBS were prepared in Figures 4.2 and 4.3, with 
the results from each methodology analysed separately.
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Distribution 1301NHEX results (Hb A%) 1401NHEX results (Hb A%) 
DBS card batch 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 
RBC Suspension Hb A% 0.6 1.0 1.5 2.0 3.1 5.0 7.0 10.9 0.6 1.0 1.5 2.0 3.1 5.0 7.0 10.9 
Instrument 
                Sebia NeoFast ND ND 1.8 ND 2.8 3.7 5.5 7.9 ND ND 1.6 ND 2.7 3.4 5.4 7.0 
Sebia NeoFast ND ND ND ND 2.6 3.3 4.6 6.9 ND ND ND 1.9 2.7 3.6 4.8 6.9 
Bio-Rad VII 0.7 1.3 1.9 2.4 3.7 5.9 8.2 12.8 0.7 1.2 2.0 2.4 3.6 5.8 8.0 12.0 
Bio-Rad VNBS ND 1.2 1.8 2.2 3.2 5.0 7.0 10.5 ND 1.3 1.4 2.1 3.1 4.9 6.9 10.6 
Bio-Rad VNBS 1 1.3 1.4 2.2 3.2 4.5 6.6 9.8 0.9 1.3 1.5 2.3 2.8 4.7 6.5 9.7 
Bio-Rad VNBS ND 0.5 1.1 1.5 2.4 4.1 6.1 9.6 ND 0.9 1.1 1.5 2.4 4.0 6.1 9.7 
Bio-Rad VNBS ND 1.1 1.5 1.8 2.8 4.6 6.2 9.7 0.9 1.2 1.3 1.7 2.9 4.5 6.0 9.8 
Bio-Rad VNBS ND 1.0 1.4 1.8 2.8 4.7 6.4 9.8 ND 1.1 1.4 1.7 2.7 4.8 6.3 9.8 
Bio-Rad VNBS 0.8 1.0 1.7 1.8 2.9 4.9 6.6 10.1 0.8 1.0 1.5 1.8 3.1 4.8 6.7 10.3 
Bio-Rad VNBS ND 0.9 1.1 1.8 2.6 4.6 6.4 10 ND 0.8 1.1 1.8 2.8 4.5 6.4 9.9 
Bio-Rad VNBS ND 0.9 1.4 1.8 2.8 4.6 6.2 9.8 ND 1.0 1.2 1.7 2.8 4.4 6.2 10.1 
Bio-Rad VNBS ND 0.9 1.2 1.8 2.7 4.3 6.3 9.6 ND 0.6 1.3 1.8 2.8 4.3 6.2 9.5 
Bio-Rad VNBS ND 0.7 1.2 1.5 2.7 4.3 6.3 9.8 ND 0.7 1.2 1.5 2.9 4.4 6.2 9.6 
Bio-Rad VNBS ND 0.9 1.3 1.8 2.8 4.6 6.5 9.8 0.8 0.9 1.3 1.8 2.7 4.5 6.4 9.7 
Bio-Rad VNBS ND 1.0 1.3 1.7 2.9 4.6 6.5 10.3 ND 1.1 1.3 1.8 2.8 4.6 6.4 10.1 
                 Table 4.2. The results for the DBS with different Haemoglobin A% concentration by instrument type for experiments 1301NHEX and 
1401NHEX. The results for each site are shown with the Hb A% of the RBC suspensions from which they were prepared.  
ND = not detected  
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Distribution 1301NHEX results (Hb A%) 1401NHEX results (Hb A%) 
DBS card batch 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 
RBC Suspension Hb A% 0.6 1.0 1.5 2.0 3.1 5.0 7.0 10.9 0.6 1.0 1.5 2.0 3.1 5.0 7.0 10.9 
ALL METHODS Hb A% 
                Number 3 13 14 13 15 15 15 15 5 13 14 14 15 15 15 15 
Mean  ~ 0.98 1.44 1.85 2.86 4.51 6.36 9.76 ~ 1.01 1.37 1.84 2.85 4.48 6.30 9.65 
SD ~ 0.22 0.27 0.26 0.31 0.58 0.75 1.25 ~ 0.22 0.23 0.26 0.27 0.56 0.69 1.25 
CV% ~ 22.95 18.65 14.21 10.88 12.94 11.82 12.83 ~ 21.99 17.02 14.23 9.35 12.52 10.98 12.99 
Minimum ND 0.50 1.10 1.50 2.40 3.30 4.60 6.90 ND 0.60 1.10 1.50 2.40 3.40 4.80 6.90 
Maximum 1.00 1.30 1.90 2.40 3.70 5.90 8.20 12.80 0.90 1.30 2.00 2.40 3.60 5.80 8.00 12.00 
VNBS ONLY Hb A% 
                Number 2 12 12 12 12 12 12 12 4 12 12 12 12 12 12 12 
Mean  ~ 0.95 1.37 1.81 2.82 4.57 6.43 9.90 ~ 0.99 1.30 1.79 2.82 4.53 6.36 9.90 
SD ~ 0.21 0.22 0.22 0.22 0.25 0.24 0.28 ~ 0.22 0.13 0.22 0.19 0.25 0.25 0.32 
CV% ~ 22.22 16.01 11.90 7.99 5.47 3.76 2.79 ~ 22.53 10.37 12.47 6.57 5.51 3.99 3.22 
Minimum ND 0.50 1.10 1.50 2.40 4.10 6.10 9.60 ND 0.60 1.10 1.50 2.40 4.00 6.00 9.50 
Maximum 1.00 1.30 1.80 2.20 3.20 5.00 7.00 10.50 0.90 1.30 1.50 2.30 3.10 4.90 6.90 10.60 
                  
Table 4.3. Descriptive statistics for the Haemoglobin A% results for DBS tested by different sites, for all methods used 
 and for the Bio-Rad vNBS HPLC instruments only. Cards were distributed from each batch to all 15 laboratories  
included in the study; the number of results returned shown excludes results returned as ND or less than (<). 
ND = not detected
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Most of the analysers failed to detect and quantitate the Hb A present in the batch 
of cards prepared from the 0.6% Hb A RBC suspension, although all except for the 
Sebia Neonat Hb Fast analysers quantitated the Hb A in the cards prepared from 
the 1.0% Hb A RBC suspension. For both exercises 1301NHEX and 1401NHEX, 
the all methods mean Hb A% value obtained from the DBS specimens showed a 
negative bias against the Hb A% result of the RBC suspension, with the exception 
of the results for the lowest Hb A% batch of cards in exercise 1401NHEX. This 
bias ranged from -2.3% to -10.5% for all instruments in exercise 1301NHEX and 
+0.8% to -11.5% in exercise 1401NHEX. 
The CV% for all instruments ranged from approximately 22% for DBS card batch 
two (RBC suspension Hb A = 1.0%) to approximately 10-13% for all instruments 
for DBS card batches five to eight (RBC suspension Hb A 3.1% to 10.9%). The 
CV% values were lower overall for the Vnbs group, where the CV% was 
approximately 22% for DBS cards prepared from a RBC suspension with a Hb A 
concentration of 1% but fell to approximately 3% at a Hb A concentration of 
10.9%. The results are illustrative rather than statistically representative for both 
the Bio-Rad VII instrument and the two Sebia Neonat Hb Fast instruments 
because of the low numbers of each. 
In both exercises, the Bio-Rad VII HPLC analyser showed an apparent over-
estimation of the Hb A% in the DBS compared to the RBC suspension. The 
converse was observed for the Sebia Capillarys Neonat Hb Fast CZE instruments, 
where the linear regression of the DBS on the RBC suspension Hb A% results 
reflected an apparent under-estimation of the Hb A% in the DBS specimens (linear 
regression of y= 0.6067x + 0.738 and y=0.571x + 0.831 for 1301NHEX and 
1401NHEX respectively). The linear regression of the results for the Bio-Rad Vnbs 
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instruments (y=0.91x + 0.02 and y= 0.90x + 0.03) reflected a small observed 
negative bias of the DBS results compared to the RBC suspension. 
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Figure 4.2. Linear regression of the 1301NHEX Haemoglobin A% results 
Legend to Figure 4.2: VNBS = Bio-Rad Variant nbs HPLC, VII = Bio-Rad Variant II HPLC,  
CZE = Sebia Neonat Hb Fast capillary electrophoresis. 
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Figure 4.3. Linear regression of the 1401NHEX Haemoglobin A% results.  
Legend to Figure 4.3: VNBS = Bio-Rad Variant nbs HPLC, VII = Bio-Rad Variant II HPLC,  
CZE = Sebia Neonat Hb Fast capillary electrophoresis.
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4.4.2 Precision 
Ten replicate analyses were made from each of two DBS cards prepared from 
RBC suspensions with Hb A concentrations from 1.0% to 10.9% (DBS card 
batches two to eight). The analyses were repeated at three sites (identified as W, 
X and Y), each using a Bio-Rad Vnbs HPLC analyser. Each site received two 
cards from each batch, identified as A and B for site W, C and D for site X and E 
and F for site Y. The results, which are shown in Table 4.4, were analysed by one-
way ANOVA firstly for variation between the DBS cards by batch and secondly 
between sites. There was no significant difference in the Hb A% results from the 
three sites (W, X and Y) at the p < 0.05 level for each Hb A concentration tested (F 
(2, 57) = 0.14 to 2.81, p = 0.069 to 0.868). However, there was a statistical 
difference at the p < 0.05 level by individual DBS card for batches two, four, seven 
and eight, prepared from RBC suspensions with Hb A concentrations of 1.0%, 
2.0%, 7.0% and 10.9% respectively. No statistical significance was seen between 
the results for card batches three, five and six (Hb A concentrations of 1.5%, 3.1% 
and 5.0% respectively). The descriptive statistics for each card showed little 
variation of clinical significance between DBS cards, regardless of the apparent 
statistical significance. The CV% for the DBS are low, ranging from 4.12% to 
5.47% for five of six cards tested from batch three (prepared from a RBC 
suspension of Hb A = 2.0%) to less than 1.0% for all cards tested from batch eight 
(Hb A% = 10.9%), showing very little variation between the replicate analyses 
prepared from the same card. These CV% values are similar to those seen in UK 
NEQAS Haematology Full Blood Count surveys for fully automated cell counters, 
where the reproducibility is regarded as very good. When the within batch variation 
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is low, very small differences in the between batch variation may become 
statistically significant. 
4.4.3 Carryover 
The experiment to determine the effect of carryover of Hb A was conducted with a 
specimen prepared to simulate a DBS eluate with a Hb A% of approximately 25% 
(equivalent to a ‘normal’ infant) analysed immediately before eluates from each of 
the eight low Hb A% specimens. The results of the carryover experiment are 
shown in Table 4.5. The carryover from a preceding specimen with a Hb A of 
approximately 25% ranged from -0.42 to 0.93%. Carryover was detected in three 
of the eight cases, prepared from RBC suspensions of 1.0%, 3.1% and 7.0% Hb 
A; the carryover therefore appeared not to be related to the concentration of the 
Hb A% in the low Hb A specimen. Taking the maximum carryover as 1% of the 
preceding specimen, a very high specimen (say 25 to 40% Hb A) preceding a 
specimen from an infant with beta thalassaemia major with an Hb A of 1.4 or 1.5% 
could be sufficient to push the beta thalassaemia major specimen over the 1.5% 
Hb A limit and this should be considered when reviewing the results. On the other 
hand, the variation in results due to carryover from a specimens with a Hb A% of 
25% was only 0.1 to 0.2% Hb A, which is the equivalent to the usual reproducibility 
seen with the instrument in the precision experiment. 
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Table 4.4. Replicate Haemoglobin A% results returned by sites W, X and Y for DBS card batches 2 to 8 (continued)  
Site Hb A% results by DBS batch and card number 
 
2A 2B 3A 3B 4A 4B 5A 5B 6A 6B 7A 7B 8A 8B 
W ND 1.3 1.8 1.6 2.3 2.2 3.2 3.1 5 5.1 7.1 6.8 10.7 10.4 
 
0.7 1.2 1.8 1.7 2.3 2.1 3.2 3.2 5.2 4.9 7 6.8 10.7 10.4 
 
0.8 1.2 1.8 1.7 2.3 2 3.2 3.1 5 4.9 6.9 6.9 10.7 10.4 
 
0.8 1.2 1.1 1.7 2.3 2.2 3.2 3.1 5 5.1 7.1 6.8 10.7 10.4 
 
0.8 1.2 1.8 1.6 2.3 2.1 3.2 3 5.1 4.9 7 6.9 10.5 10.3 
 
0.8 1.2 1.8 1.8 2.3 2.1 3.1 3.1 5.2 5 7.1 7 10.7 10.4 
 
ND 1.3 1.9 1.7 2.3 2.1 3.3 3.2 5.1 5 7 6.9 10.5 10.4 
 
0.7 1.2 1.8 1.6 2.2 2.1 3.1 3 5 5.1 7 6.8 10.6 10.4 
 
0.8 1.2 1.8 1.8 2.3 2.1 3.2 3.2 5.2 5 7 6.8 10.6 10.2 
  ND 1.2 1.8 1.7 2.3 2.1 3.1 3.1 5.2 4.9 7 6.9 10.5 10.4 
Mean 0.77 1.22 1.74 1.69 2.29 2.11 3.18 3.11 5.1 4.99 7.02 6.86 10.62 10.37 
SD 0.0488 0.0422 0.2271 0.0738 0.0316 0.0568 0.0632 0.0738 0.0943 0.0876 0.0632 0.0699 0.0919 0.0675 
CV% 6.33 3.46 13.05 4.37 1.38 2.69 1.99 2.37 1.85 1.75 0.90 1.02 0.87 0.65 
 
2C 2D 3C 3D 4C 4D 5C 5D 6C 6D 7C 7D 8C 8D 
X 0.9 1.2 1.6 1.8 2.2 2.2 3.1 3.1 5.1 5 7.1 6.8 10.5 10.7 
 
0.9 1.1 1.6 1.8 2.2 2.2 3.2 3.1 5.1 5.2 7 6.8 10.5 10.6 
 
1 1.1 1.6 1.9 2 2 3 3.2 5 5 6.9 6.9 10.5 10.7 
 
1.1 1.1 1.7 1.8 2.2 2.2 3.1 3.2 4.9 5 7.1 6.8 10.5 10.5 
 
0.9 1.2 1.6 1.8 2.2 2.1 3.2 3.2 5 4.9 7.1 6.9 10.6 10.5 
 
0.9 1.2 1.8 1.8 2.2 2.1 3.1 3.2 5 5.2 7.1 7 10.5 10.7 
 
0.9 1.3 1.8 1.9 2.3 2.3 3.2 3.3 4.9 5.2 7 6.9 10.5 10.5 
 
0.8 1.1 1.6 1.8 2.3 2.1 3 3.2 5.1 5.1 6.9 6.8 10.5 10.6 
 
0.9 1.2 1.8 1.6 2.3 2.3 3.2 3.2 5 5 6.9 6.8 10.3 10.5 
 
1 1.2 1.7 1.8 2.3 2.1 3.1 3.1 4.9 5.2 7 6.9 10.5 10.6 
Mean 0.93 1.17 1.68 1.8 2.22 2.16 3.12 3.18 5 5.08 7.01 6.86 10.49 10.59 
SD 0.0823 0.0675 0.0919 0.0816 0.0919 0.0966 0.0789 0.0632 0.0816 0.1135 0.0876 0.0699 0.0738 0.0876 
CV% 8.85 5.77 5.47 4.54 4.14 4.47 2.53 1.99 1.63 2.23 1.25 1.02 0.70 0.83 
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Table 4.4 (continued).  
 
Legend to Table 4.4: ND = not detected, SD = standard deviation, CV% = coefficient of variation.  
Site Hb A% results by DBS batch and card number 
 
2E 2F 3E 3F 4E 4F 5E 5F 6E 6F 7E 7F 8E 8F 
Y 1.3 1.2 1.6 1.8 2.3 2.2 3.2 3.2 5.1 5 7.1 7 10.4 10.6 
 
1.1 1 1.8 1.6 2.3 2 3.2 3.2 5.2 5.2 7 7.1 10.5 10.1 
 
1.1 1 1.8 1.8 2.3 2 3.2 3.2 5.1 5 6.9 7 10.5 10.5 
 
1.2 1 1.8 1.8 2.1 2.2 3.1 3.2 5.1 5 7 6.9 10.3 10.6 
 
1.1 1.1 1.6 1.8 2.2 2.1 3.2 3.2 4.9 5.1 6.9 7.1 10.3 10.6 
 
1.1 1 1.8 1.8 2.2 2.2 3 3.1 5.1 5 7 7 10.4 10.6 
 
1.3 1.3 1.7 1.9 2.3 2 3.2 3.3 5 5.1 6.9 7.1 10.4 10.6 
 
1.2 1.2 1.6 1.8 2.2 2.1 3.1 3.1 5.1 5 6.9 7 10.7 10.7 
 
1.2 1.2 1.8 1.8 2.3 2.1 3.2 3.2 5 5.2 7 6.9 10.3 10.3 
 
1.2 1.2 1.7 1.8 2.3 2.1 3.1 3.1 5 5.2 6.9 6.9 10.4 10.5 
Mean 1.18 1.12 1.72 1.79 2.25 2.1 3.15 3.18 5.06 5.08 6.96 7 10.42 10.51 
SD 0.0789 0.1135 0.0919 0.0738 0.0707 0.0816 0.0707 0.0632 0.0843 0.0919 0.0699 0.0816 0.1229 0.1792 
CV% 6.68 10.14 5.34 4.12 3.14 3.89 2.24 1.99 1.67 1.81 1.00 1.17 1.18 1.71 
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Carryover from specimen with Haemoglobin A% ≈ 25% 
DBS batch 1 2 3 4 5 6 7 8 
H1 26.5 26.4 26.4 26.5 26.4 26.3 26.5 26.3 
H2 26.2 26.5 26.4 26.5 26 26.3 26.2 26.3 
H3 26.4 26.3 26.3 26 26.5 26.5 26.3 26.6 
L1 0 1.2 1.6 1.9 3.1 5.1 6.9 10.3 
L2 0 1.1 1.4 2.1 3 5 6.8 10.4 
L3 0 1 1.6 2 3 4.9 6.9 10.3 
L1-L3 0 0.2 0 -0.1 0.1 0.2 0 0 
H3-L3 26.4 25.3 24.7 24 23.5 21.6 19.4 16.3 
% carryover 0.00 0.79 0.00 -0.42 0.43 0.93 0.00 0.00 
 
       
 
 
Table 4.5. Carryover calculated from a preceding specimen with a Haemoglobin A concentration of approximately 25%. 
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4.5 Discussion 
The NHS STP has suggested a Hb A of 1.5% or less as indicative of probable 
beta thalassaemia major in newborn infants with a gestational age of greater than 
thirty-two weeks, supported by evidence from a major prospective and 
retrospective study of infants tested at four screening centres in England (Streetly 
2013). The experiments described in this chapter attempted to evaluate the 
performance of instruments used routinely in newborn haemoglobinopathy 
screening in the UK prepared from RBC suspensions with Hb A concentrations 
from 0.6% to 10.9%. 
Two instruments designed for newborn DBS screening for haemoglobinopathies 
were used: the Bio-Rad Variant™ Newborn Screening (Vnbs) HPLC analyser with 
the sickle cell short programme and the Sebia Capillarys Neonat Hb Fast™ 
system. In addition, one HPLC analyser designed for adult haemoglobinopathy 
screening, the Bio-Rad Variant II analyser with the beta thalassaemia short 
programme, was used by one participating laboratory as this was the method used 
for their secondary investigation of positive screens detected by their primary 
screening method. 
In summary, the results for all instruments demonstrated good linearity, the Bio-
Rad VII apparently over-estimated the Hb A% in the DBS specimens compared to 
the RBC suspensions from which they were prepared, whereas the Sebia Neonat 
Hb Fast system under-estimated Hb A% in the DBS specimens compared to the 
cell suspensions. The best correlation between the DBS and the RBC suspension 
Hb A% results was seen with the Bio-Rad Vnbs instruments. Most instruments 
failed to detect or quantitate Hb A at a concentration below 1% and the Sebia 
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Neonat Fast instruments only reliably detected and quantitated Hb A% at 
concentrations of above 2.0%. Carryover from a preceding DBS simulating a 
sample from a ‘normal’ infant with an Hb A of 25% was not significant using the 
Bio-Rad Vnbs instrument and could be accounted for by the uncertainty of the 
measurement. A limitation of the experiment was that it did not test the carryover 
from a preceding DBS with much higher Hb A%, e.g. 40%, as might be found with 
a sample from a very post mature infant or a sample contaminated with a 
substantial amount of adult blood (or even of adult blood taken in error). The 
carryover and reproducibility experiments were also only performed using Bio-Rad 
Vnbs instruments, because of the limited number of low Hb A% DBS cards 
available, which was a weakness and would warrant repetition with Sebia Neonat 
Hb Fast instruments. 
Verification of a manufacturer's claims for an instrument is required before it is 
used in the laboratory for diagnostic testing. There are a number of guidelines and 
recommendations available that are applicable to this process (e.g. Bourner 2014, 
Briggs 2014, Stephens 2015, CLSI EP-17-A2, CLSI EP-6A, CLSI EP 15-A2, CLSI 
EP5-A2); although these are mostly relevant to the evaluation of automated cell 
counting instruments they contain principles relevant to any quantitative 
procedure.  
Both instruments are described as qualitative rather than quantitative by their 
manufacturers and no LOD is specified for Hb A for either. The detection and 
quantitation of Hb A by the Bio-Rad Vnbs analyser in all the batches of DBS cards 
except the batch prepared from a red cell suspension of 0.6% Hb A is comparable 
to the stated LOD of 1% for Hb fractions S, C, D, E. The detection of Hb A by the 
Sebia Neonat Hb Fast system was not reliable for DBS cards prepared from red 
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cell suspensions with Hb A of 2% or less, suggesting that the system was not as 
sensitive in detecting and quantitating Hb A at very low levels as the Vnbs. A 
limitation of the study is that only two Neonat Hb Fast instruments were available 
to take part and hence this observation would benefit from additional work. The 
Neonat Hb Fast system has been shown to be comparable to the Bio-Rad Vnbs 
HPLC system when testing both liquid umbilical cord blood samples (Wolff 2012) 
and capillary DBS samples (Murray 2011). However, the evaluation of the Sebia 
Neonat Hb Fast system using liquid umbilical cord blood samples noted three 
discrepancies between the results from the CZE and HPLC systems, one of which 
was a sample with Hb A of 1.4% by HPLC that was not detected by CZE (Wolff 
2012). This is in agreement with the results from the Sebia Neonat Hb Fast 
systems tested in this study. When the quantitation of different Hb fractions in 
patients’ DBS samples using the Sebia Neonat Hb Fast system was compared 
with the Bio-Rad Vnbs analyser, the quantitation of Hb A% was good (correlation 
of y = 0.75x + 4.54, R2=0.87) (Murray 2011) but showed a similar under-estimation 
of Hb A% by the Sebia Neonat Hb Fast as seen in the experiment described in this 
chapter, where the correlation was y = 0.61x + 0.74, R2=0.96, and y = 0.57x + 
0.83, R2=0.97. The design of the studies was different in that the evaluation with 
patients’ DBS (Murray 2011) examined the correlation between the Sebia Neonat 
Hb Fast and the Bio-Rad Vnbs using the same DBS samples, whereas the 
experiment in this chapter compared the results of the DBS samples tested by the 
Sebia Neonat Hb Fast with the ‘expected results’ of the red cell suspensions from 
which the DBS had been prepared. The ‘expected’ results of the red cell 
suspensions had been assayed using a Bio-Rad Vnbs. The apparent difference in 
the results obtained using the Sebia Neonat Hb Fast system is most likely to be 
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due to a difference in the method and the algorithms used by the two instruments 
for calculation of the peak areas (Murray 2011). 
The difference in the performance between the Bio-Rad and the Sebia newborn 
screening analysers could lead to additional infants being given a screen positive 
result for beta thalassaemia major using a cut-off of 1.5% if they were tested using 
the Sebia Neonat Hb Fast instrument. This is 'failing safe' but might require an 
adapted strategy for follow-up, depending on the screening instrument used. This 
could entail a simple confirmation of screen positives by a second biochemical 
method or by DNA analysis. Screening is not intended to be 100% effective but 
the level of technical error should be confined to the statistical uncertainty around 
the cut-off; the risk of an increased number of false positives if reported without 
consideration of the confounding factors could cause unnecessary anxiety for 
parents. In the major retrospective and prospective study to examine the 
appropriateness of the 1.5% cut-off, Streetly noted that a limitation of the work was 
that it was not a full country survey and more work is in hand to address this 
(Streetly 2013). There was no information given on the methodology used for Hb 
A% in the study. 
The instruments used in newborn screening are designed for qualitative screening 
only, although a percentage quantitation is given. It will therefore rest with the 
laboratory to validate the instrument for this purpose. The challenge for the 
laboratories will be to obtain sufficient samples at or around the critical cut-off 
Hb A concentration: there were just 268 'Hb F only' infants born in the UK in the 
first ten years of the implementation of universal newborn screening (NHS Sickle 
Cell and Thalassaemia Screening Data Report 2015/16: trends and performance 
analysis, 2017). This low number will make it difficult for laboratories to rely on 
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patients’ specimens for validation and verification of analysers. It may be that UK 
NEQAS Haematology could provide support for laboratories by providing sets of 
cards at a range of Hb A%, prepared in a similar fashion to those used in this 
study and kept in storage. The cards would need retesting and renewal at intervals 
to ensure the quality was adequate.  
The inclusion of simulated beta thalassaemia DBS cards in the repertoire of cases 
sent out as part of the EQA scheme would allow better performance assessment 
of the laboratories; however, the presence of Hb A2 in the adult blood used in the 
studies described is a confounding factor and if used as EQA material the source 
and purpose of the case(s) would have to be made clear in the instructions given 
to participants. At present, UK NEQAS Haematology does not request the 
percentage of any Hb fraction present in the cases distributed in the Newborn 
Sickle Screening scheme and this would require modification to accommodate 
additional low Hb A% cases to performance assess the detection of infants with 
beta thalassaemia major.
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Chapter 5: The fitness for purpose of UK NEQAS 
Haematology scoring methods for the assessment of 
Haemoglobin A2 performance
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5.1 Aim 
To examine the effectiveness of current UK NEQAS Haematology performance 
scoring methods for the detection of out-of-consensus Hb A2 performance. 
5.2 Introduction 
External quality assessment (EQA) is a means by which the laboratory 
demonstrates on a regular basis that its results are comparable to those produced 
by other testing sites and that they conform to the standards expected for patient 
care (Libeer, 2001; Plebani, 2005; Miller, 2011). The use of a performance score 
and acceptable performance specifications ensures the objective evaluation and 
reporting of large numbers of participants’ results by the EQA provider. Measures 
of performance assessment are required for an accredited EQA scheme (ISO 
17043). 
Key procedures in the assessment of EQA results are the assignment of a target 
value and the allowed limits of acceptable performance (Fraser, 1999). The target 
value may be assigned using a higher-order CRM or reference method, although 
this requires the EQA material to be commutable and traceable to a CRM or 
method (Thienpont, 1995; Uldall, 1996; Thienpont, 2003; Vesper, 2009). For most 
measurands, there is no reference material or method available and the target 
value in these circumstances may be determined from the formulation of the 
material (e.g. the known ‘weighed-in’ quantity of a measurand), the results of a 
panel of expert laboratories or the consensus mean or median of the results from 
the participating testing sites after the removal of outlying results (ISO 13528; 
Jones, 2017b). It has been estimated that 90% of EQA providers use the 
consensus of participants’ results as the target value (Wong, 2005). There are 
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several alternatives in the choice of consensus target value, depending on the 
commutability of the survey material, the range of methods in use and the numbers 
of participants registered. Where the survey material is commutable, it is possible 
to use the ‘all laboratory consensus mean’, which makes no differentiation between 
the instruments or methods used for analysis and demonstrates the comparability 
between different analysers as well as individual laboratories. However, the use of 
a consensus mean of data from more than one instrument or method favours the 
method with the greatest number of participants and may make their performance 
appear superior in any ‘state-of-the-art’ comparison and the mean of the peer 
group means may be used to give an equal weight to all instrument types in the 
group (Van Houcke, 2012). The median may also be used as a robust estimator of 
the consensus target value and the est. SD is calculated from the IQR divided by 
1.349 (Tukey, 1977). Since the median is a robust estimator, it is not necessary to 
trim the data to remove outliers. 
Where there is a demonstrated lack of commutability of the survey material the 
target value for EQA performance assessment is generally derived from the 
trimmed peer group mean, the peer group being described by the method or 
analyser type. A minimum of twenty participants is the standard number to form a 
peer group in UK NEQAS Haematology for statistical robustness, although it has 
beem suggested that peer groups of as few as six participants may be used 
(Coucke, 2012). UK NEQAS survey material used for the Abnormal Haemoglobins 
scheme is commutable for the methods in use at the time of writing, as 
demonstrated in the study described in Chapter Three. 
There are a number of different approaches that have been devised to measure 
participants’ performance in EQA. These may be grouped into methods based on: 
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 Passing or failing against a published criterion of acceptable performance, 
 The use of a ‘look-up’ principle where a participation score is allocated on 
the basis of how well the result conforms to the target or clinical outcome. 
 The calculation of a score based on a continuous scale such as the z-score 
(Ley and Ezer, 1974; Coucke, 2012).  
How these are applied to the assessment of participants’ performance differs 
according to the EQA scheme design. In many cases, especially where the score 
is used for ensuring the laboratory is licensed to practise, the score is reported for 
a single distribution only and there is no calculation of a cumulative score over a 
period of time. An example of this approach in haemoglobinopathy EQA is the 
system used by the College of American Pathologists where the result submitted is 
reported in terms of the distance from the target value and whether it is within 
upper and lower acceptable performance limits (CAP, 2017). 
The international standards ISO 13528 and ISO 17043 recommend the use of the 
z-score or similar derivatives as a measure of how far the participant’s result is 
from the centre of the distribution or target value, as a multiple of the dispersion of 
the data or the scale (ISO 13528, ISO 17043). A basic z-score describes how 
many standard deviations from the target value the result is; a score of equal to or 
greater than 3.0 is regarded as the action signal for unsatisfactory performance 
and a score of between 2.0 and 3.0 as a warning indicator (ISO 13528). Given a 
normal distribution of results from a group of competent laboratories, approximately 
0.3% would be expected to have a z-score above 3.0 and approximately 5% of 
participants a z-score of between 2.0 and 3.0 (Coucke, 2017). The use of a z-score 
and statistically determined performance limits focuses on the technical aspects of 
EQA performance and facilitates a state-of-the-art comparison of performance 
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between laboratories and methods. It is important to understand what the 
performance limits mean in terms of patient safety, especially around the cut-off 
points for clinical decision-making such as screening for beta thalassaemia 
carriers. The use of performance limits determined from published biological 
variation data has been described by a number of authors (Panteghini, 2015, 
Sandberg, 2015) and analytical goals for Hb A2 have suggested 7% as a minimum 
goal for the TE as a compromise between biological variation, expert opinion and 
clinical need (Mosca, 2013). This TE represents a variation in absolute Hb A2 
measurement of approximately 0.25% for a ‘true’ Hb A2 value of 3.6%. Other 
authors have recommended that duplicate measurements of Hb A2 should be 
within 0.2% of Hb A2 of the final result (Stephens, 2015). 
The UK NEQAS Haematology performance assessment and scoring system was 
initially introduced in 1996 for the assessment of automated cell counting schemes 
(England, 1995) and later adapted for other schemes, including the 
haemoglobinopathies. UK NEQAS Haematology uses a consensus trimmed mean 
as target value: data is made robust to the influence of outliers by 10% trimming 
(5% of results from the top and bottom), followed by log transformation to give an 
approximately symmetrical distribution before calculation of the consensus trimmed 
mean value. Depending upon the scheme design, the consensus mean may be the 
all laboratory trimmed mean (ALTM), the method trimmed mean (MTM) or 
individual instrument group (SMTM). A number of methods for outlier removal have 
been described (Algorithm A of ISO 13528; Grubbs, 1969; Dixon, 1950; Tukey, 
1977; Rousseeuw, 1993; Wilrich, 2007) although there is little difference in the 
methods used where the participant group is greater than twenty (Coucke, 2012).  
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UK NEQAS Haematology uses a z-score, which it terms the deviation index (DI) to 
describe how far the individual participant’s result is from the target value. The DI 
relates the difference between the participant’s result and the target to a robust 
estimator of the dispersion of the data, the historic standard deviation (HSD) 
(Tukey, 1977; Healy, 1979), which is calculated from the results of the six most 
recent distributions, excluding the current one. The use of a robust estimator such 
as the HSD is to smooth the variation in the SD from one distribution to another 
and its consequent impact on the DI.  
The UK NEQAS Haematology analytical performance score is a cumulative, 
retrospective indicator of performance calculated from the sum of the DI values for 
the most recent six specimens containing the analyte after removal of the 
arithmetic sign (the ‘absolute’ DI value). The statistical performance limits are 
adjusted by including a multiplier in the score that weights the DI values so that a 
score of equal to or greater than 100 is classified as persistent unsatisfactory 
performance in any UK NEQAS Haematology scheme (UK NEQAS Participants’ 
Manual, 2017). The multiplier varies by analyte and can be used to adjust the 
sensitivity of the scoring procedure. To avoid unduly penalising a participant for a 
single ‘blunder’, e.g. the transposition of results at data entry that could result in 
high DI values not related to analytical performance, any DI value greater than 3.5 
is truncated to 3.5 before calculation of the analytical performance score. The 
untruncated DI is still reported in the participant’s report. The UK NEQAS 
Haematology performance tariff automatically refers any score of equal to or 
greater than 100 for review; scores between 80 and 100 are reported to the 
participating laboratory as borderline and scores below 80 as satisfactory. Long-
term, retrospective scoring of participants’ performance is an established feature of 
  
157 
EQA assessment but it requires frequent survey distributions to make the 
assessment effective within a clinically relevant timeframe. This is a challenge in 
haemoglobinopathy EQA and frequency may only be sufficient in large schemes. 
Within Europe, the frequency of distribution of EQA in the haemoglobinopathies is 
generally relatively infrequent (Vives-Corrons, 2014) making cumulative 
performance scoring impractical. In these situations, schemes are more likely to 
assess performance specimen by specimen, without a formal monitoring of 
performance trends. 
UK NEQAS Haematology uses the Hb A2 method trimmed mean or MTM as the 
target value for performance assessment, largely for historical reasons. The two 
main method groups in use for performance assessment at the time of writing were 
CZE and HPLC, for which performance is scored by method group. Although not 
used for performance assessment by UK NEQAS, the SMTM, calculated by 
individual instrument type, is reported for information for analysers with more than 
twenty instruments registered. Instrument manufacturers and laboratory managers 
express a wish to see the SMTM value as they feel that this gives a like-for-like 
comparison on the technical performance of their analyser type (UK NEQAS 
Haematology unpublished Steering Committee papers, 2015). 
The NHS STP’s algorithm for the identification of a beta thalassaemia carrier 
makes no allowance for the analytical method used; therefore, the use of the ALTM 
may be a more appropriate target against which to assess performance than the 
MTM. The purpose of the study described is to review UK NEQAS Haematology’s 
participants’ data to investigate the effectiveness of the current scoring system for 
the assessment of performance. Of particular concern is the extent to which an 
individual, ‘one-off’ EQA error, which could potentially contribute to an incorrect 
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diagnosis had it occurred with a patient’s specimen, might go undetected by the 
performance scoring process and whether adjustments to the scoring system could 
be made to improve the detection of such errors. The study will review the 
relationship between the performance score and individual DI results, the 
appropriateness of the target value used for performance assessment, what a DI 
value means in terms of absolute Hb A2 measurement and the impact of adjusting 
the multiplier on the numbers of participants identified as unsatisfactory 
performers. 
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5.3 Methods 
5.3.1 Data analysis 
UK NEQAS Haematology participants’ data was analysed using a bespoke 
external quality assessment (EQA) data management system provided by KPMD 
Ltd (Sheffield, UK) for the calculation of the ALTM, the MTM and the SMTM values, 
the DI and the analytical performance scores as part of the regular UK NEQAS 
Haematology data analysis and reporting process (UK NEQAS Haematology 
Participants’ Manual, 2017). 
In brief, trimmed participants’ data (10% of results in total, i.e. 5% top and bottom) 
is log-transformed. A robust standard deviation (RSD) - the historical SD (HSD), 
calculated for the data set from the most recent six specimens (not including the 
current distribution), is used to smooth the effect of the variation in the dispersion 
of data from one distribution to another on the DI (Healy, 1979). 
The deviation index (DI) is calculated using log-transformed data as shown in 
Equation 5.1. At the time of writing, the MTM is used as the target value (   ). 
    
        
    
 
Equation 5.1. Calculation of the Deviation Index (DI) 
Where      is the participant’s result 
    is the trimmed mean (ALTM, MTM or SMTM, as 
appropriate) 
     is a robust SD (the HSD) 
The DI is is used to calculate the UK NEQAS analytical performance score: the DI 
values for the most recent six results returned by a participant are summed after 
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removal of the arithmetical sign and truncation of DI values to a maximum of 3.5. 
The sum of the six values is multiplied by nine for Hb A2 at the time of writing, to 
weight the score so that an analytical performance score equal to or greater than 
100 is deemed indicative of persistent unsatisfactory performance. The multiplier 
value of nine was arrived at empirically to place approximately 5% of participants in 
the persistent unsatisfactory performance category at any one survey. This is 
deemed a manageable number and allows the scheme to focus support for 
adverse performance on the laboratories with the greatest problems. Adjustment of 
the multiplier allows the sensitivity of the scoring to be altered. 
Additional statistical analysis for the study was undertaken using STATA 14 (Stata 
Corp, Texas, USA) and Microsoft Excel 2010 (Microsoft Corporation, California, 
USA). 
5.3.2 Data used for the study, distributions 1304AH to 1603AH 
The results of thirty-four survey material pools performance assessed for Hb A2 in 
eighteen surveys 1304AH to 1603AH were used in the study. The majority of the 
results (more than 95%) had been entered by the participants directly into the UK 
NEQAS Haematology Results service and had not been corrected for data entry 
errors. The remainder were entered by UK NEQAS Haematology staff using 
double-data entry. The raw data returned was edited before analysis in the study to 
remove blank returns, partial data returns and results from manual methods. All 
data was anonymised before use. 
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5.3.3 The distribution of Deviation Index results by analytical performance 
score 
The results were sorted by survey material pool into nine categories according to 
their absolute DI value (equal to or greater than three, equal to or greater than two 
but less than three, or less than two) and the laboratory's analytical performance 
score for Hb A2 (equal to or greater than 100, equal to or greater than 80 but less 
than 100, or less than 80).  
The Hb A2 results for each specimen in each of the nine categories were screened 
to identify ‘blunders’ and potential misdiagnoses. ‘Blunders’ in EQA are erroneous 
results that arise as a consequence of reporting data for the EQA scheme in a 
format that is different from that used by the laboratory for patients’ results, e.g. the 
entry of a result in a different order from usual, the conversion of results to a 
different unit of measurement for submission to the scheme or a typographical data 
entry error for results that would normally be transmitted automatically via a 
computer interface. For the purpose of this study, a ‘blunder’ was defined as a 
result so out-of-consensus that it was unlikely to be a Hb A2 measurement, 
identified by scrutiny of each out-of-consensus result in the context of the expected 
result for the specimen and the others in the survey in which it was distributed. 
Based on these criteria, any Hb A2 result less than 0.5% or greater than 10% was 
reviewed as a potential blunder, such as the transposition of Hb A2 and Hb F or 
Hb S results or major clerical errors. 
Potential misdiagnoses were defined as results that could lead to a clinically 
incorrect interpretation had they been reported on a patient’s sample, using the 
NHS STP’s cut-off value for Hb A2 of greater than 3.5% as indicative of a beta 
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thalassaemia carrier. The ALTM was used as the ‘correct’ value for this 
comparison. 
5.3.4 The use of different target values for performance assessment 
Four different target values were calculated for each survey material pool. Three 
were available from the UK NEQAS Haematology database (the ALTM, MTM and 
SMTM). The fourth, called the ‘Adjusted ALTM’, was calculated for each survey 
material pool as the mean of the sub-method means for the instrument groups; 
calculated to eliminate the potential impact of different numbers of instrument 
groups on the calculation of the ALTM. 
The difference between each result in the study and each of the four means was 
calculated, using the ALTM and adjusted ALTM for the survey material pool and 
the MTM and SMTM appropriate for the method principle (HPLC or CZE) and the 
analyser. The mean and SD of the differences against each target were calculated 
by analyser group for all results in the study. 
5.3.5 Calculation of performance scores using different multiplication 
(weighting) factors 
All results and instrument groups for distributions 1304AH to 1603AH were 
rescored against the usual MTM target values using multipliers of ten, eleven and 
twelve and the numbers of persistent unsatisfactory performance scores counted 
by the multiplier value. The impact of different multipliers on the performance 
scores of participants with out-of-consensus results was assessed.  
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5.4 Results 
5.4.1 Data used for the study, distributions 1304AH to 1603AH 
Each survey material pool contained Hb A, Hb A2 and Hb F with ALTM Hb A2 
results from 1.47% to 5.03%. The numbers of results for each pool ranged from 
289 to 332. From 11,607 initial returns, a total of 10,463 Hb A2 results were used in 
the study. The most commonly represented HPLC analyser was the Bio-Rad 
Variant II running either the beta thalassaemia short programme or the dual kit 
programme. The ‘miscellaneous HPLC’ group included Agilent 1100 and 1200, 
Menarini HA8140, Kontron, Shimadzu LC10 and LC20, Varian Prostar, Waters and 
Zivak HB100 analysers and laboratories that had not provided the HPLC analyser 
model. The majority of CZE analysers were Sebia Capillarys; a small number of 
results were returned from a Beckman Coulter P/ACE MDQ analyser and a Helena 
V8 analyser. For the purposes of this study, all Sebia CZE analysers were 
analysed as a single group because of the negligible difference between the 
results produced by the three analysers, as shown in Chapter Two (Figure 2.11). 
The total numbers of results by analyser group are shown in Table 5.1. 
5.4.2 The distribution of Deviation Index results by analytical performance 
score 
The distribution of absolute DI values by score and survey material pool is shown 
in Table 5.2.  
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Method group Sub-method group No.of results % 
Capillary zone 
electrophoresis 
Sebia  1761 16.8 
Miscellaneous CZE 40 0.4 
Total CZE 1801 17.2 
High 
Performance 
Liquid 
Chromatography 
Bio-Rad D10 943 9.0 
Bio-Rad Variant Classic 331 3.2 
Bio-Rad Variant II Beta thal short 
programme 
2245 21.5 
Bio-Rad Variant II Dual kit programme 815 7.8 
Menarini HA8160 1165 11.1 
Trinity Primus 2 629 6.0 
Tosoh G7 712 6.8 
Tosoh G8 1271 12.1 
Miscellaneous HPLC 551 5.3 
Total HPLC 8662 82.8 
TOTAL  10463  
 
Table 5.1. The numbers of results used in the study by method and  
sub-method group 
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Specimen 
ALTM Hb 
A2 (%) 
N DI 
Score 
Blunders 
Potential 
misdiagnoses >100 <100>80 <80 
1304AH1 
  
289 
>3 1 2 4 1 4 
4.28 >2<3 0 1 7 0 3 
  <2 5 11 258 0 0 
1304AH2 
  
289 
>3 1 1 0 0 1 
2.85 >2<3 1 2 1 0 1 
  <2 4 11 268 0 0 
1305AH3 
  
292 
>3 2 1 6 0 3 
2.15 >2<3 1 3 6 0 0 
  <2 7 8 258 0 0 
1306AH1 
  
296 
>3 0 2 2 2 1 
2.71 >2<3 1 2 2 0 0 
  <2 1 11 275 0 0 
1306AH2 
  
296 
>3 0 2 1 0 0 
2.28 >2<3 1 2 4 0 0 
  <2 1 11 274 0 0 
1401AH1 
  
297 
>3 1 0 0 0 0 
2.81 >2<3 3 3 2 0 0 
  <2 3 7 278 0 0 
1401AH3 
  
297 
>3 5 2 2 0 0 
2.4 >2<3 1 2 3 0 0 
  <2 1 6 275 0 0 
1402AH1 
  
307 
>3 1 1 0 0 0 
2.57 >2<3 1 1 4 0 0 
  <2 1 9 289 0 0 
1402AH3 
  
307 
>3 0 1 3 0 3 
3.99 >2<3 3 3 7 0 3 
  <2 0 7 283 0 6 
1403AH1 
  
308 
>3 2 1 3 1 0 
2.35 >2<3 0 4 15 0 0 
  <2 1 9 273 0 0 
1403AH2 
  
308 
>3 3 5 10 2 0 
1.97 >2<3 0 5 19 0 0 
  <2 0 4 262 0 0 
1404AH2 
  
310 
>3 0 2 2 1 0 
2.66 >2<3 2 4 9 0 0 
  <2 2 7 282 0 0 
1404AH3 
  
309 
>3 2 3 3 1 1 
2.35 >2<3 0 3 8 0 0 
  <2 2 7 281 0 0 
Table 5.2 Numbers of Haemoglobin A2 results by absolute Deviation Index (i.e.with 
arithmetical sign removed) and performance score. (Continued on next page) 
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Specimen 
ALTM Hb 
A2 (%) 
N DI 
Score 
Blunders 
Potential 
misdiagnoses >100 <100>80 <80 
1405AH1 
  
306 
>3 3 1 0 0 2 
4.31 >2<3 1 0 15 0 1 
  <2 4 22 260 0 0 
1405AH2 
  
304 
>3 5 5 18 1 0 
1.47 >2<3 0 6 28 0 0 
  <2 3 12 227 0 0 
1406AH1 
  
308 
>3 4 1 3 1 0 
2.31 >2<3 4 9 5 0 0 
  <2 3 9 270 0 0 
1406AH2 
  
308 
>3 5 3 0 0 1 
2.31 >2<3 4 6 5 0 0 
  <2 2 10 273 0 0 
1406AH3 
  
307 
>3 7 2 1 0 1 
2.13 >2<3 1 7 2 0 0 
  <2 3 10 274 0 0 
1501AH1 
  
311 
>3 2 1 1 0 0 
2.71 >2<3 1 2 4 0 0 
  <2 6 18 276 0 0 
1502AH1 
  
305 
>3 1 2 1 0 2 
5.03 >2<3 3 3 13 0 0 
  <2 7 19 256 0 0 
1502AH2 
  
305 
>3 3 6 10 0 2 
2.08 >2<3 4 2 12 0 0 
  <2 4 16 248 0 0 
1502AH3 
  
303 
>3 8 9 14 0 1 
1.58 >2<3 1 6 26 0 0 
  <2 2 9 228 0 0 
1503AH1 
  
305 
>3 1 2 0 1 0 
2.59 >2<3 3 4 8 0 0 
  <2 5 15 267 0 0 
1504AH1 
  
304 
>3 1 2 0 0 1 
2.78 >2<3 3 1 0 0 0 
  <2 8 9 280 0 0 
1504AH2 
  
303 
>3 6 4 0 0 1 
2.24 >2<3 3 1 5 0 0 
  <2 3 7 274 0 0 
1505AH2 
  
311 
>3 0 0 0 0 0 
2.48 >2<3 4 3 3 0 0 
  <2 7 10 284 0 0 
 
Table 5.2 (Continued) 
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Specimen 
ALTM Hb 
A2 (%) 
N DI 
Score 
Blunders 
Potential 
misdiagnoses >100 <100>80 <80 
1505AH3 
  
310 
>3 2 2 2 1 1 
1.98 >2<3 3 3 9 0 0 
  <2 6 8 275 0 0 
1506AH2 
  
314 
>3 4 0 3 0 2 
2.45 >2<3 5 2 5 0 0 
  <2 2 5 288 0 0 
1506AH3 
  
312 
>3 4 0 1 1 0 
2.52 >2<3 4 4 4 0 0 
  <2 3 3 289 0 0 
1601AH1 
  
326 
>3 2 0 1 0 1 
2.45 >2<3 6 5 5 0 0 
  <2 4 5 298 0 0 
1601AH2 
  
326 
>3 6 1 1 0 1 
2.39 >2<3 1 1 0 0 0 
  <2 5 8 303 0 0 
1602AH1 
  
332 
>3 1 2 2 0 0 
2.37 >2<3 4 4 7 0 0 
  <2 5 11 296 0 0 
1602AH3 
  
328 
>3 3 4 6 0 2 
1.94 >2<3 5 8 27 0 0 
  <2 2 4 269 0 0 
1603AH2 
  
330 
>3 0 2 6 0 3 
2.45 >2<3 3 2 9 0 0 
  <2 7 7 294 0 0 
TOTALS 
  
10463 
 
282 511 9670 13 48 
  
 
2.7% 4.9% 92.4% 0.1% 0.5% 
 
Table 5.2 (Continued )2 
  
                                                          
2
 Table 5.2 shows the distribution of Haemoglobin A2 results by Deviation Index (DI) and performance score 
for surveys 1304AH to 1603AH, with the number of probable blunders and potential misdiagnoses. DI values 
are shown with the arithmetical sign removed. 
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A total of 264 / 10,463 (2.4%) results had DI values of greater than 3.0, of which 
eighty-six had an unsatisfactory performance score of equal to or greater than one 
hundred. Of the remaining 178 results with DI values greater than 3.0, seventy-two 
had a borderline performance score (score of eighty to one hundred) and 106 had 
a satisfactory score of less than eighty. Thirteen results (0.1% of the 10,463 results 
in the study) were classified as probable ‘blunders’ and all had DI values greater 
than 3.0. The causes of the ‘blunders’ were typographical errors on the part of the 
participant, e.g. entering 2.5% as 205%, and the transposition of the Hb A2 result 
for another parameter, e.g. Hb A%, Hb S% or Hb F%. A total of 470 (4.5%) of the 
results in the study had DI values of between 2.0 and 3.0 and 9,729 (92.7%) had 
DI values of less than 2.0. There were no blunders identified with DI values of less 
than 3.0. These results are summarised in Table 5.3. 
Forty-eight results were identified as potential misdiagnoses, i.e. a sample with an 
ALTM of less than 3.5% reported as greater than 3.5% and vice versa. Table 5.4 
shows the summary of the distribution by performance score and absolute DI value 
of the forty-eight results. Thirty-five of the potential misdiagnoses had a DI value 
greater than 3.0; seven had DI values between 2.0 and 3.0 and six DI values of 
less than 2.0. Only one of the thirteen potential misdiagnoses with a DI value of 
less than 3.0 had a score of greater than one hundred and would have triggered an 
automatic performance review. 
Thirty-six of the potential misdiagnoses had DI values greater than 3.0 or 
performance scores greater than one hundred, so would be easy to screen out for 
review. Of the remaining twelve results, six had absolute DI values between 2.0 
and 3.0; one of these results was a ‘false positive’, i.e. a Hb A2 result greater than 
3.5% reported for a sample with a normal ALTM Hb A2 value and five were ‘false 
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negatives’, i.e. normal results reported for samples with target ALTM Hb A2 values 
greater than 3.5%. Six results had absolute DI values less than 2.0 and 
performance scores less than eighty (in the red shaded area of Table 5.4), which 
meant that they would not be identified for further investigation either from a raised 
or borderline score or DI value. All six were from the same survey material pool 
(1402AH3, ALTM Hb A2 value 3.99%) and were ‘false negatives’, with Hb A2 results 
of 3.4 to 3.5%. The DI values ranged from -1.46 to -1.83 and all were HPLC users. 
  
  
170 
 
DI N 
Score 
Blunders Potential 
misdiagnoses >100 <100>80 <80 
>3 264 (2.4%) 86 72 106 13 (0.1%) 35 
>2<3 470 (4.5%) 77 114 279 0 7 
<2 9729 (92.7%) 119 325 9285 0 6 
TOTAL 10463 282 511 9670 13 48 
 
Table 5.3. Summary of results by absolute DI values and analytical performance 
scores with the numbers of blunders and potential misdiagnoses 
 
 
DI 
Score 
>100 <100>80 <80 
>3 5 13 17 
>2<3 1 2 4 
<2 0 0 6 
TOTAL 6 15 27 
 
 
Table 5.4. Summary of absolute DI values and corresponding analytical 
performance scores for results that would represent a potential misdiagnosis if they 
were patients’ samples.3  
  
                                                          
3
 The grey shaded area shows the results that might escape review based on a borderline analytical 
performance score and DI value. The red area results that had both a satisfactory score and DI value. The 
yellow shaded area shows specimens that would be easily identified for follow up because of a raised score 
(>100) or DI (>3.0). 
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Figures 5.1 to 5.6 show the distribution of the DI values by performance score for 
the results of six survey material pools (1304AH1, 1305AH3, 1402AH3, 1502AH1, 
1502AH2 and 1601AH1) relative to the persistent unsatisfactory performance and 
borderline unsatisfactory performance action points.  
In each Figure, results with a score greater than one hundred represent persistent 
unsatisfactory performance, calculated from the most recent six results. Where the 
DI for the current survey falls close to zero (or is at least less than 2.0), the 
performance is satisfactory for the current survey and may indicate a performance 
issue that has been resolved, as the score ‘lags’ in its responsiveness to corrective 
actions. Performance scores above one hundred with DI values greater than +2 or 
less than -2 for any survey indicate persistent unsatisfactory performance that has 
not been resolved. Between one and nine laboratories fell into this category at 
each distribution; since the scores are cumulative, some of these cases may 
represent the same participant from one survey to the next. In this case, the 
performance issues will be under review and investigation. 
Results with an analytical performance score between eighty and one hundred are 
classed as ‘borderline’. A rising score in this zone, with a DI value greater than 2.0, 
may represent an adverse performance trend that would benefit from early 
corrective action. Scores between eighty and one hundred should always be 
reviewed for trends in performance, if only by the participant laboratory. 
Any individual DI value greater than +2 or less than -2 warrants review and values 
greater than +3 or less than -3 may indicate a serious performance issue (ISO 
13528). This action should be undertaken regardless of the performance score. 
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Figure 5.1. Haemoglobin A2 analytical performance scores by deviation index for 
specimen 1304AH1 (Hb A2 ALTM 4.28%). DI values >3.5 truncated to 3.5. 
 
Figure 5.2. Haemoglobin A2 analytical performance scores by deviation index for 
specimen 1305AH3 (Hb A2 ALTM 2.15%). DI values >3.5 truncated to 3.5. 
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Figure 5.3. Haemoglobin A2 analytical performance scores by deviation index for 
specimen 1402AH3 (Hb A2 ALTM 4.99%). DI values >3.5 truncated to 3.5. 
 
Figure 5.4. Haemoglobin A2 analytical performance scores by deviation index for 
specimen 1502AH1 (Hb A2 ALTM 5.03%). DI values >3.5 truncated to 3.5. 
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Figure 5.5. Haemoglobin A2 analytical performance scores by deviation index for 
specimen 1502AH2 (Hb A2 ALTM 2.08%). DI values >3.5 truncated to 3.5. 
 
Figure 5.6. Haemoglobin A2 analytical performance scores by deviation index for 
specimen 1601AH1 (Hb A2 ALTM 2.45%). DI values >3.5 truncated to 3.5. 
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5.4.3 The target value used for performance assessment 
The differences between the participants’ results and the ALTM, Adjusted ALTM, 
SMTM and MTM were calculated and the mean of the differences for all data in the 
study determined by instrument group for each of the four target values. The 
means of the differences by instrument group are shown in Table 5.5 and Figure 
5.7.There was no observable difference in the means of the differences of the 
participants’ results by ALTM, Adjusted ALTM or MTM for any instrument group. 
There appears to be no advantage in adjusting the target value to correct for the 
different numbers of each instrument type in the ALTM by using the mean of the 
sub-method means, suggesting that the ALTM is not significantly skewed by the 
numbers of different instrument types in the data used in this study. There also is 
little variation in the mean differences of the ALTM and the MTM consensus target 
values. The mean differences of the participants’ results against the ALTM, 
adjusted ALTM and MTM reflect the biases observed in the performance of the 
different analysers. 
As might be expected, the means of the differences calculated using the SMTM is 
closer to zero than when using the other target values, by a factor of approximately 
ten. The only exception to this observation is for the miscellaneous HPLC group. 
For the CZE group the means of the differences against all four target values are 
very similar and close to zero; the SMTM and MTM would be expected to be the 
same for this group since they include the same set of instruments. 
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Instrument 
group 
  Target Value 
  ALTM Adj ALTM SMTM MTM 
CZE N 1801 1801 1801 1801 
  Mean difference -0.0077 -0.0083 0.0023 0.0110 
  SD 0.1537 0.1564 0.1445 0.1481 
BRD10 N 943 943 943 943 
  Mean difference 0.1004 0.1008 0.0076 0.0976 
  SD 0.2819 0.2806 0.2656 0.2795 
BRVCL N 331 331 331 331 
  Mean difference 0.0152 0.0194 0.0013 0.0152 
  SD 0.1685 0.1696 0.1365 0.1671 
BRVII Bthal N 2245 2245 2245 2245 
  Mean difference 0.0608 0.0607 0.0018 0.0577 
  SD 0.2097 0.2109 0.1802 0.2081 
BRVII DK N 815 815 815 815 
  Mean difference -0.0624 -0.0634 0.0079 -0.0663 
  SD 0.2031 0.2019 0.1941 0.2029 
HA8160 N 1165 1165 1165 1165 
  Mean difference -0.057 -0.0551 0.0109 -0.0584 
  SD 0.3337 0.3353 0.3189 0.3332 
HPLC MISC N 551 551 551 551 
  Mean difference -0.0014 -0.0032 0.0139 -0.0059 
  SD 0.3057 0.3058 0.2877 0.3056 
PRIMUS N 629 629 629 629 
  Mean difference -0.1236 -0.1251 0.01 -0.128 
  SD 0.2202 0.2194 0.2097 -0.2211 
TOSOH G7 N 712 712 712 712 
  Mean difference 0.1827 0.1867 0.0081 0.1827 
  SD 0.3195 0.3879 0.3416 0.3912 
TOSOH G8 N 1271 1271 1271 1271 
  Mean difference -0.0478 -0.0495 0.0045 -0.0524 
  SD 0.3017 0.3005 0.2549 0.3027 
 
Legend to Table 5.5:  CZE:   Sebia capillary zone electrophoresis;  
BR D10:  Bio-Rad D10 HPLC 
BRVCL: Bio-Rad Variant Classic HPLC 
  BRVII BThal: Bio-Rad Variant II, Beta thal short programme HPLC 
 BRVII DK: Bio-Rad Variant II, Dual Kit programme, HPLC 
HA8160: Menarini HA8160 HPLC 
  HPLC MISC: Miscellaneous HPLC 
  PRIMUS: Trinity Primus 2 HPLC 
  TOSOH G7: Tosoh G7 HPLC 
  TOSOH G8: Tosoh G8 HPLC 
Table 5.5 Mean differences of the returned results against  
different target values, by instrument group.   
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Legend to Figure 5.7:  CE:   Sebia capillary zone electrophoresis;  
BR D10:  Bio-Rad D10 HPLC 
BRVCL: Bio-Rad Variant Classic HPLC 
  BRVII BThal: Bio-Rad Variant II, Beta thal short programme HPLC 
 BRVII DK: Bio-Rad Variant II, Dual Kit programme, HPLC 
HA8160: Menarini HA8160 HPLC 
  HPLC MISC: Miscellaneous HPLC 
  PRIMUS: Trinity Primus 2 HPLC 
  TOSOH G7: Tosoh G7 HPLC 
  TOSOH G8: Tosoh G8 HPLC 
 
Figure 5.7 Distribution of mean differences of results against ALTM,  
Adjusted ALTM, SMTM and MTM, by instrument group 
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5.4.4 Calculation of performance scores using different multiplication 
(weighting) factors 
At the time of writing the multiplier used in the calculation of analytical performance 
score is nine. In this study 2.7% of results (282 / 10,463) had scores greater than 
one hundred using a multiplier of nine. This multiplier was selected empirically 
when scoring was introduced for Hb A2 in 2004 to place approximately 5% of 
participants in the persistent unsatisfactory performance category (England, 1995). 
Altering the multiplier up or down adjusts the sensitivity of the score; increasing the 
multiplier increases the number of participants identified with persistent 
unsatisfactory performance but this increases the associated performance 
management workload. The impact of increasing the multiplier on the number of 
participants identified as persistent unsatisfactory performers was assessed by trial 
and error using multipliers of ten, eleven and twelve. Table 5.6 shows the average 
DI value over six specimens that would produce a score of one hundred with 
different multipliers and the number of participants that would be identified as 
unsatisfactory performers. 
 
Multiplier Average DI No. of PUP scores 
9 1.85 282 (2.7%) 
10 1.67 457 (4.4%) 
11 1.52 708 (6.8%) 
12 1.39 1002 (9.6%) 
 
Table 5.6 Average DI values over six specimens required to produce a 
performance score of one hundred using different multipliers and the number of 
results in the study identified as persistent unsatisfactory performance (PUP) by 
multiplier  
  
179 
The DI value varies according to the dispersion of the results for the survey 
material pool as well as the difference of the individual result from the target mean, 
even when smoothed by using the HSD. Table 5.7 shows the DI values produced 
for a range of differences from the target value using data from ten survey material 
pools with varying Hb A2 results. Applying an acceptable analytical performance 
limit of ± 0.25% of Hb A2 (Mosca 2013) to the figures in Table 5.7 would classify 
any result that is more than ± 0.3% from the target value as out-of-consensus (note 
that UK NEQAS Haematology Hb A2 results are returned to one decimal place only 
and the value of 0.25% has been rounded up to 0.3%). Using multipliers of nine, 
ten, eleven and twelve with the average DI from the ten survey material pools 
suggests that a multiplier of eleven would give a performance score equal to or 
greater than one hundred for an actual difference from the target value of 
approximately 0.3% of Hb A2. 
The six potential misdiagnoses identified with scores less than eighty and DI 
values less than two were reviewed after being re-scored with different multipliers; 
although their scores increased with the increase in multiplier, all results still had 
scores less than one hundred with multipliers of ten and eleven and four had 
scores of less than eighty. One had a score of greater than one hundred and two 
had scores of greater than eighty with a multiplier of twelve. 
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R-M 
 Hb A2% 
Deviation index 
Avge DI 
Score by multiplier 
Hb A2 
2.31% 
Hb A2 
2.48% 
Hb A2 
3.99% 
Hb A2 
2.85% 
Hb A2 
2.15% 
Hb A2 
2.57% 
Hb A2 
1.94% 
Hb A2 
2.31% 
Hb A2 
2.52% 
Hb A2 
4.31% 
9 10 11 12 
-0.5 2.8 2.2 1.6 2.1 2.7 2.2 3.2 2.3 2.2 1.0 2.03 109 122 134 146 
-0.4 2.2 1.7 1.3 1.7 2.1 1.7 2.4 1.8 1.7 0.8 1.58 85 95 104 114 
-0.3 1.7 1.2 1.0 1.2 1.5 1.3 1.8 1.3 1.2 0.6 1.16 63 70 77 84 
-0.2 1.2 0.7 0.7 0.8 0.9 0.8 1.1 0.8 0.8 0.3 0.74 40 44 49 53 
-0.1 0.7 0.3 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.1 0.36 20 22 24 26 
0 0.2 0.2 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.07 4 4 5 5 
0.1 0.3 0.6 0.2 0.3 0.6 0.4 0.6 0.4 0.4 0.3 0.37 20 22 25 27 
0.2 0.7 1.0 0.5 0.7 1.1 0.8 1.1 0.8 0.7 0.4 0.71 38 43 47 51 
0.3 1.1 1.4 0.8 1.0 1.5 1.2 1.6 1.2 1.1 0.7 1.05 57 63 70 76 
0.4 - 1.7 1.0 1.3 2.0 1.5 2.0 1.6 1.4 0.9 1.34 72 80 88 96 
0.5 - 2.1 1.3 1.7 2.4 1.9 2.5 1.9 1.7 1.1 1.66 90 100 110 120 
 
Table 5.7 Deviation Index values by difference from the target Haemoglobin A2% for ten survey material pools (Hb A2 targets of 1.94 to 4.31%) 
and the analytical performance score produced using different multipliers.  
Suggested acceptable performance limits are shown by the shaded areas of the table, using a limit of ±0.3% Hb A2 from the target. R is the 
result returned and M the consensus trimmed mean target value. Scores in red indicate persistent unsatisfactory performance. 
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5.5 Discussion 
A number of methods are available for the evaluation of EQA data and there is no 
ideal method for statistical performance assessment in EQA (Coucke, 2017). 
There is a recognised need for greater transparency in the setting of analytical 
performance specifications (APS) and a clear understanding of their limitations, 
which should be made available to participants and professional, regulatory or 
oversight bodies (Jones, 2017b). This study examined the current indicators for 
monitoring participants’ performance of Hb A2 measurement in the UK NEQAS 
Haematology Abnormal Haemoglobins scheme, how they reflect and report 
performance to the laboratory and how they might be developed. 
The UK NEQAS Haematology analytical performance score is a descriptor of the 
long-term, retrospective performance of the laboratory for an analyte. Its purpose 
is to screen the EQA results returned by participants against objective 
performance specifications and identify laboratories whose performance warrants 
further investigation and review, either by the scheme or the participant. The 
scoring system is based on the principles described in international standards 
(ISO 13528 and ISO 17043); however, it was developed for performance 
assessment of automated cell counting, where the interpretation of the test results 
and their application in clinical diagnosis and monitoring are different from the 
measurement of Hb A2. Hb A2 is expressed as a quantitative value but the 
application of a strict cut-off for the identification of a beta thalassaemia carrier, as 
in the NHS STP’s algorithm, renders its interpretation almost qualitative or 
outcome based. The use of a strict cut-off Hb A2 value to screen for beta 
thalassaemia carriers with the classical raised Hb A2 phenotype (Hb A2 greater 
than 3.8%) is relatively straightforward but the identification of carriers of mild beta 
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thalassaemia mutations with borderline Hb A2 values (3.3 to 3.8%) is a greater 
challenge (Mosca 2008, Giambona 2008; Stephens, 2012).  
The APS used by UK NEQAS Haematology for the evaluation of Hb A2 data are 
defined as the ‘state-of-the-art’, i.e. the highest level of analytical performance 
possible at the time. The scheme is complex in design, however, and includes an 
interpretation of the results obtained against a clinical scenario. The interpretative 
element of the scheme is not currently scored but doing so would give an 
alternative model of APS based on outcome and the application of clinical 
decision-making (Sandberg 2015). 
To assess the state of the art, it is necessary to assign an appropriate target value 
against which performance is measured. The continued use of the MTM by UK 
NEQAS on historical grounds must be questioned, as there is no more justification 
in separating CZE methods from HPLC as separating one HPLC analyser from 
another. Little difference was shown between the MTM and ALTM for individual 
analyser models and there is little evidence that the use of the ALTM puts any 
instrument group at a disadvantage. However, the use of the mean of the sub-
method means (described as the ‘adjusted ALTM’ in the study) should be kept 
under review as technology and the numbers of participants using different 
methodologies change. The use of the SMTM as the target value might improve 
the apparent performance of individual analyser groups; however, its use for 
performance assessment is counter-intuitive when no allowance for method 
difference is made in the NHS STP’s algorithm and the bias seen between 
analysers in EQA performance has also been demonstrated with clinical material 
(Paleari, 2012; Paleari, 2017). There is also the danger that the use of the SMTM 
will ‘normalise’ the existence of a bias between different analysers rather than 
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acting as a driver to improve harmonisation of performance. A barrier to 
harmonisation is the lack of a reference standard for Hb A2 other than the now 
nearly thirty years' old International Reference Material (WHO 89/666). 
The Hb A2 analytical performance score is an indicator of long-term bias and 
imprecision; the DI on the other hand is an indicator of the TE for an individual 
result. When these two performance indicators were compared, a number of 
results with satisfactory DI values were associated with scores indicative of 
persistent unsatisfactory performance (PUP) and vice versa. This serves to 
illustrate that both comparators need to be taken into account when assessing 
performance. This is of particular relevance because the score retains a ‘memory’ 
of past unsatisfactory performance and remains high in comparison to the DI 
values in the immediate period following actions to a correct performance problem. 
A larger proportion of results (2.4%) had DI values greater than 3.0 than predicted 
from a normal distribution (0.3%) and this reflects the observation that the 
distribution of EQA data may be leptokurtic, with a taller, more slender peak and 
heavier tails than a normal distribution, resulting in a larger proportion of 
participants than expected with z-scores of ±3.0 (Heydorn, 2008). Although DI 
values are reported to participants in each distribution report, a review of DI values 
is not currently included in the UK NEQAS Haematology APS for Hb A2. The 
scheme should implement a review of DI values as part of the summary of 
performance made to participants and consider the introduction of a category of a 
one-off unsatisfactory performance error or UP based on a DI value of more than 
3.0.  
UK NEQAS Haematology should pilot the use of a different multiplier to increase 
the sensitivity of the performance score. Increasing the multiplier to eleven would 
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apply the suggested analytical goals based on biological variation for Hb A2 
(Mosca 2013). This will bring a greater proportion of labs into the zone of 
borderline or UP and there is a risk that the specificity of the score may be 
reduced. Using a multiplier of eleven will more than double the number of 
laboratories with PUP scores according to this study and the use of an automated, 
rules-based performance assessment system that flags the trends in performance 
in the survey report may be necessary to manage the workload. This 
implementation of a change to the multiplier would introduce a step change in the 
performance scores and require careful shadow scoring and communication to 
participants, explaining why and how previously satisfactory performance had 
become borderline or unsatisfactory. 
Increasing the multiplier to eleven did not push the six results that represented a 
potential misdiagnosis into the PUP range, although two moved into the borderline 
category. All six results were from the same distribution and the survey material 
pool had the lowest beta thalassaemic Hb A2 target value in the study (3.99%), 
although it was above the Hb A2 range expected for a carrier of a mild beta 
thalassaemia mutation. The use of the of the 3.5% cut-off value for defining a 
potential misdiagnosis in this study may have been too blunt as a discriminator, 
although this is how it is intended for use by the NHS STP. The NHS STP’s 
algorithm includes consideration of the MCH result and all the survey material 
pools in the study had been issued with a MCH result consistent with a beta 
thalassaemia carrier, i.e. less than 27 pg. Review of the coded and written 
interpretive comments provided by the six laboratories in question for this 
specimen revealed that five of the six had suggested possible beta thalassaemia 
carrier status for the ‘patient’. This raises the idea that the benefit of the scheme 
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would be enhanced if an element of assessment by outcome or clinical decision 
making were introduced through the scoring of the interpretive comments as well 
as the analytical result, i.e. taking an holistic approach to performance 
assessment. The educational impact of such an approach would benefit from the 
inclusion of more specimens at or around the cut-off Hb A2 value of 3.5%. 
In summary, the current use of the DI value and performance score detects the 
majority of PUP participants when the results are assessed in terms of clinical 
outcome, i.e. whether the laboratory has correctly identified a specimen as from a 
beta thalassaemia carrier or not. There is scope for increasing the sensitivity of the 
procedure by amending the multiplier used in scoring, adding a review of the DI 
values at each distribution and removing the anomaly of using the MTM as a 
target value. The use of the mean of sub-group means should be kept under 
review with changes in methods used by participants. Finally, there may be some 
benefit to participants' understanding of the relationship between the DI and 
performance score if this could be displayed graphically as in this study, even if on 
an annual summary basis. 
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Chapter 6: Errors in fraction identification and 
interpretation of results
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6.1 Aim 
To investigate the frequency and types of errors made by different categories of 
participants when reporting fraction identification and case interpretation in the UK 
NEQAS Abnormal Haemoglobins external quality assessment scheme and 
whether these would prove a barrier to scoring of these parameters. 
6.2 Introduction 
The UK NEQAS Haematology Abnormal Haemoglobins scheme is designed to 
assess as far as practicable all aspects of the laboratory investigation of the 
haemoglobinopathies by non-molecular techniques. Haemoglobin fraction 
identification has been a part of the scheme since it commenced in the 1970s but 
the interpretation of results against a clinical scenario to replicate the procedure 
that would be applied to a patient’s sample is a more recent introduction. 
The identification of variant Hb fractions is presumptive based on the 
physicochemical features of the Hb molecule. Because of the large number of Hb 
variants known (Weatherall and Clegg, 2001; Bain, 2006) and their co-migration in 
protein chemistry-based separation techniques, the identification of a variant Hb 
using non-molecular methods should be based on the results of two laboratory 
tests using different principles (NHS STP Antenatal Laboratory Handbook 2017; 
Ryan, 2010; Traeger-Synodios, 2015). Where laboratories do not have a 
confirmatory method(s) available to them in-house, they may comply with this 
requirement by sending patients’ samples for testing to a second laboratory. This 
action is not recommended in external quality assessment (EQA) as it might 
constitute 'collusion' between participants; the referral laboratory may receive 
specimens from a number of screening laboratories and therefore will test multiple 
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identical EQA specimens; an error by the referral laboratory will have an impact on 
the EQA performance of the screening laboratory, making the scoring of 
performance and the allocation of adverse penalties difficult. 
Result interpretation and recommendation of further actions are essential features 
of haemoglobinopathy testing and should take into account other laboratory 
results, e.g. the FBC, iron status and blood film morphology, the patient’s ethnic 
background and the reasons for testing (Clarke, 2000; Bain, 2006; Bain, 2010). 
Each UK NEQAS Abnormal Haemoglobins specimen is accompanied by a clinical 
scenario against which participants are required to interpret the results they obtain. 
Laboratories undertaking antenatal screening in the English NHS receive 
education, training and advice in this area from the NHS STP and the laboratory 
diagnosis of the haemoglobinopathies is the subject of national and international 
guidelines (Ryan, 2010; Traeger-Synodios, 2015). The NHS STP’s Laboratory 
Handbook is freely available as a source of professional guidance to all 
laboratories. 
Some element of performance assessment is required for EQA scheme 
accreditation against ISO 17043 (ISO 17043:2010) and is an expected part of 
EQA scheme design (Urassa, 2016). There is no formal performance scoring of 
the fraction identification and interpretation elements of the UK NEQAS Abnormal 
Haemoglobins scheme although all laboratories receive an overall educational 
summary of the incorrect returns in the report of each distribution. An out-of-
consensus fraction identification by a UK laboratory is followed up by letter from 
the scheme; however, in the absence of a performance score, laboratories outside 
the UK receive no active indication of the need for performance improvement. 
There are models and precedents for scoring of qualitative and interpretive EQA 
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results (Kettelhut, 2003; James, 2012) and the performance assessment of the 
qualitative sickle solubility test option in the scheme is already in place.  
The number of non-UK participants registered for full participation in the scheme, 
i.e. fraction identification, quantitation and interpretation, has increased 
significantly since the scheme’s inception and exceeds the number of UK 
participants at the time of writing. The extension of performance scoring to fraction 
identification and interpretation will include all laboratories and there must be 
sufficient consensus between laboratories for the scoring to be credible, which 
may be a particular challenge for interpretation because of different oversight 
standards in place in different countries. The presumptive nature of Hb fraction 
identification and different levels of service expertise amongst laboratories need to 
be taken into account for the fair and effective performance assessment of both 
fraction identification and case interpretation. To make scoring in these areas 
effective, it is essential to understand the number and possible types of error made 
by participants, including errors that result from the design of the scheme itself. 
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6.3 Methods 
6.3.1 Data analysis 
Data was analysed using Microsoft Excel 2010 with the downloaded Toolpak 
(Microsoft Corporation, California, USA) and STATA 14 (StataCorp, Texas, USA). 
The fraction identification and interpretive comment codes submitted by 
participants registered in the UK NEQAS Haematology Abnormal Haemoglobins 
scheme in the six surveys distributed between August 2015 and June 2016 
(surveys 1504AH to 1603AH) were used in the study. The raw data was edited 
before analysis to remove blank and incomplete results, results returned where the 
specimen quality had been reported as unsatisfactory and those from non-clinical 
participants, e.g. instrument manufacturers, pharmaceutical companies and quality 
assurance laboratories. Participants were allocated to one of five laboratory types: 
English NHS Trusts, non-English NHS Trusts (i.e. NHS Trusts based in Scotland, 
Wales and Northern Ireland), UK private laboratories, laboratories based in the 
Republic of Ireland (RoI) and laboratories outside the British Isles (Non-British 
Isles laboratories). All data was anonymised before use. 
6.3.2 Fraction identification assessment 
UK NEQAS Haematology identifies the fractions ‘essential’ for diagnosis for each 
specimen, e.g. Hb A and Hb S for a sickle cell carrier patient, plus other fractions 
that would be ‘expected’ to be present, e.g. Hb A2 and Hb F. The essential and 
expected Hb fractions had been allocated for the specimens in the study in the 
original survey reports to participants. 
The numbers of correct and incorrect reports were determined by laboratory type. 
Participants' returns were classified as correct if all Hb fractions essential for 
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diagnosis were reported with no additional fractions other than the expected ones. 
Incorrect fraction identification results were classified into four categories following 
scrutiny of the individual returns by the participant including free text comments 
they had given with their submissions: 
1. Unable to identify (UI): reporting a non-specified (NS) fraction or a 
differential fraction identification (e.g. Hb S or Hb C) stating they were 
unable to identify further with the method(s) available or that the 
specimen would be referred to another laboratory for identification. 
Occasional laboratories reporting their instrument as out of use in a 
written comment but who had returned a nominal fraction identification 
(e.g. Hb A or non-specified (NS) fraction) were also included in this 
category.  
2. Haemoglobin A not recorded (ANR): reporting a result correct in all 
respects except for the omission of Hb A. These results are potentially 
confusing, e.g. reporting a sickle cell carrier specimen (Hb A and Hb S) 
as 'Hb S' could imply a diagnosis of sickle cell disease. Investigation of 
the error with participants usually shows that the Hb A fraction was 
recorded at analysis but overlooked during data entry. 
3. Transposition of specimens or results (Tx): a pre or post-analytical 
error with potentially serious consequences. The transposition of EQA 
specimens can be identified in a distribution where the specimens have 
different Hb variant patterns or different Hb A2 or Hb F concentrations. 
They are identified as a separate category of error because a single 
transposition will result in two incorrect fraction identification 
submissions.  
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4. All other errors (Other): this category included all remaining fraction 
identification errors, e.g.: 
 Failure to report essential fractions (other than failure to report 
Hb A, which has been counted separately). 
 Reporting fractions in addition to the expected fractions without 
an adequate explanation, e.g. reporting Hb S and Hb C or Hb C 
and Hb E without explaining that the laboratory is unable to 
identify further with the methods available or reporting a NS 
fraction in addition to the expected fractions. 
 Reporting an incorrect fraction, e.g. reporting Hb D instead of 
Hb S. 
 A combination of any of these errors or a combination of one or 
more of these errors with the failure to report Hb A. 
6.3.3 Confirmation of fraction identification by more than one method 
The methods used for Hb fraction identification were investigated by laboratory 
type and specimen content for the specimens distributed in surveys 1504AH to 
1603AH. 
6.3.4 Interpretive comments assessment 
Six cases were selected to assess the use of UK NEQAS Haematology 
interpretive comment codes: 1504AH1, 1504AH2, 1505AH2, 1601AH3, 1603AH1 
and 1603AH3, representing a range of the haemoglobinopathy cases distributed in 
the study period.  
Coded comments are used for reporting the interpretation of UK NEQAS Abnormal 
Haemoglobins specimens to allow the automated analysis of several hundred 
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participants’ results. The coded interpretive comments available fall into two 
categories: those offering a diagnosis or describing the results obtained, e.g. 
'sickle cell carrier', 'delta-beta thalassaemia carrier' or ‘raised Hb F', and comments 
giving recommendations for further action, e.g. 'partner testing indicated'. Essential 
and acceptable comment codes were allocated to each specimen as part of the 
study according to the background case details given and the guidance on 
interpretation and recommendation given in the NHS STP's Antenatal Laboratory 
Handbook. Essential comments were those considered necessary for 
unambiguous reporting; acceptable comments were those that did not confuse or 
contradict the diagnosis. The list of coded comments available is shown in 
Appendix 3. 
The interpretive comments returned by the two largest groups of participants (the 
English NHS Trusts group and the Non-British Isles laboratories) were compared. 
Each group was of sufficient size to provide statistically meaningful results and the 
English NHS Trusts group is subject to active oversight by the NHS STP, in 
contrast to the Non-British Isles group. Participants who had made errors in 
fraction identification were still included in the interpretive comment analysis. This 
may seem counterintuitive and is not practice in other UK NEQAS Haematology 
schemes; however, it served to illustrate some of the causes of error in 
interpretation for the purpose of the study. There is a mismatch in some cases 
between incorrect fraction identification and correct interpretation, e.g. a laboratory 
may fail to report Hb S in fraction identification, but will report the consensus 
Hb S% and a correct interpretation, consistent with the incomplete fraction 
identification being a data entry error. 
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Interpretive comments and recommendations for action were assessed as 
'correct', ‘partially correct’ or 'incorrect' depending on their agreement with the 
essential and acceptable comment codes, using the following criteria: 
 Correct: all essential comments listed, with or without the acceptable 
comments. 
 Partially correct: one or more essential comments omitted but only 
essential and/or acceptable comments used.  
 Incorrect: using a comment that was not on the essential or acceptable 
list, even if the essential/acceptable comments had been reported. 
Diagnostic comments and recommendations for action were assessed separately. 
Where the interpretive comment was considered incorrect, no assessment of the 
recommendations for action was undertaken.  
The interpretive comments and recommendations for action were assessed in two 
ways: an overall analysis of the comments returned by the two major laboratory 
types and an analysis of the combination of comments returned by the individual 
laboratories. Although the total summary of comments returned by laboratory type 
is indicative of the overall state-of–the-art, the combination of comments used by 
the individual laboratory is important for an understanding the provision of 
unambiguous advice to the clinician. 
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6.4 Results 
6.4.1 Laboratories included in the study 
The results from 283 to 308 participants per distribution for the six distributions 
(three specimens per distribution) between August 2015 and June 2016 were 
included in the study, giving a total of 1799 sets of results from laboratories in the 
UK and thirty-three other countries. The laboratories included in each survey are 
shown by country in Table 6.1. After the UK, the largest numbers of participants 
were located in Belgium, Turkey, Portugal, Italy and Israel.  
Table 6.2 and Figure 6.1 show the numbers of participants by laboratory type. The 
proportion of results returned by non-British Isles laboratories ranged from 
140/283 (49.5%) in August 2015 to 161/307 (52.4%) in June 2016.  
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Country 
Distribution 
1504AH 1505AH 1506AH 1601AH 1602AH 1603AH 
Australia 1 1 1 1 1 1 
Austria 3 3 3 3 3 3 
Belgium 30 30 29 32 29 29 
Bulgaria 1 1 1 1 1 1 
Cyprus 1 1 1 1 1 1 
Czech Republic 1 1 1 1 1 0 
Denmark 1 1 1 1 1 1 
Finland 1 1 1 1 1 1 
France 1 2 2 2 2 2 
Germany 2 3 3 3 3 3 
Greece 2 2 2 2 2 2 
India 1 1 1 1 1 1 
Israel 13 13 13 12 12 13 
Italy 17 18 18 19 17 17 
Jamaica 0 1 1 1 0 1 
Kenya 1 1 1 1 0 0 
Kuwait 5 5 6 6 6 6 
Luxembourg 1 1 1 1 1 1 
Malta 1 1 1 1 1 1 
Netherlands 0 0 1 1 1 0 
Netherlands Antilles 1 1 1 1 1 1 
Norway 6 6 5 6 6 6 
Poland 1 1 1 1 1 1 
Portugal 16 18 19 21 21 22 
Republic of Ireland 6 7 7 6 7 5 
South Africa 1 1 1 1 1 1 
Spain 0 1 1 1 3 4 
Sultanate of Oman 1 1 1 1 1 1 
Sweden 3 2 3 3 3 3 
Switzerland 5 5 5 5 5 5 
Turkey 20 21 23 25 28 30 
UK 137 142 141 141 144 141 
United Arab Emirates 3 3 3 3 2 2 
Viet Nam 0 0 0 0 1 1 
TOTAL 283 296 299 306 308 307 
 
Table 6.1. Number of participants returning results by country for  
distributions 1504AH to 1603AH (August 2015 to June 2016) 
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Laboratory type Distribution 
 
1504AH 1505AH 1506AH 1601AH 1602AH 1603AH 
NHS (English Trusts) 117 121 120 120 123 120 
NHS (Non-English Trusts) 17 17 17 17 17 17 
UK private sector 3 3 3 3 3 3 
Republic of Ireland 6 6 6 5 6 4 
Non British Isles 140 149 153 161 159 163 
TOTAL 283 296 299 306 308 307 
 
Table 6.2. Numbers of laboratories returning results in each survey, by laboratory type 
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Figure 6.1. The proportion of fraction identification results by laboratory type in the study, distributions 1504AH to 1603AH. 
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6.4.2 Specimens included in the study 
A range of haemoglobinopathy cases were simulated in the eighteen specimens 
distributed in the study period, including six sickle cell carriers, one Hb C carrier, 
several alpha thalassaemia carriers (some coexistent with sickle cell carrier 
status), six with a raised Hb F% (from 5.0% to 21.3%) and two ‘normal’ specimens 
with no evidence of an abnormal Hb variant or thalassaemia, as shown in Table 
6.3, with the essential and expected Hb fractions for each specimen.  
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Specimen Case summary 
Essential 
fractions 
Expected 
fractions 
1504AH1 
29 year old Indian female patient tested antenatally. In conjunction with normal red cell indices, screening showed no 
evidence of an abnormal Hb variant or thalassaemia carrier. Partner screening was not indicated. 
Hb A 
Hb A, Hb A2, 
Hb F 
1504AH2 
18 year old Greek female patient screened because of a 'low blood count'. Screening showed a raised Hb F% (11.3%) and 
a thalassaemic blood count, consistent with a diagnosis of probable delta-beta thalassaemia carrier. 
Hb A, Hb F 
Hb A, Hb A2, 
Hb F 
1504AH3 
25 year old Black African male patient tested pre-operatively. Haemoglobinopathy screening showed him to be a carrier of 
Hb S (Hb S = 31.%), blood count indices consistent with a probable coexistent alpha thalassaemia carrier  
Hb A, Hb S 
Hb A, Hb S,  
Hb A2, Hb F 
1505AH1 
16 year old female patient of Nigerian origin, tested as part of the investigation of anaemia. The Hb concentration low with 
normal red cell indices. Screening showed her to be Hb S carrier of (Hb S = 32%) with possible coexistent alpha 
thalassaemia carrier and/or iron deficiency. 
Hb A, Hb S 
Hb A, Hb S,  
Hb A2, Hb F 
1505AH2 
28 year old Northern European female patient tested antenatally. In conjunction with normal red cell indices, 
haemoglobinopathy screening showed no evidence of an abnormal Hb variant or thalassaemia carrier; the Hb F% was 
slightly raised (6.3%), consistent with pregnancy. Partner screening was not indicated. 
Hb A, Hb F 
Hb A, Hb A2, 
Hb F 
1505AH3 
31 year old Italian female patient tested as part of antenatal screening. Haemoglobinopathy screening showed no 
abnormal Hb variant and a normal Hb A2%. The Hb F% (14.6%) was consistent with Hereditary Persistence of Fetal 
Haemoglobin in conjunction with a normal blood count. Partner testing is indicated. 
Hb A, Hb F 
Hb A, Hb A2, 
Hb F 
1506AH1 
29 year old male patient of Jamaican origin tested pre-operatively. Screening showed him to be a Hb S carrier. The Hb S% 
(27.3%) with a microcytic blood count, was consistent with coexistent alpha thalassaemia carrier and/or iron deficiency. 
Hb A, Hb S 
Hb A, Hb S, 
Hb A2, Hb F 
1506AH2 
26 year old Romanian female patient tested as part of antenatal screening. Haemoglobinopathy screening showed no 
abnormal Hb variant present and no evidence of thalassaemia carrier in conjunction with a normal blood count. The raised 
Hb F% (5.0%) was consistent with pregnancy. Partner testing was not indicated. 
Hb A, Hb F 
Hb A, Hb A2, 
Hb F 
1506AH3 
41 year old African male patient tested as part of the investigation of anaemia. Haemoglobinopathy screening showed no 
abnormal Hb variant present with a normal Hb A2 and Hb F%. His blood count was consistent with iron deficiency and/or 
possible alpha thalassaemia carrier. 
Hb A 
Hb A, Hb A2, 
Hb F 
Table 6.3 Cases distributed in surveys 1504AH to 1603AH (August 2015 to June 2016) – continued on next page  
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Specimen Case summary 
Essential 
fractions 
Expected 
fractions 
1601AH1 
31 year old Nigerian male whose partner is pregnant and a sickle cell carrier. No evidence of a haemoglobin variant or 
thalassaemia carrier, with a normal blood count. 
Hb A 
Hb A, Hb A2, 
Hb F 
1601AH2 
34 year old N. European female patient screened antenatally. Screening showed no abnormal haemoglobin variant or 
thalassaemia, Hb F% was 10.6% and a normal full blood count. Partner testing was indicated. 
Hb A, Hb F 
Hb A, Hb A2, 
Hb F 
1601AH3 
27 year old Jamaican female undergoing antenatal haemoglobinopathy screening and found to be a sickle cell carrier (Hb 
S=38.5%), with normal blood count data. Partner testing was indicated. 
Hb A, Hb S 
Hb A, Hb S,  
Hb A2, Hb F 
1602AH1 
30 year old Chinese man whose partner is pregnant and an alpha zero thalassaemia carrier. Screening showed no 
abnormal Hb variant, a normal Hb A2% and red cell indices consistent with alpha thalassaemia carrier. Accurate genetic 
counselling and testing of the couple was indicated. 
Hb A 
Hb A, Hb A2, 
Hb F 
1602AH2 
24 year old African female undergoing antenatal haemoglobinopathy screening as part of antenatal testing and found to be 
a sickle cell carrier (Hb S = 32.4%). The Hb S% and the low red blood cell indices were consistent with coexistent alpha 
thalassaemia carrier and/or iron deficiency. 
Hb A, Hb S 
Hb A, Hb S,  
Hb A2, Hb F 
1602AH3 
26 year old Nigerian female undergoing antenatal haemoglobinopathy screening. There was no evidence of an abnormal 
Hb variant and the blood count indices were normal; the Hb A2 was normal but the Hb F was 21.3% consistent with 
Hereditary Persistence of Fetal Hb. Partner testing was indicated. 
Hb A, Hb F 
Hb A, Hb A2, 
Hb F 
1603AH1 
29 year old Jamaican female undergoing antenatal haemoglobinopathy screening and found to be a sickle cell carrier. The 
Hb S was low (24.9%) and the red cell indices reduced, both consistent with coexistent alpha thalassaemia carrier. Partner 
testing was indicated. 
Hb A, Hb S 
Hb A, Hb S,  
Hb A2, Hb F 
1603AH2 
18 year old Asian male being investigated for a low haemoglobin concentration. Haemoglobinopathy screening was 
normal, with a normal Hb A2 and HbF. Further investigation of possible alpha thalassaemia carrier and/or iron deficiency 
was indicated. 
Hb A 
Hb A, Hb A2, 
Hb F 
1603AH3 
29 year old Nigerian female undergoing antenatal haemoglobinopathy screening and found to be a carrier of Hb C, with a 
blood count at the lower end of the normal reference interval and a normal Hb F%. Partner testing was indicated. 
Hb A, Hb C 
Hb A, Hb C,  
Hb A2, Hb F 
Table 6.3 Continued 
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6.4.3 Overall analysis of errors made in fraction identification 
Table 6.4 shows the number and type of fraction identification error reported for 
each specimen by laboratory type. 
The use of the ‘Non-specified fraction’ (NS) category varied by laboratory type. 
Laboratories within the UK and the RoI used the option thirteen times in 2,619 
responses (0.5%) and its use corresponded to ‘unable to identify’ or ‘transposition’ 
errors in fraction identification with the exception of two English NHS laboratories 
who reported a NS fraction for specimen 1603AH3. 1603AH3 was the Hb C carrier 
and in both cases the laboratories reported a small NS fraction in addition to the 
expected fractions. Laboratories outside the UK and the RoI used the NS category 
seventy-seven times in 2,778 responses (2.8%). Again, it was frequently used for 
responses in the UI category but there were forty instances of a NS fraction being 
reported in the ‘Other’ category compared to two instances among the UK and RoI 
laboratories, for a similar number of responses overall in each group. There were 
also more ANR errors among Non-British Isles laboratories for a similar number of 
responses (116/2,778, 4.2%, of Non-British Isles laboratories compared to 
8/2,619, 0.3%, of laboratories in the UK and RoI). 
Table 6.5 and Figure 6.2 show the average percentage of the different fraction 
identification errors for each specimen in the study by laboratory type and 
essential fractions present. The average percentage by specimen type was used 
to correct for the varying numbers of specimens with the different Hb fraction 
patterns in the study.  
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Laboratory 
type 
Specimen 
number 
Essential 
fractions 
Correct 
responses 
Incorrect 
responses 
Type of FID error 
UI ANR Tx Other 
English NHS 1504AH1 A 117 0 0 0 0 0 
 1504AH2 AF 117 0 0 0 0 0 
 1504AH3 AS 115 2 2 0 0 0 
 1505AH1 AS 118 3 2 0 0 1 
 1505AH2 AF 120 1 1 0 0 0 
 1505AH3 AF 118 3 1 0 0 2 
 1506AH1 AS 117 3 2 0 1 0 
 1506AH2 AF 119 1 0 1 0 0 
 1506AH3 A 118 2 0 1 1 0 
 1601AH1 A 120 0 0 0 0 0 
 1601AH2 AF 119 1 0 0 1 0 
 1601AH3 AS 118 2 0 0 1 1 
 1602AH1 A 121 2 1 1 0 0 
 1602AH2 AS 118 5 2 1 2 0 
 1602AH3 AF 118 5 1 1 2 1 
 1603AH1 AS 116 4 2 0 1 1 
 1603AH2 A 119 1 1 0 0 0 
 1603AH3 AC 109 11 4 0 1 6 
 Totals  2117 46 19 5 10 12 
Non-English 1504AH1 A 16 1 0 1 0 0 
NHS 1504AH2 AF 16 1 0 1 0 0 
 1504AH3 AS 15 2 0 1 0 1 
 1505AH1 AS 17 0 0 0 0 0 
 1505AH2 AF 17 0 0 0 0 0 
 1505AH3 AF 16 1 0 0 0 1 
 1506AH1 AS 17 0 0 0 0 0 
 1506AH2 AF 16 1 0 0 0 1 
 1506AH3 A 16 1 0 0 0 1 
 1601AH1 A 17 0 0 0 0 0 
 1601AH2 AF 17 0 0 0 0 0 
 1601AH3 AS 17 0 0 0 0 0 
 1602AH1 A 17 0 0 0 0 0 
 1602AH2 AS 16 1 0 0 0 1 
 1602AH3 AF 17 0 0 0 0 0 
 1603AH1 AS 17 0 0 0 0 0 
 1603AH2 A 17 0 0 0 0 0 
 1603AH3 AC 15 2 1 0 0 1 
 Totals 
 
296 10 1 3 0 6 
Table 6.4 (part 1). The number of incorrect fraction identification (FID) results 
returned for each specimen, by laboratory type, for English and Non-English NHS 
Trust participants.  
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Laboratory 
type 
Specimen 
number 
Essential 
fractions 
Correct 
responses 
Incorrect 
responses 
Type of FID error 
UI ANR Tx Other 
UK Private 1504AH1 A 3 0 0 0 0 0 
 1504AH2 AF 3 0 0 0 0 0 
 1504AH3 AS 3 0 0 0 0 0 
 1505AH1 AS 3 0 0 0 0 0 
 1505AH2 AF 3 0 0 0 0 0 
 1505AH3 AF 3 0 0 0 0 0 
 1506AH1 AS 3 0 0 0 0 0 
 1506AH2 AF 3 0 0 0 0 0 
 1506AH3 A 3 0 0 0 0 0 
 1601AH1 A 3 0 0 0 0 0 
 1601AH2 AF 3 0 0 0 0 0 
 1601AH3 AS 3 0 0 0 0 0 
 1602AH1 A 3 0 0 0 0 0 
 1602AH2 AS 3 0 0 0 0 0 
 1602AH3 AF 3 0 0 0 0 0 
 1603AH1 AS 3 0 0 0 0 0 
 1603AH2 A 3 0 0 0 0 0 
 1603AH3 AC 3 0 0 0 0 0 
 Totals  54 0 0 0 0 0 
Republic 1504AH1 A 5 0 0 0 0 0 
of 1504AH2 AF 5 0 0 0 0 0 
Ireland 1504AH3 AS 5 0 0 0 0 0 
 1505AH1 AS 6 0 0 0 0 0 
 1505AH2 AF 6 0 0 0 0 0 
 1505AH3 AF 6 0 0 0 0 0 
 1506AH1 AS 6 0 0 0 0 0 
 1506AH2 AF 6 0 0 0 0 0 
 1506AH3 A 6 0 0 0 0 0 
 1601AH1 A 5 0 0 0 0 0 
 1601AH2 AF 4 1 0 0 0 1 
 1601AH3 AS 5 0 0 0 0 0 
 1602AH1 A 6 0 0 0 0 0 
 1602AH2 AS 5 1 0 0 1 0 
 1602AH3 AF 5 1 0 0 1 0 
 1603AH1 AS 4 0 0 0 0 0 
 1603AH2 A 4 0 0 0 0 0 
 1603AH3 AC 4 0 0 0 0 0 
 Totals 
 
18 3 0 0 2 1 
Table 6.4 (part 2). The number of incorrect fraction identification (FID) results 
returned for each specimen, by laboratory type, for UK Private laboratory and 
Republic of Ireland participants. 
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Laboratory 
type 
Specimen 
number 
Essential 
fractions 
Correct 
responses 
Incorrect 
responses 
Type of FID error 
UI ANR Tx Other 
Non-British  1504AH1 A 124 17 1 10 0 6 
Isles 1504AH2 AF 123 18 3 8 0 7 
 1504AH3 AS 124 17 3 8 0 6 
 1505AH1 AS 134 15 1 7 1 6 
 1505AH2 AF 131 18 1 7 0 10 
 1505AH3 AF 131 18 1 7 1 9 
 1506AH1 AS 136 17 2 7 0 8 
 1506AH2 AF 133 20 1 8 0 11 
 1506AH3 A 138 15 1 7 0 7 
 1601AH1 A 149 12 1 7 0 4 
 1601AH2 AF 146 15 1 7 0 7 
 1601AH3 AS 147 14 2 6 0 6 
 1602AH1 A 144 15 1 6 1 7 
 1602AH2 AS 139 20 4 4 5 7 
 1602AH3 AF 140 19 2 5 4 8 
 1603AH1 AS 146 17 3 7 0 7 
 1603AH2 A 152 11 1 4 2 4 
 1603AH3 AC 119 44 16 1 2 25 
 Totals 
 
2456 322 45 116 16 145 
 
Table 6.4 (part 3). The number of incorrect fraction identification (FID) results 
returned for each specimen, by laboratory type, for Non-British Isles participants.4 
 
  
                                                          
4
 Note to table 6.4: The errors were categorised into unable to identify (UI), Hb A not reported (ANR), 
transposition of specimens or results (Tx) and other errors (Other) 
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Essential 
fractions 
Lab Type 
Average 
no. of 
results 
Average % of FID errors 
UI ANR Tx Other 
Hb A Eng NHS 120 0.3% 0.3% 0.2% 0.0% 
  Non-Eng NHS 17 0.0% 1.2% 0.0% 1.2% 
  UK Private 3 0.0% 0.0% 0.0% 0.0% 
  RoI 5.2 0.0% 0.0% 0.0% 0.0% 
  Non British Isles 155.4 0.6% 4.4% 0.4% 3.6% 
Hb A + Hb F Eng NHS 120.3 0.4% 0.3% 0.4% 0.4% 
  Non-Eng NHS 17 0.0% 1.0% 0.0% 2.0% 
  UK Private 3 0.0% 0.0% 0.0% 0.0% 
  RoI 5.7 0.0% 0.0% 2.9% 2.9% 
  Non British Isles 152 1.0% 4.6% 0.5% 5.7% 
Hb A + Hb S Eng NHS 120 1.4% 0.1% 0.7% 0.4% 
  Non-Eng NHS 17 0.0% 1.0% 0.0% 2.0% 
  UK Private 3 0.0% 0.0% 0.0% 0.0% 
  RoI 5.3 0.0% 0.0% 3.1% 0.0% 
  Non British Isles 154.3 1.6% 4.2% 0.6% 4.3% 
Hb A + Hb C Eng NHS 120 3.3% 0.0% 0.8% 5.0% 
  Non-Eng NHS 17 5.9% 0.0% 0.0% 5.9% 
  UK Private 3 0.0% 0.0% 0.0% 0.0% 
  RoI 4 0.0% 0.0% 0.0% 0.0% 
  Non British Isles 163 9.8% 0.6% 1.2% 15.3% 
 
Table 6.5. Average percentage of fraction identification errors by laboratory type 
and Haemoglobin fraction pattern 
 
Legend to Table 6.5 and Figure 6.2 
UI: Unable to identify 
ANR: Hb A not reported 
Tx: Transposition of specimens or results 
Other: All other fraction identification errors 
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Figure 6.2. The average percentage of fraction identification errors, shown by laboratory type  
and pattern of essential Haemoglobin fractions. 
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Figure 6.2 shows: 
1. There were no errors made by UK Private laboratories but this group 
was very small (three). Note also that the number of RoI laboratories 
was small (between four and six per specimen) and therefore a single 
error results in a correspondingly large percentage change. 
2. For all Hb fraction patterns, Non-British Isles laboratories made the 
greatest number of errors. In particular, Non-British Isles laboratories 
made a greater number of errors in the ANR and the Other categories. 
3. For the normal (Hb A), raised Hb F (Hb A + Hb F) and sickle carrier (Hb 
A + Hb S) specimens, the percentage of errors made by laboratories in 
the UK and RoI was 3% or less in any category. 
4. For the Hb C carrier (Hb A + Hb C) specimen, all laboratories made 
more errors in the UI and Other categories than for the other specimens, 
perhaps reflecting that this specimen was a greater diagnostic challenge 
and less familiar to participants as an EQA specimen. (Note that UK 
NEQAS Haematology distributes a maximum of one Hb C carrier 
specimen per year compared to between four and six each of the raised 
Hb F and sickle carrier specimens). 
6.4.4 The use of confirmatory methods for Haemoglobin variant 
identification 
Participants are asked to mark the methods used for fraction identification using 
‘tick-boxes’ at data entry from the following options: electrophoresis at acid or 
alkaline pH, HPLC, IEF, CZE, sickle solubility testing and mass spectrometry. The 
choice of methods is made by the participant depending upon the content of the 
specimen; there is no restriction on the number of methods that can be used. The 
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numbers of laboratories using more than one method for fraction identification are 
shown in Table 6.6 by laboratory type. The numbers of laboratories in the RoI and 
the UK Private group were small overall: in the RoI group there was little difference 
by specimen type suggesting that the laboratories tested the samples by all the 
methods available regardless of content. The UK Private group did not use a 
confirmatory method for any specimen, suggesting that the three laboratories only 
had a single method available.  
The major difference in the reported use of confirmatory methods was between UK 
NHS Trusts (both English and Non-English) and the Non-British Isles laboratories: 
 For specimens with a Hb variant present, the median percentage of 
laboratories using more than one method for testing was 69.2% (range 56.7 
to 72.5%) for English NHS Trusts and 76.5% (range 70.6 to 82.4%) for 
Non-English NHS Trusts. By contrast, for Non-British Isles laboratories the 
median percentage using more than one method was 18.9% (range 16.8 to 
19.9%). 
 For samples with no Hb variant present and a normal Hb F concentration, 
the median percentage of laboratories testing by more than one method 
was 8.3% (range 4.3 to 10.8%) for English NHS Trusts and 35.3% (range 
35.3 to 41.2%) for Non-English NHS Trusts, suggesting that a number of 
Non-English Trust laboratories are testing ‘normal’ specimens by more 
methods than necessary. The median percentage of Non-British Isles 
laboratories testing ‘normal’ specimens by more than one method was 
10.8% (range 9.9 to 12.7%).  
 Where the specimen contained a raised Hb F, the median percentage of 
laboratories testing by more than one method was slightly higher than for 
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‘normal’ samples at 17.9% for English NHS Trust laboratories (range 9.1 to 
27.0%) and 44.2% (range 35.3 to 64.7%) for Non-English NHS Trusts. For 
Non-British Isles laboratories the median was 12.2% (range 10.5 to 13.9%). 
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Specimen  
Essential 
Fractions 
Numbers using a confirmatory method by Laboratory type 
NHS (English 
Trusts) 
NHS (Non-
English 
Trusts) 
UK 
private 
RoI 
Non 
British 
Isles 
1504AH1 Hb A 5 6 0 4 14 
    4.3% 35.3% 0.0% 66.7% 10.0% 
1504AH2 Hb A+Hb F 22 8 0 4 15 
    18.8% 47.1% 0.0% 66.7% 10.7% 
1504AH3 Hb A+Hb S 77 13 0 4 27 
    65.8% 76.5% 0.0% 66.7% 19.3% 
1505AH1 Hb A+Hb S 87 14 0 4 28 
    71.9% 82.4% 0.0% 66.7% 18.9% 
1505AH2 Hb A+Hb F 11 7 0 4 18 
    9.1% 41.2% 0.0% 66.7% 12.2% 
1505AH3 Hb A+Hb F 22 8 0 4 19 
    18.2% 47.1% 0.0% 66.7% 12.8% 
1506AH1 Hb A+Hb S 83 13 0 4 30 
    69.2% 76.5% 0.0% 66.7% 19.9% 
1506AH2 Hb A+Hb F 11 6 0 4 21 
    9.2% 35.3% 0.0% 66.7% 13.9% 
1506AH3 Hb A 8 6 0 4 19 
    6.7% 35.3% 0.0% 66.7% 12.7% 
1601AH1 Hb A 10 6 0 4 16 
    8.3% 35.3% 0.0% 80.0% 9.9% 
1601AH2 Hb A+Hb F 21 6 0 4 17 
    17.5% 35.3% 0.0% 80.0% 10.5% 
1601AH3 Hb A+Hb S 78 13 0 4 29 
    65.0% 76.5% 0.0% 80.0% 17.9% 
1602AH1 Hb A 11 7 0 4 17 
    8.9% 41.2% 0.0% 66.7% 10.8% 
1602AH2 Hb A+Hb S 85 13 0 4 27 
    69.7% 76.5% 0.0% 66.7% 17.1% 
1602AH3 Hb A+Hb F 33 11 0 4 19 
    27.0% 64.7% 0.0% 66.7% 12.1% 
1603AH1 Hb A Hb S 87 13 0 3 31 
    72.5% 76.5% 0.0% 60.0% 19.3% 
1603AH2 Hb A 13 6 0 3 19 
    10.8% 35.3% 0.0% 60.0% 11.8% 
1603AH2 Hb A+Hb C 68 12 0 3 27 
    56.7% 70.6% 0.0% 60.0% 16.8% 
 
Table 6.6 Numbers of laboratories reporting a confirmatory method  
for fraction identification by laboratory type  
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6.4.5 Overall analysis of interpretive comments reported  
The coded comments returned for each of the six specimens in the study are 
shown graphically in Figures 6.3 to 6.8 and summarised in Tables 6.7 to 6.12. 
Each table shows the total number of returns from all participants by comment 
code, ordered by frequency of use, and the returns for the English NHS Trust and 
the Non-British Isles laboratories. The five most frequently used comment codes in 
the English NHS Trust and the Non-British Isles groups are ranked from one (most 
used) to five. Essential interpretive codes are shown in green and acceptable 
codes in orange. The number of different coded comments used by the two groups 
is shown for each specimen together with the average number of codes returned 
per laboratory. 
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Figure 6.3. Interpretive comment codes returned for specimen 1504AH1 by 
English NHS Trust laboratories and Non-British Isles laboratories. The case 
simulated an antenatal patient with no evidence of an abnormal Haemoglobin 
variant or thalassaemia and red cell indices. 
Coded comment 
Total all 
labs 
English NHS Non-British Isles 
N Rank N Rank 
400 262 114 1 126 1 
451 146 102 2 30 2 
402 53 27 3 21 3 
403 15 5 4 7 5 
404 14 2 5 11 4 
453 6 0 
 
6 
 452 6 0 
 
5 
 455 3 0 
 
2 
 431 2 0 
 
1 
 454 2 0 
 
1 
 419 1 0 
 
1 
 432 1 0 
 
1 
 No. codes used 12 5 12 
Avge No. codes/lab 1.9 2.2 1.7 
Table 6.7. Coded comments returned for specimen 1504AH1 by laboratory type. 
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Figure 6.4. Interpretive comment codes returned for specimen 1504AH2 by 
English NHS Trust laboratories and Non-British Isles laboratories. The case 
simulated a young female delta-beta thalassaemia carrier (non-antenatal patient). 
Coded comment 
Total all 
labs 
English NHS Non-British Isles 
N Rank N Rank 
435 183 92 1 72 2 
441 151 61 2 73 1 
455 112 55 4 44 4 
402 94 70 3 18 
 454 92 34 5 48 3 
434 65 19 
 
39 5 
452 49 9 
 
35 
 433 36 24 
 
7 
 432 14 1 
 
12 
 404 6 5 
 
1 
 453 4 0 
 
4 
 400 3 1 
 
2 
 431 3 1 
 
2 
 415 2 0 
 
2 
 451 2 0 
 
2 
 No. codes used 15 12 15 
Avge No. codes/lab 3.1 3.4 2.9 
Table 6.8. Coded comments returned for specimen 1504AH2 by laboratory type. 
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Figure 6.5. Interpretive comment codes returned for specimen 1505AH2 by 
English NHS Trust laboratories and Non-British Isles laboratories. The case 
simulated an antenatal patient with normal red cell indices and a slightly raised 
Haemoglobin F% (6.3%) consistent with pregnancy. 
Coded comment 
Total all 
labs 
English NHS Non-British Isles 
N Rank N Rank 
441 212 81 3 106 1 
400 127 83 1 30 4 
451 99 83 1 14 
 434 84 17   62 2 
452 57 21 5 34 3 
402 44 31 4 13 
 454 39 9   25 5 
403 20 13   7 
 404 12 4   8 
 435 12 0   11 
 455 12 1   8 
 453 2 1   1 
 431 1 0   1 
 432 1 0   1   
No. codes used 14 11 14 
Avge No. codes/lab 2.7 3.1 2.4 
Table 6.9. Coded comments returned for specimen 1505AH2 by laboratory type.  
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Figure 6.6. Interpretive comment codes returned for specimen 1601AH3 by 
English NHS Trust laboratories and Non-British Isles laboratories. The case 
simulated an antenatal sickle cell carrier. 
Coded comment 
Total all 
labs 
English NHS Non-British Isles 
N Rank N Rank 
411 294 121 2 143 1 
452 250 122 1 107 2 
403 105 76 3 17 4 
454 67 24 4 43 3 
404 9 3 5 6 
 455 9 1   8 5 
415 4 0   4 
 441 3 2   1 
 412 2 0   2 
 425 2 0   2 
 426 2 0   2 
 431 2 0   2 
 451 2 0   2 
 400 1 1   0 
 432 1 0   1 
 453 1 1   0   
No. codes used 16 9 14 
Avge No. codes/lab 2.6 3 2.3 
 
Table 6.10. Coded comments returned for specimen 1601AH3 by laboratory type.   
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Figure 6.7. Interpretive comment codes returned for specimen 1603AH1 by 
English NHS Trust laboratories and Non-British Isles laboratories. The case 
simulated an antenatal sickle cell carrier and probable coexistent alpha 
thalassaemia trait. 
Coded comment 
Total all 
labs 
English NHS Non-British Isles 
N Rank N Rank 
411 273 117 1 130 1 
452 219 117 1 102 2 
455 145 90 3 55 3 
432 111 55 4 45 5 
433 92 37 5 46 4 
454 69 23   44 
 
426 28 0   28 
 
404 19 12   4 
 
431 11 3   7 
 
453 7 2   5 
 
402 3 2   1 
 
412 3 1   2 
 
415 2 1   1 
 
434 2 0   1 
 
400 1 0   1 
 
421 1 0   1 
 
425 1 0   1 
 
451 1 0   1   
No. codes used 18 12 18 
Avge No. codes/lab 3.6 4 3.2 
Table 6.11. Coded comments returned for specimen 1603AH1 by laboratory type.   
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Figure 6.8. Interpretive comment codes for 1603AH3, English NHS Trust and 
Non-British Isles laboratories. The case was an antenatal patient with Hb C carrier. 
Coded comments 
Total all 
labs 
English NHS Non-British Isles 
N Rank N Rank 
412 271 114 2 133 1 
452 215 117 1 98 2 
403 93 72 3 14 4 
454 69 19 5 44 3 
402 46 35 4 11 
 455 16 4   12 
 404 15 8   6 
 432 15 1   14 4 
415 12 5   6 
 411 8 1   7 
 400 4 1   3 
 451 4 1   3 
 414 3 0   3 
 433 3 0   3 
 417 2 0   2 
 426 2 0   2 
 419 1 0   1 
 421 1 0   1 
 431 1 0   1 
 441 1 0   1   
No. codes used 20 12 20 
Avge No. codes/lab 2.9 3.3 2.5 
Table 6.12. Coded comments returned for specimen 1603AH3 by laboratory type.   
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With the exception of specimen 1505AH2, the essential comments were the top-
ranked comments by both the English NHS and the Non-British Isles groups and 
more than 80% of the total comments returned were in consensus with the 
essential and acceptable comments (see Table 6.13). The percentage agreement 
varied by laboratory type and specimen: the consensus with the essential and 
acceptable comments for English NHS Trusts was 100% for the normal specimen 
(1504AH1), 98.0% to 98.9% for the specimens with Hb variants (1601AH3, 
1603AH1 and 1603AH3) and 85.8 and 86.3% for the specimens with raised Hb F 
(1504AH2 and 1505AH2). The consensus of the Non-British Isles laboratories with 
the essential and acceptable comments was lower: 92.0% for the normal 
specimen and 88.8 to 95.3% for specimens with an abnormal Hb variant. The 
greatest difference was seen in the comments returned by the Non-British Isles 
laboratories for the raised Hb F specimens: the consensus with the essential and 
acceptable comments was 80.3% for the delta-beta thalassemia carrier specimen 
(1504AH2) but only 58.6% for specimen with a slightly raised Hb F (1505AH2).  
The consensus agreement with the target values is important as less than 80% 
consensus may indicate that the specimen will lack credibility for EQA 
performance assessment and should be reported for educational purposes only. 
UK NEQAS Haematology experience is that performance assessment of a 
specimen with a less than 80% consensus will result in an unacceptably high 
number of objections and complaints from participants. 
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Specimen 
English NHS Trusts Non-British Isles 
Total 
comments 
Ess/Acc 
comments 
% 
Total 
comments 
Ess/Acc 
comments 
% 
1504AH1 250 250 100.0% 212 195 92.0% 
1504AH2 372 321 86.3% 361 290 80.3% 
1505AH2 345 296 85.8% 321 188 58.6% 
1601AH3 351 347 98.9% 340 324 95.3% 
1603AH1 460 451 98.0% 475 426 89.7% 
1603AH3 378 374 98.9% 365 324 88.8% 
 
Table 6.13. Consensus of coded comments returned with the essential and 
acceptable comments, by laboratory type. 
 
The number of coded comments reported per laboratory is indicative of the 
complexity of the case: an average of two comments suggests a simple case with 
one interpretive comment and one giving recommendations for action, an average 
of three an intermediate complexity case requiring two or more interpretive 
comments and four a complex case requiring three or more interpretive comments 
and / or more than one recommendation for action (e.g. partner testing and referral 
to a consultant haematologist). The English NHS Trust laboratories reported more 
codes per specimen in their answers (mean 3.2, range 2.2 to 4.0) than the Non-
British Isles group (mean 2.5, range 1.7 to 3.2). In contrast, the Non-British Isles 
group used a wider range of codes for each specimen (range twelve to twenty) 
compared to the English NHS Trusts (range five to twelve). Using the Mann-
Whitney U test the difference in the numbers of comments/laboratory and the total 
number of codes used was statistically significant (p < 0.001) by laboratory type. 
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6.4.6 The combination of interpretive comments returned by individual 
laboratories 
The correct combination of comments is essential to report an unambiguous 
diagnostic interpretation to the clinician. The overall summary of the codes 
returned by all participants can hide the fact that contradictory codes have been 
reported in a combination that could prove confusing in the case of a real patient. 
The numbers of correct, partially correct and incorrect combinations of interpretive 
comments by laboratory type are summarised in Table 6.14. 
As with the overall analysis of the codes returned, there was a difference by both 
laboratory type and specimen. English NHS laboratories returned fewer incorrect 
interpretations (70/717, 9.6% of total returns) and recommendations for action 
(17/647, 2.6% of eligible returns) than the Non-British Isles laboratories (209/835, 
25.0% and 120/626, 19.2% respectively). The majority of incorrect interpretations 
were returned for the two specimens with raised Hb F% (1504AH2 and 1505AH2): 
75.7% (53/70) of incorrect interpretations returned by English NHS Trusts and 
58.4% (122/209) by Non-British Isles laboratories. The Non-British Isles group also 
returned a high number of incorrect interpretations for specimens 1603AH1 (sickle 
cell carrier with probable coexistent alpha thalassaemia trait; 38/209 or 18.2% 
incorrect) and 1603AH3 (Hb C carrier; 33/209 or 15.8% incorrect). 
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Recommendations for action 
    English NHS Trusts Non-British Isles 
Specimen Interpretation N Correct Partial Incorrect N/A N Correct Partial Incorrect N/A 
1504AH1 Correct 116 101 15 0 - 122 30 82 10 - 
  Partially correct 2 0 2 0 - 1 0 0 1 - 
  Incorrect 0 - - - 0 3 - - - 3 
1504AH2 Correct 75 75 0 0 - 55 55 0 0 - 
  Partially correct 8 8 0 0 - 20 20 0 0 - 
  Incorrect 35 - - - 35 53 - - - 53 
1505AH2 Correct 50 38 5 7 - 12 1 9 2 - 
  Partially correct 51 40 6 5 - 56 9 34 13 - 
  Incorrect 18 - - - 18 69 - - - 69 
1601AH3 Correct 118 118 0 0 - 135 102 0 33 - 
  Partially correct 0 0 0 0 - 0 0 0 0 - 
 
Incorrect 4 - - - 4 13 - - - 13 
1603AH1 Correct 55 55 0 0 - 44 39 0 5 - 
  Partially correct 60 57 0 3 - 66 46 0 20 - 
  Incorrect 5 - - - 5 38 - - - 38 
1603AH3 Correct 112 110 0 2 - 115 79 0 36 - 
  Partially correct 0 0 0 0 - 0 0 0 0 - 
  Incorrect 8 - - - 8 33 - - - 33 
                        
  TOTAL 717 602 28 17 70 835 381 125 120 209 
Table 6.14. Correct and incorrect interpretations and recommendations for action returned by English NHS Trusts and Non-British Isles 
laboratories by specimen distributed. Incorrect interpretations were not assessed for the correctness of the recommendations for action  
(N/A = Not Applicable) 
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Looking at each individual specimen, the main observations were: 
6.4.6.1 Specimen 1504AH1 simulated an antenatal patient with no evidence 
of an abnormal Hb variant or thalassaemia. The specimen was 
straightforward, with an average of 1.9 coded comments returned 
per participating laboratory. There were no incorrect interpretations 
or recommendations returned by English NHS Trusts. The Non-
British Isles group of participants returned three incorrect 
interpretations: a diagnosis of beta thalassaemia carrier (reporting a 
Hb A2 result of 3.6%), an unidentified fraction and possible alpha 
thalassaemia carrier. The incorrect recommendations for action by 
Non-British Isles laboratories were recommending partner testing in 
a normal ‘patient’. The major difference in the coded comments 
returned by English NHS Trusts and Non-British Isles laboratories 
was the greater use of the coded comment 451 (Partner testing not 
indicated) by English NHS Trusts. 
6.4.6.2 Specimen 1504AH2 simulated a patient with a ‘low blood count', 
found to be a carrier of delta-beta thalassaemia. The average 
number of coded comments used per laboratory was 3.1. The case 
was a non-antenatal ‘patient’ and there is no NHS STP guidance on 
the correct recommendations for action; therefore, all 
recommendations were classified as 'correct'. Given that the ‘patient’ 
was a young woman, counselling would be advisable but partner 
testing may be irrelevant unless she is pregnant or planning a 
pregnancy. Thirty five (35/118, 29.7%) English NHS and 53/128 
(41.4%) Non-British Isles laboratories returned an incorrect 
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interpretation for this case. Eighteen NHS English Trusts and thirty-
six Non-British Isles laboratories did not give the essential 
interpretation of delta-beta thalassaemia carrier. Other incorrect 
returns by both laboratory types related to the use of coded 
comments for HPFH or alpha thalassaemia carrier in addition to the 
essential comments, the use of no evidence of thalassaemia (with or 
without the coded comment for delta-beta thalassaemia), or the use 
of coded comment 404 (no evidence of beta thalassaemia) without 
the use of the coded comment for delta-beta thalassaemia. 
Occasional Non-British Isles laboratories also used coded comments 
for the presence of an abnormal Hb variant or beta thalassaemia 
carrier. None of the laboratories giving the diagnosis of beta 
thalassaemia carrier reported a Hb A2 greater than 3.5%. The major 
difference between the two laboratory types was the greater use of 
the coded comment 402 (No evidence of sickle haemoglobin) by the 
English NHS Trusts group. 
6.4.6.3 Specimen 1505AH2 simulated an antenatal patient with normal red 
cell indices and a slightly raised Hb F (6.3%), consistent with 
pregnancy. The average number of coded comments used per 
laboratory was 2.7. Eighteen (18/119, 15.1%) English NHS Trusts 
reported an incorrect interpretation for the case compared to 69/137 
(50.4%) of Non-British Isles laboratories. The incorrect 
interpretations mainly related to the omission of one or more of the 
essential diagnostic comments (eighteen English NHS Trusts and 
fifty-eight Non-British Isles laboratories), the use of coded comments 
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for HPFH in addition to the essential comments (eleven Non-British 
Isles laboratories) and occasional laboratories using coded 
comments for alpha thalassaemia carrier. One Non-British Isles 
laboratory gave the interpretation of beta thalassaemia trait carrier, 
although reported a Hb A2 result of 2.1%. Only two laboratories did 
not give an interpretation related to a raised Hb F: one reported the 
consensus Hb F%, the other did not measure Hb F% but noted it as 
‘normal’ in a free text comment. Twelve (12/119, 10.1%) English 
NHS Trusts gave an incorrect recommendation for action: the 
recommendations were for partner testing or referral to a consultant 
haematologist, which is not recommended by the NHS STP unless 
the Hb F is greater than 10.0%. This case showed the greatest 
divergence between the two laboratory types in the 
recommendations given, with a greater use of the coded comment 
451 (Partner testing is not indicated) by the English NHS Trust 
laboratories.  
6.4.6.4 Specimen 1601AH3 simulated an antenatal patient and a sickle cell 
carrier. The average number of coded comments returned per 
laboratory was 3.0. Four (4/122, 3.3%) English NHS Trusts reported 
an incorrect interpretation: all reported the case as a sickle cell 
carrier but three gave additional out-of-consensus comments of No 
evidence of a Hb variant or thalassaemia and/or Raised Hb F, 
reporting Hb F concentrations of 1.0 to 1.5%. The remaining 
laboratory did not report the case as a sickle cell carrier as they 
would have referred the specimen to another laboratory for further 
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testing had this been a patient’s sample, i.e. they were ‘unable to 
identify’. Thirteen (13/148, 8.8%) Non-British Isles laboratories 
returned an incorrect interpretation: five did not report the case as a 
sickle cell carrier, of which three reported a Hb variant carrier and 
two homozygous sickle cell disease. The remainder reported a sickle 
cell carrier but in addition: one reported Hb C carrier (but in fact were 
unable to identify because the analyser used did not distinguish 
between Hb S and Hb C), two reported an unidentified or NS fraction 
but again were unable to identify, two reported beta thalassaemia 
carrier (reporting Hb A2 results of 3.6% and 4.1%), one sickle-beta 
thalassaemia, one raised Hb F (Hb F of 1.1%) and one alpha 
thalassaemia carrier. These interpretations either alone or in 
combination with sickle cell carrier could result in confusion if this 
were a patient’s sample. Thirty-three Non-British Isles laboratories 
gave an incorrect recommendation for action: two reported partner 
screening as not indicated and the remainder made no 
recommendation on partner testing. The main difference between 
the laboratory types in terms of the coded comments used was a 
greater use of the coded comment 403 (No evidence of 
thalassaemia) and the near 100% use of the recommendation that 
partner testing is indicated (coded comment 452) by English NHS 
Trust laboratories compared to 72% of Non-British Isles laboratories. 
6.4.6.5 Specimen 1603AH1 simulated an antenatal patient and a sickle cell 
carrier with coexistent alpha thalassaemia trait. The specimen had 
the highest number of codes used per laboratory (3.6). Five (5/120, 
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4.2%) English NHS Trusts reported an incorrect interpretation: three 
incorrectly reported the patient as a beta thalassaemia carrier, either 
in addition to a sickle cell carrier (two giving Hb A2 results of 3.8% 
and 4.0%) or alone (reporting a Hb A2 of 4.4%), one reported a Hb 
variant carrier and one Hb C carrier. Both the latter two used an 
analyser unable to differentiate Hb S and Hb C and were in fact 
‘unable to identify’. Thirty eight (38/148, 25.7%) Non-British Isles 
laboratories reported an incorrect interpretation: thirty four reported 
the case as a sickle-beta thalassaemia carrier or beta thalassaemia 
carrier, either in addition to or in place of a diagnosis of sickle cell 
carrier. Two reported a Hb C carrier in addition to sickle cell carrier 
but were using an analyser unable to differentiate between the two 
variants, one reported homozygous sickle cell disease (failing to 
report Hb A in their fraction identification) and one reported no 
abnormality detected. The use of the coded comments for possible 
alpha thalassaemia carrier (coded comments 432 and 433) by both 
groups is of interest. This ‘patient’ is almost certainly an alpha 
thalassaemia carrier given the all methods mean Hb S concentration 
of 24.9%; since she is of Caribbean origin, she would most likely 
have been a homozygote for alpha plus thalassaemia (Weatherall 
and Clegg, 2001). Approximately 30% of both laboratory types used 
coded comment 433 (Possible alpha zero thalassaemia carrier and / 
or iron deficiency), about the same proportion as used the essential 
coded comment 432 (Possible alpha plus thalassaemia carrier and / 
or iron deficiency). For the purposes of this study, code 433 was 
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considered acceptable as the outcome of both was ‘safe’ and 
accurate diagnosis of alpha thalassaemia status can only be 
achieved using molecular techniques; however, this observation 
suggests that either the coded comments available require 
clarification or simplification or that additional education of 
participants may be required. The main difference between the 
laboratory types with respect to recommendations for action was the 
advice that partner testing is indicated (coded comment 452), which 
was given by 98% of English NHS Trusts compared to 79% of Non-
British Isles laboratories. The recommendation for testing for iron 
deficiency (coded comment 455) was used by 75% of English NHS 
Trusts and 36% of Non-British Isles laboratories. 
6.4.6.6 Specimen 1603AH3 simulated an antenatal patient and a Hb C 
carrier. The number of coded comments used per laboratory was 
3.3. Eight (8/120, 6.7%) English NHS Trusts gave an incorrect 
interpretation: six did not give the interpretation of Hb C carrier, one 
gave a normal interpretation, one a diagnosis of sickle cell carrier 
and four a Hb variant carrier but were in fact probably ‘unable to 
identify’. One reported a NS fraction in addition to Hb C carrier and 
one an alpha thalassaemia carrier. All except the laboratory returning 
a ‘normal’ interpretation advised partner testing. Thirty three (33/148, 
22.3%) Non-British Isles laboratories returned an incorrect 
interpretation making a number of errors: failure to report an 
interpretation, reporting sickle cell carrier, Hb variant carrier, Hb E or 
Hb OArab carrier, alpha thalassaemia carrier, beta thalassaemia 
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carrier in addition to Hb C carrier or a normal result. The laboratories 
reporting the specimen as a sickle cell carrier were those that had 
incorrectly reported Hb S in their fraction identification and two of the 
three reporting the specimen as ‘normal’ had transposed their 
specimens or results. Two English NHS laboratories and thirty six 
Non-British Isles laboratories gave incorrect recommendations for 
action, failing to indicate partner testing is indicated. The main 
difference between the comments returned overall by each 
laboratory type was the greater use of coded comments 402 (No 
evidence of sickle haemoglobin), 403 (No evidence of thalassaemia) 
and the recommendation that partner testing is indicated (coded 
comment 452) by English NHS Trusts. 
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6.5 Discussion 
The interpretation of laboratory results is part of the post-analytical phase of 
laboratory diagnosis and there is a growing awareness of the need to include pre 
and post-analytical processes in laboratory quality management, including the 
quality assurance of interpretation (Plebani, 2009a; Piva, 2009; Plebani, 2010; 
Sciacovelli, 2011; Hammerling, 2015). Inclusion of interpretation in EQA 
performance may be as part of an ‘end to end’ scheme such as the Abnormal 
Haemoglobins scheme or as a separate interpretive comments scheme (Plebani, 
2009b; Vasikaran, 2016), but it is recognised as effective in performance 
improvement in the diagnostic interpretation of genetic conditions (Hastings, 2008; 
Hastings, 2010). The provision of a numerical score is highly effective in 
performance improvement in qualitative EQA (James, 2012). For EQA to be 
effective, participants must regard the criteria by which their laboratory practice is 
converted into a numerical performance score as credible, whether for a 
quantitative, qualitative or interpretive test. Credibility may require demonstration 
of commutability of survey material or the appropriate grouping of methods in a 
state-of-the-art quantitative scheme (Sciacovelli, 2010), the comparison of 
performance to a recognised international guideline or standardised system of 
nomenclature and/or a scheme that recognises different levels of expertise in the 
participants. The acceptable performance standards and the design model of the 
scheme should also be clearly apparent to participants (Jones, 2017b). 
This study showed that there are significant differences in the use of interpretive 
comments by English NHS Trust laboratories in comparison to Non-British Isles 
laboratories in the numbers of comments used per laboratory and the range of 
comments reported. The observed differences suggest that the English NHS Trust 
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laboratories give a more comprehensive interpretation of each case, using more 
codes per laboratory in each interpretation, e.g. commenting on the Hb variant 
status and thalassaemia status for each patient, including where one or both of 
these is 'normal'. The English NHS laboratories use a smaller range of codes 
overall, suggesting a more accurate and consistent interpretation by this group of 
laboratories. All laboratory types have access to published guidelines on the 
laboratory diagnosis of haemoglobinopathies and the superior performance of the 
English NHS Trust group in interpretation may reflect the proactive oversight of the 
NHS STP including the guidance provided in the Laboratory Handbook (NHS STP 
Antenatal Laboratory Handbook, 2017) and face-to-face training days. 
For most of the first twenty years of operation of the UK NEQAS Abnormal 
Haemoglobins scheme, the predominant laboratory type registered was UK NHS-
based. In 2001, 215 of 265 (81%) participants were UK NHS laboratories with just 
39 (14.7%) non-UK laboratories in the scheme (UK NEQAS Haematology Biennial 
Report, March 2001). In the study, the proportion of laboratories outside the British 
Isles registered for Hb fraction identification, quantitation and interpretation had 
increased to 161 of 307 (52.4%) clinical participants returning results at June 
2016. The significant number of laboratories outside the remit of UK oversight 
bodies requires a review of the scheme to assess how the non-UK laboratories 
can be incorporated into performance assessment. The non-UK laboratories 
represent an important source of statistical robustness for the scheme in the face 
of a shrinking UK participant base; the scheme also has a duty of care to use 
education to improve the quality of laboratory testing wherever tests are 
undertaken. This is a particular challenge when dealing with interpretation rather 
than quantitation, where the scheme is dealing with instruments, reagents and 
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controls that are manufactured to the same standards on an international basis. 
Interpretation by contrast relies on the training and expertise of laboratory staff and 
the professional practice in the country or region in which the laboratory is located. 
The agreement of both English NHS Trusts and Non-British Isles laboratory types 
with the top-ranked essential interpretive comments and the greater than 80% 
consensus of interpretive comments for five of six specimens in the study indicate 
that there is sufficient agreement between the major groups of participants to 
make performance assessment credible for both laboratory types. 
There are particular differences between the groups however, e.g. the inclusion by 
Non-British Isles laboratories of the interpretation of Hb S-beta thalassaemia 
disease and / or beta thalassaemia carrier in sickle cell carrier cases, especially 
where there are microcytic red cell indices as a result of the commonly-occurring 
coexistent inheritance of alpha thalassaemia trait. The Hb A2 measurement by 
HPLC may be elevated artefactually in the presence of Hb S (Stephens, 2012) but 
many Non-British Isles participants quote a raised Hb A2 as evidence for the 
coexistence of beta thalassaemia. Some of these errors may result from the 
heuristics of clinical decision-making and improved direct EQA interaction with 
participants may be a learning tool by which laboratory practice can be modified.  
The incidence of the different types of fraction identification errors varied according 
to the nature of the specimen and geographical location. Detected Tx and UI 
errors in the study were generally low for all laboratory types, although these 
errors may be underestimated as a like-for-like Tx will go undetected and an UI 
error without supporting commentary from the laboratory would be counted as an 
'Other' error. The percentage of UI errors was higher for the one Hb C carrier (Hb 
A + Hb C) specimen distributed and this may reflect unfamiliarity with the 
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condition, both in the EQA scheme and as a clinical case amongst some 
participants. The incidence of ANR errors by Non-British Isles laboratories was 
approximately fourfold higher than by UK laboratories for the frequently distributed 
specimen types, probably because ANR errors are actively followed up with UK 
laboratories by UK NEQAS as part of performance management. Interestingly, the 
incidence of ANR errors for the Hb C carrier case was low for all laboratory types, 
possibly because a lack of familiarity with the case made all laboratories focus 
more fully on accurate reporting.  
The incidence of ‘other’ errors was highest amongst Non-British Isles laboratories 
for all specimens. In some cases, these errors may be clerical in nature. The data 
capture method for fraction identification in the UK NEQAS Abnormal 
Haemoglobins scheme was designed when the scheme was first developed. The 
participant marks the fractions present from a selection of Hb A, Hb S, Hb C, Hb 
D, Hb E, Hb A2, Hb F and ‘non-specified’ (NS) fraction. Where participants are 
using methods that do not distinguish between Hb C and Hb E, they may select 
‘Hb C or Hb E’, an historic option reflecting the inability to separate these fractions 
by alkaline electrophoresis, which was the predominant screening method twenty 
years ago; however, there is no similar allowance for current HPLC methods that 
do not differentiate between Hb S and Hb C. There is a higher incidence of 
reporting NS fractions and additional abnormal fractions by non-British Isles 
laboratories; occasional laboratories regularly mark all the common fractions 
present, perhaps in the hope that one will be correct, and the use of the NS option 
may be poorly understood.  
The compliance with the recommendation to confirm the identification of an 
abnormal variant by two methods based on different physicochemical method 
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principles is apparently poor amongst all laboratory types. Approximately 63% of 
English NHS Trusts reported using two or more methods for specimens containing 
Hb S or Hb C compared to approximately 45% of Non-British Isles laboratories. 
Only five to ten percent reported using more than one method for normal 
specimens (Hb A, with a normal Hb F%) suggesting that participants are making 
the effort to mark the methods used on each specimen and not just entering the 
same options regardless of content. The data entry options for the scheme no 
longer capture the true workflow in the laboratory since there is no opportunity to 
enter referral to another laboratory except in written comments, which are difficult 
to performance assess efficiently from several hundred participants.  
An option may be to allow laboratories with only one method available to register 
as ‘screening’ laboratories and opt out of confirmatory testing for EQA specimens. 
There is precedent for this in the different levels of registration in the UK NEQAS 
Haematology Blood Films for Parasitology programme, which allows participants 
to register for 'screening only' or for 'parasite species identification', depending on 
their self-declared level of service provision (UK NEQAS Haematology 
Participants' Manual, 2017). The scheme should consider amendment of the 
terminology used in data entry to reflect the use of retention time ‘windows’ or 
‘zones’ rather than suggesting that a precise fraction identification is possible, 
capturing data in the ‘what did you see’ followed by ‘how would you report this’ or 
'what actions would you take' fashion,. This would allow the removal of the NS 
fraction option, to be replaced by ‘unable to identify’ or UI with the requirement to 
give the position and percentage of the peak, an assessment of its significance 
and what follow up actions are needed. Additional guidance on data entry and tips 
for successful participation specific to the Abnormal Haemoglobins scheme, 
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published in the Participants' Manual and linked to the data entry pages or 
instruction sheets for the scheme could also improve the quality of the data 
captured. 
UK NEQAS Haematology is unable to provide some rarely available but clinically 
significant Hb variants, e.g. Hb OArab, which are rare amongst UK blood donors. 
Even the provision of Hb D and Hb E carriers as EQA specimens is a challenge; 
none was distributed in the year studied and it is rare for these variants to be 
distributed more than once every five to ten years, neither did the scheme 
distribute a beta thalassaemia carrier case during the period due to difficulties in 
sourcing a donor. Given that good quality management depends upon staff 
education and training as well as quality control and EQA, the scheme could utilise 
online case provision to fill these gaps, with background case details with 
laboratory results from a range of analysers and methods from which the 
participant can select their own. The cases would not only allow performance 
assessment in a traditional EQA fashion but would also provide an educational 
resource for laboratory staff. 
A major challenge to the expansion of performance assessment is the additional 
workload for scheme personnel that it will incur. In this study, there was a total of 
approximately six fraction identification errors per specimen by UK laboratories in 
the study, which are currently followed up. There were an additional eighteen per 
specimen on average by non-British Isles laboratories, i.e. the workload would be 
quadrupled for fraction identification, without the additional impact of performance 
assessment of interpretation for all participants. The number of interventions 
should decrease with time as a result of performance improvement in response to 
monitoring but the long-term success of the initiative will depend upon the 
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sustainability of the process. For this reason, it is essential to review the 
registration options for participants, the data capture mechanism and the 
introduction of rules-based systems to automate the management of first 
incidences of unsatisfactory performance. The methods of fraction identification 
must be linked with interpretive comment assessment to take account of the 
laboratory's service provision. The scheme must ensure that the data it gathers is 
as free of ‘blunders’ as possible, so that it provides the best reflection of current 
laboratory practice. 
UK NEQAS has a duty of care to the laboratories and the patients they serve, 
regardless of where the laboratory is based, and to work to improve laboratory 
performance through education, especially in the rare anaemias where the 
relatively small number of participants in an individual country may result in greater 
reliance on the support provided by international service providers (Vives-Corrons, 
2014). The increasing international profile of the scheme means that the scheme 
must become more proactive in performance assessment in this complex area for 
all participants. The major barrier is the workload that will be associated with the 
extension of scoring to the qualitative aspects of the scheme as well as to non-UK 
laboratories. 
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7.1 Discussion 
The thalassaemia disorders and other significant haemoglobinopathies are 
amongst the most common single gene disorders worldwide and predicted to pose 
an increasing health burden to countries of all income levels (Weatherall, 2010; 
Piel, 2016). They are regarded as rare in Europe (Regulation (EC) 141/2000) and 
the majority of haemoglobinopathy and thalassaemia disease patients are born in 
poorly resourced regions of the world (Weatherall, 2011). According to data from 
the NHS Sickle and Thalassaemia Screening Programmes there are twenty to 
thirty babies with possible beta thalassaemia major born in the UK annually (NHS 
Sickle and Thalassaemia Screening Programme Data Report 2015/16). 
Treatment for beta thalassaemia major is palliative, comprising regular blood 
transfusion and iron chelation, which have significantly improved life expectancy in 
thalassaemia sufferers, although the regime requires lifelong compliance from the 
patient and has a major impact on their quality of life (Telfer, 2005; Clarke, 2010). 
The treatment of transfusion-dependent thalassaemia is also costly: a 
retrospective study of fifty transfusion-dependent beta thalassaemia major patients 
estimated the mean total cost of treatment per patient per year in the United 
States as $128,062 (Sheth, 2017). Recent estimates of the annual cost of treating 
transfusion-dependent beta thalassaemia major in Turkey, by comparison, were 
lower, at $14,360; however, the number of transfusion-dependent beta 
thalassaemia major patients in the country results in annual medical costs of more 
than 58 million US$ per year (Antmen, 2017). In 1999, the lifetime treatment costs 
for a patient with beta thalassaemia major in the UK were estimated to be 
approximately £200,000 (Karnon, 1999). The only potential cure is allogeneic 
haemopoietic stem cell transplantation (HSCT), of which more than three 
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thousand have been performed worldwide for beta thalassaemia (Angelucci, 2008; 
Gaziev, 2008; Angelucci, 2010; Lucarelli, 2012). HSCT requires an HLA-
compatible donor but more recent work has suggested the use of genetically 
corrected autologous HSCT may be a prospect where no HLA-matched donor is 
available (Acuto, 2014). The majority of beta thalassaemia disease patients are in 
low and middle-income countries where the cost of palliative support makes HSCT 
an attractive, although still costly option (Mehta, 2013). A low cost, effective HSCT 
programme has been described in Pakistan, where costs have been controlled 
through limiting the highly engineered protective environments associated with the 
procedure in high income countries without compromising the outcome in the pilot 
(Faulkner, 2011). 
The main means of control for both the thalassaemia disorders and other 
significant haemoglobinopathies is through screening programmes to detect 
carriers, with the opportunity this provides for informed reproductive choice (Cao, 
2013). In the absence of definitive molecular testing, detection of carriers is 
presumptive requiring knowledge of the application and interpretation of the 
appropriate laboratory tests. Detection of beta thalassaemia carriers relies on a 
small difference between the normal and pathological reference ranges of the 
minor Hb fraction, Hb A2. With some mutations, the carrier is described as ‘silent’ 
because the Hb A2 concentration is borderline or overlaps the normal reference 
range (Old, 2012). Consequently, the laboratory detection of beta thalassaemia 
carriers requires excellent laboratory quality to ensure that testing is both accurate 
and precise. Quality assurance, comprising internal quality control (IQC) and 
external quality assessment (EQA), laboratory accreditation and audit, are 
  
240 
objective measures of performance by which the diagnostic testing provider 
demonstrates the competence of their service. 
UK NEQAS Haematology provides one of the most comprehensive programmes 
of EQA for the laboratory diagnosis of haemoglobinopathies worldwide. Its major 
comparators in terms of service provision are the College of American 
Pathologists' (CAP) PT programme and the Royal College of Pathologists in 
Australasia Quality Assurance Programme (RCPAQAP). UK NEQAS Haematology 
provides haemoglobinopathy EQA in partnership with other EQA providers in 
some smaller countries in Europe and the Middle East, who have opted not to 
develop their own schemes. There are commercial providers, who offer what has 
been defined in IFCC guidelines as proficiency testing (PT) rather than EQA, to 
large numbers of participants but these services are more limited in terms of 
frequency, scope and above all educational content (Maziotta, 2003). A 
questionnaire undertaken by the author on the provision of EQA in the field of rare 
anaemias on behalf of the ENERCA project showed a variable provision of 
haemoglobinopathy EQA in Europe (Vives-Corrons, 2014) in terms of scope and 
frequency of distribution.  
The scope of the UK NEQAS programme had developed considerably in the 
fifteen years prior to the time of writing, with the addition of emergency sickle 
screening, newborn screening using both liquid capillary and dried blood spots and 
molecular testing options, as well as the ‘end-to-end’ testing starting with a clinical 
scenario and finishing with a suggested diagnostic interpretation. During the same 
period, there has been a change in the balance of the laboratories registered, from 
a largely UK base in 2001 (15% of laboratories outside the UK) to just over 50% of 
laboratories registered for full participation based outside the UK at the time of the 
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study. The changing profile of the scheme demonstrates the increased 
significance attached to EQA in laboratory quality management, driven by the 
implementation of the international accreditation standard ISO 15189:2012, and 
the importance attached to quality management and EQA participation in 
professional guidance documents (Ryan, 2010; Vives-Corrons, 2014; Traeger-
Synodinos, 2015; Stephens, 2015). A greater number of participating laboratories 
is a driver in itself for EQA development as it allows more robust statistical 
analysis and makes the scheme viable where there may be insufficient demand in 
a single country. However, the increased diversity of participants’ geographical 
location brings challenges, which the scheme must address to ensure it fulfils its 
duty of care to both the laboratories and the patients they serve, without reduction 
in the service provided to its core UK participants. 
One of the functions of EQA is to provide a ‘state-of-the-art’ overview of laboratory 
performance. The field of Hb A2 measurement has seen the almost complete 
adoption of automation in the past fifteen years, with high performance liquid 
chromatography (HPLC) and capillary zone electrophoresis (CZE) replacing earlier 
manual electrophoretic and chromatographic methods of quantitation. At the time 
of this study, there were no laboratories registered with UK NEQAS Haematology 
for Hb A2 measurement using tandem mass spectrometry (TMS) for Hb A2 
quantitation, although initial enquiries and one request for registration from a non-
British Isles laboratory has been received since the study’s completion. Improved 
performance, as measured by a reduction in the coefficient of variation (estimated 
CV%) from 14.25% to 8.87%, has been seen within the UK NEQAS HPLC users in 
the period 2001 to 2016. Although the removal of less effective instrument models 
may have contributed to this, the reduction suggests other factors may also have 
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had a role, including an increased awareness of the quality of diagnostic testing 
amongst both instrument users and manufacturers, with the driving force of the 
NHS Sickle and Thalassaemia Screening Programme and international bodies 
such as the IFCC and ICSH. Despite the reduction in CV%, the performance of 
participants still does not meet the published biological variation (BV) standards 
although at the time of writing the Ricos BV database 
(See https://www.westgard.com/biodatabase1.htm ) only references one BV 
reference for Hb A2 (Mosca, 2013), as used for the ‘acceptable performance limits’ 
in the evaluation of Hb A2 data in this study. 
This study has shown that despite improvements in performance there remain 
differences in Hb A2 measurement between analyser types as well as between 
users of the same analyser, to the extent that an antenatal patient may receive a 
different diagnosis depending upon the testing method used by the laboratory. 
Further work is required on the standardisation of Hb A2 measurements (Paleari, 
2017) as this will provide manufacturers with a product to which they can 
demonstrate their results are traceable. This study supports the production of new 
Hb A2 standards at more than one concentration as the variation between 
instruments appears to differ according to the Hb A2 concentration. The only 
currently available Hb A2 reference material (the WHO Reference Reagent 
89/666) was prepared at two Hb A2 concentrations (normal and beta thalassaemia 
range) but only the beta thalassaemia material was supported by the WHO (Hb A2 
concentration 5.3%). This limits its use, although it can be diluted with umbilical 
cord blood from an infant with no detectable Hb A2 to check linearity (Stephens, 
2015). 
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The aim of all EQA providers is to use a survey or assay material that is identical 
to clinical specimens and commutable for all methods, as well as traceable to a 
reference standard. UK NEQAS Haematology provides a liquid whole blood 
specimen of human origin for its Abnormal Haemoglobin scheme, smaller in 
volume than most clinical specimens but otherwise suitable for analysis without 
reconstitution or further preparation. The study examined whether the difference in 
anticoagulant and age of the EQA material compared to clinical samples had an 
impact on Hb A2 measurement, which would limit the usefulness of the survey 
material and confound performance assessment. The study provided evidence 
that UK NEQAS survey material in the Abnormal Haemoglobins is comparable in 
performance for Hb A2 measurement to blood taken into 
ethylenediaminetetraacetic acid (EDTA), the usual anticoagulant for this 
investigation. Earlier work suggested that specimens for Hb A2 are stable for up to 
three weeks if stored at 2 to 8 ⁰C in EDTA and if taken into other anticoagulants 
(Tietz, 1990; Shokrani, 2002; Maharini, 2014) but none specifically examined the 
combined effect of both anticoagulant and storage on Hb A2 measurement. This 
part of the study warrants continued work as new Hb A2 measurement methods 
come into use. As designed, the EDTA vs. CPD anticoagulated sample 
experiment is not sustainable as a validation method. For future validations it may 
be possible to undertake parallel testing of a new method or model with the EQA 
survey material against one with a track record in the EQA scheme, extended over 
a period of time equivalent to a survey distribution cycle. One consequence of 
producing a whole blood specimen from a single blood donation for several 
hundred laboratories is that the specimen volume is limited (approximately 1 mL) 
and may require analysis in an ‘open’ mode, increasing the opportunity for 
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specimen transposition errors. The study of fraction identification errors showed a 
generally low rate of detected transposition errors (from zero to around 1%) for all 
participants. Transposition is a serious pre-analytical laboratory error; in EQA it is 
a ‘double-edged’ sword in that it incurs adverse performance penalties but is also 
an educational opportunity to increase awareness of the impact of pre-analytical 
errors in screening for genetic disorders. One area that UK NEQAS should 
consider when detecting a transposition error is to ask the laboratory to confirm 
that there has been no transposition of the EQA sample and a patient’s sample, 
which would be a major problem for the scheme in that efforts to improve quality 
had precipitated an error with a patient’s result.  
EQA is often restricted in its geographical reach because of the limitations of the 
specimens used. A commutable specimen may be desirable but not sufficiently 
stable or available in sufficient volume for use on an international basis, restricting 
the effectiveness of EQA in a market where analysers, reagents and calibrators 
are manufactured and marketed globally (Jones, 2017a). The demonstration that 
the UK NEQAS Abnormal Haemoglobins survey material is both comparable in 
performance to clinical samples and stable for sufficient time to allow international 
comparison of Hb A2 performance is significant and confirms the scheme’s 
provision of performance assessment to laboratories internationally. One 
observation of relevance in the discussion of survey material quality is the greater 
frequency of reported apparent ‘non-specified’ fractions by Non-British Isles 
laboratories, seen in the evaluation of fraction identification results in the study. 
The reporting of NS fractions may indicate a lack of understanding in the purpose 
of this category and a desire by the participant to ‘cover all options’; however, the 
scheme should consider whether there is any element of additional deterioration in 
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the specimen during transit causing additional minor peaks associated with an 
aging specimen, although deterioration of this sort has not been seen in stability 
studies undertaken in-house. This could be addressed by asking participants from 
all geographical locations to return the chromatograms or electropherograms of 
the EQA specimen, and undertaking a visual assessment of the quality of the 
separation by location of the participant. 
Screening for beta thalassaemia major is not part of the NHS newborn screening 
programme; however, there is a proposal that a Hb A concentration of less than 
1.5% may be indicative of the condition in newborns of greater than thirty-two 
weeks' gestation (Streetly, 2013). The study assessed the performance of the 
newborn screening methods available at the time to quantitate Hb A% at this low 
concentration, using a sample from an adult homozygous delta-beta thalassaemia 
patient (Hb pattern of Hb F and Hb A2) spiked with varying amounts of normal 
umbilical cord blood (Hb F + Hb A). A difference was seen between the HPLC and 
CZE analysers used for haemoglobinopathy screening in UK newborn screening 
laboratories. Both methods are designed specifically for newborn screening and 
marketed as qualitative rather than quantitative. The Bio-Rad vNBS HPLC 
analyser was capable of measuring Hb A% at levels of 1.0% but the sensitivity of 
the Sebia Neonat Fast CZE system was not reliable at Hb A concentrations below 
2.0%, which might affect quantitation of Hb A at or around 1.5%. Although the 
number of CZE systems studied was small, the findings were supported by other 
literature (Wolff, 2012). The first ten years of the NHS Newborn Screening 
Programme reported the births of 268 ‘Hb F only’ infants in England 
(approximately twenty to thirty per year), which were possible beta thalassaemia 
major babies (NHS Sickle and Thalassaemia Screening Programme Data Report, 
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2015/16). Given that in 2015/16 there were twenty-four ‘thalassaemia affected’ 
pre-natal diagnosis (PND) fetal results and that pregnancy outcome data shows 
that 49.7% of pregnancies affected by beta thalassaemia were known to have 
ended in termination, this suggests that there are still unanticipated beta 
thalassaemia major births in the UK. There is no immediate medical intervention 
for beta thalassaemia major in the newborn, as there is in sickle cell disease, but 
early identification could prepare parents for the impact of a thalassaemic child 
and enable early referral to a consultant haematologist, prior to the development of 
clinical symptoms (Hoppe, 2009). The limitations of the technology used in the 
laboratory must therefore be understood to minimise as far as possible parents 
being giving an incorrect outcome of newborn screening, either receiving false 
reassurance or being unduly alarmed, and may assist in the formulation of policy 
on referral of potentially affected infants for definitive diagnosis. 
The provision of samples from a beta thalassaemia major infant as a specimen for 
newborn screening EQA is a challenge because of the small number of clinical 
cases and the difficulty of obtaining an umbilical cord sample from an affected 
infant. The use of a manipulated adult sample without explanation of its 
provenance may result in different, confused interpretations, e.g. a diagnosis of 
homozygous Hb E or Hb E-beta thalassaemia as a result of the presence of Hb 
A2, limiting the effectiveness of the survey. It may be possible to send out such an 
adult sample and amend the scoring criteria to reflect that the key indicator was to 
report a lack of Hb A; alternatively, the scheme could supply samples of differing 
Hb A%, as an educational exercise to reinforce the participant’s awareness of the 
performance of their analyser. This fits with the objective of the scheme to improve 
laboratory performance through education. 
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The statistical analysis of participants’ data is one of the variables that may 
confound EQA provision (Jones, 2017b; Miller 2011; Kristensen, 2017; Coucke, 
2017). Regardless of whether the scheme design is to assess performance 
against criteria based on regulatory, state-of-the-art, biological variation or clinical 
outcomes, there is a desire from laboratory managers and instrument 
manufacturers to see the statistical evaluation of their analyser against its peers, 
probably for the early identification of adverse performance trends. Within UK 
NEQAS Haematology, the performance scoring system has been designed to give 
a long-term and retrospective assessment of performance for quantitative analytes 
against a consensus mean target of participants’ results, trimmed to remove 
outliers. The system was designed to avoid penalising a participant for a one-off, 
out of consensus result. The scoring system is familiar and well understood by 
participants (Participants’ questionnaire, 2015, reported in unpublished Steering 
Committee papers), but there is concern over both the length of time it may take 
for an unsatisfactorily performing laboratory to be detected for Hb A2 measurement 
and the fact that the score will not detect a one-off error that would constitute 
misdiagnosis if it were a patient’s sample. This study found that there were 
48/10,463 cases of potential misdiagnosis of beta thalassaemia on the basis of Hb 
A2 measurement, forty-two of which were made by participants with satisfactory 
performance scores, plus an additional thirteen potential misdiagnoses identified 
as non-analytical errors such as reporting Hb A% or Hb S% instead of Hb A2% etc. 
These are relatively small numbers, approximately 0.5% of the total, which might 
be detected by some other validation step in the case of a patient. However, each 
of these potentially represented a misdiagnosis of beta thalassaemia, which might 
result either in unnecessary partner testing or a beta thalassaemia carrier 
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antenatal patient being missed. From the perspective of the EQA scheme, these 
potential misdiagnoses are missed learning opportunities that should be used to 
give feedback on performance to the laboratory. Modifications to the scoring 
criteria, e.g. by increasing the multiplier to increase the sensitivity of scoring and 
screening for participants with a deviation index (DI) value of greater than three for 
any specimen would allow the scheme to utilise these opportunities better. The 
scheme should also pilot the use of the ALTM as the target value as there is no 
evidence based reason for continuing to use the MTM, the use of which is based 
on the differences that may have existed for earlier manual methods. There is no 
evidence that the use of ALTM benefits or penalises large or small instrument 
groups but this should be kept under review and consideration given to the use of 
a ‘mean of means’ in the future. 
The inclusion of interpretive EQA is a major area of development for all EQA 
providers, whether as part of 'end-to-end' EQA or the provision of a separate case 
interpretation service. The scoring of interpretation has a number of challenges not 
found in the monitoring of quantitative testing. In particular, the scoring must take 
into account the scope of the service provided by the laboratory, the methods it 
uses and its diagnostic expertise to ensure that assessment is objective and 
effective. This study has highlighted differences in errors of interpretation between 
English NHS Trust laboratories under the oversight of the NHS STP and Non-
British Isles laboratories. English NHS Trust laboratories demonstrated a more 
comprehensive and accurate use of interpretive comments, supporting the positive 
impact of an active programme of education and performance oversight. 
Educational action and feedback by UK NEQAS Haematology may improve the 
performance of laboratories outside the UK with the introduction of scoring for 
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interpretation and proactive follow up of errors by all laboratories, regardless of 
geographical location, as in other specialities (Kettelhut, 2003; Jennings, 2009). 
There are a number of distinct advantages in implementing active performance 
management for all participants as it should improve the quality of data gathered, 
give a better representation of the areas for improvement and add value to 
participation for laboratories wherever they are based. An initial challenge in the 
introduction of scoring for interpretation will be how to represent performance if 
there is a material difference between participant groups; it is possible to assess 
participants according to geographical location but this may be professionally 
sensitive where one country or region performs less well than another. However, 
there was sufficient consensus between the major English NHS and Non-British 
Isles laboratories to suggest that scoring of interpretation should be piloted and 
include all participants. 
A UK NEQAS Haematology survey of participants’ attitudes (Participants’ 
questionnaire 2015, unpublished Steering Committee papers) has shown that 
participants support the introduction of different levels of registration in the 
haemoglobinopathies to take account of the repertoire and expertise of the 
laboratory, for example allowing laboratories with only one analytical method 
available to register as ‘screening’ laboratories. This pattern of registration has 
been used by UK NEQAS Haematology for performance assessment in blood 
parasite screening and identification by blood film morphology, where again there 
was a disparity between the scope of services and expertise of different 
laboratories. An amendment to the scheme design of this nature could also have 
an educational impact on participants, removing the apparent ‘approval’ of their 
identifying a Hb variant as Hb S or Hb C etc. on a single method. In order to 
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achieve this, UK NEQAS Haematology will need to redesign the workflow for data 
capture and evaluation to reflect the manner in which the laboratory has generated 
their results and provide a more holistic approach to EQA performance. 
Although the scheme issued a comprehensive range of samples in the study 
period, the proportions of abnormal cases has deteriorated since 2001 when the 
annual report showed the inclusion of three beta thalassaemia carriers, one Hb D 
carrier and five Hb S carriers out of twelve specimens (UK NEQAS Haematology 
Biennial Scheme Report 2001). The scheme may be able to resolve the provision 
of common conditions distributed with additional support from NHSBT but there 
will remain some, e.g. Hb OArab carrier, Hb E carrier and homozygous or compound 
heterozygous disease states, that are unlikely to be available in sufficient 
frequency as a whole blood specimen for performance assessment. In this 
situation, the gaps could be filled with ‘dry’ cases, either as an additional, online 
EQA specimen or on an educational basis. Dry cases will need to be offered as an 
online programme to allow participants to pick the instrument or method outputs 
appropriate to their laboratory and to ensure adequate quality of reproduction of 
chromatograms or other information sources, as well as to manage the data 
return. This type of programme has proved useful to the laboratory for education, 
continuing professional development and competency as well as for EQA 
(Brereton, 2008; Hastings, 2008). Registration by participant reference number 
(PRN) or laboratory identifier for online cases could be linked to performance with 
standard ‘wet’ specimens and an assessment of the overall improvement in scores 
in the scheme undertaken as a piece of further work. 
The demand for high quality EQA for the haemoglobinopathies is likely to grow 
with the increased requirement for screening and diagnosis of the disorders in 
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both endemic and traditionally non-endemic countries. The potential development 
of global EQA will also require EQA providers with expertise in material 
preparation and data analysis across a wide geographical range. At home, the 
disorders will remain a diagnostic challenge with an increasingly diverse 
population and the globin gene mutations encountered (Henderson. 2009). 
Changes in the provision of diagnostic services with increased ‘hub and spoke’ 
configurations and centralisation of specialist diagnostics as described in Lord 
Carter of Coles’ review of Pathology Services in England and a more recent NHS 
Improvement report (Karakusevic, 2016), may also demand the development of 
different modes of performance assessment.  
The outcomes of this study have shown that the unique resource of the scheme’s 
data can demonstrate areas of concern in laboratory performance. The study has 
highlighted initial and further areas of development for UK NEQAS Haematology in 
the tailoring of performance assessment to clinical practice in the laboratory 
diagnosis of the haemoglobinopathies and the extension of feedback to all 
laboratories to improve their services to patients. 
7.2 Recommendations 
This study has covered a number of areas for haemoglobinopathy EQA provided 
by UK NEQAS Haematology. To ensure that the programme remains fit for 
purpose for its current participant base, the scheme should consider the following 
developments: 
7.2.1 Review and amendment of the current scoring algorithm for Hb A2. 
The first change should be the amendment of the target value used for Hb 
A2 performance assessment from the method trimmed mean (MTM) to the 
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all laboratory trimmed mean (ALTM). This should be undertaken as soon as 
possible (i.e. before the end of 2018) subject to the necessary validation of 
changes to the database and change control. The use of different target 
values is not evidence-based and may penalise participants using CZE 
analysers unfairly because of the smaller inter-analyser variation with the 
CZE group in comparison to the HPLC group. The impact of this change will 
be evaluated through monitoring the number and analyser type of 
instruments in the PUP category for Hb A2, which should be kept to no 
more than 5% of participants. Once the impact of this change has been 
assessed, the scheme should pilot increasing the multiplier for Hb A2 to 
increase the sensitivity of the performance assessment. Again, the 
guideline for the proportion of PUP laboratories should be approximately 
5%. 
7.2.2 The addition of a ‘misdiagnosis’ category to Hb A2 performance 
assessment 
In addition to long-term performance assessment, the scoring system 
should alert participants to errors in EQA that would result in a misdiagnosis 
if they occurred with a patient’s specimen. This is most easily achieved by 
introducing the flagging and review of any EQA result with a DI value equal 
to or greater than 3 in addition to the changes to the scoring algorithm in the 
current year. Not all of these results will need to be notified actively to 
participants but those that represent a misdiagnosis (e.g. a beta 
thalassaemia specimen reported as normal and vice versa) should be 
followed up actively. 
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7.2.3 The introduction of scoring for fraction identification and 
interpretative comments 
Although out-of-consensus fraction identification is notified to UK 
participants, it is essential that scoring for this and for interpretive 
comments is introduced within 12 to 18 months. This will entail a redesign 
of the data entry workflow better to reflect current laboratory practice, with 
different classes of participant registration, e.g. to allow for screening and 
diagnostic laboratories. The scoring of interpretation is linked to fraction 
identification as the laboratory methods used may restrict or dictate the 
interpretive options available. The major challenge with scoring of 
interpretation is the establishment of the ‘model’ or expected answer; 
although consensus is informative, the most commonly reported item may 
not be the most clinically significant. The provision of a model answer will 
require a panel of recognised experts in the field. 
7.2.4 The introduction of ‘dry’ cases for haemoglobinopathy EQA and/or 
educational purpose 
‘Dry’ cases provide an educational opportunity and performance 
assessment of scenarios that include rare haemoglobinopathy carriers or 
disease states. They should be relatively easy to establish in the next 
phase of the development of the new UK NEQAS Haematology digital 
platform. They will require a single sample of blood from a patient with the 
condition of interest, to be tested through the various screening and 
diagnostic methods available so that the participant can view the results in 
a familiar output, together with a background clinical scenario and other 
laboratory results. The results returned may be reported without scoring for 
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educational or competency assessment or may be scored against the same 
criteria as the more usual ‘wet’ specimens. The addition of multiple choice 
questions and additional background information, revealed in a stepwise 
fashion to the user could allow the assessment to be tailored according to 
the knowledge, training and experience of individual healthcare scientists. 
Before commitment to a viable commercial developed software product, this 
development will require modelling in an open source platform, such as 
Google drive or Survey Monkey, trialling a minimum of six cases over the 
space of a year. Once established, the cases could form a library for use by 
subscribing laboratories or individuals. 
7.2.5 The application of active performance assessment to all participants, 
regardless of geographical location 
The extension of active performance assessment to all participants has 
been identified as necessary to fulfil the duty of care the Scheme has to all 
participants and to maintain the integrity and quality of the data returned for 
analysis. Since more than 50% of participating laboratories are outside the 
UK and RoI at the time of writing, this will significantly increase the volume 
of performance notifications. English is widely spoken amongst participating 
laboratories; however, some action may be required to overcome language 
barriers. This may be as simple as providing a directory of numbered 
comments translated into the languages most commonly used amongst 
participants. Additional performance monitoring will increase the Scheme’s 
workload and will only be manageable with the implementation of an 
automated, rules-based system of performance assessment. This will 
require an algorithm of rules to be developed and tested with historical data 
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before coding by the UK NEQAS Haematology commercial database 
provider. Initial pilot testing will be with a single scheme and a relatively 
non-controversial parameter, such as participation performance. Once 
established for UK participants, the process will be rolled out to non-UK 
laboratories. 
7.2.6 The development of graded Hb A% cases for use in the newborn 
sickle screening scheme 
The extension of the work undertaken on the measurement of Hb A% as 
part of newborn haemoglobinopathy screening is novel. Clinical, liquid 
blood specimens from newborn infants with Hb A% less than 1.5% in 
sufficient volume for EQA are rare and the most reliable source will be 
simulated material prepared from an adult patient without Hb A (e.g. a 
patient homozygous for delta-beta thalassaemia) ‘spiked’ with normal cord 
blood to give different of Hb A% values. The drawback of such simulated 
material is that it contains Hb A2, which may confound the interpretation; in 
this case, it is best to identify the specimens as suitable for Hb A% only and 
issued as a separate exercise from other EQA material. The data returned 
will provide no less information on performance, especially of different 
analysers and this would be useful work to follow up. Such exercises could 
be run as part of the regular schedule of exercises, with one annual 
distribution and surplus dbs cards could be made available to subscribing 
laboratories on request for use in instrument evaluation. 
7.2.7 Evaluation of the recommended changes 
The recommended changes are far-reaching and will take a minimum of 
one to two years to implement fully for a participant base of more than 300 
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laboratories. The changes will incur costs in terms of software development 
and staff resources; however, if correctly implemented, they should improve 
the service to participant laboratories and ensure that the Scheme 
maintains its competitive position. Evaluation at all stages of 
implementation is important to ensure that the services are addressing the 
needs of participating laboratories and other stakeholders, e.g. oversight 
bodies and commercial manufacturers. Assessment of stakeholder 
satisfaction and the effectiveness of the changes will take several forms: 
1. Focus group evaluation during planning and pilot stages 
The key focus groups are the Scheme’s expert scientific advisory panel, 
the strategic Steering Committee and the NQAAP, which is the oversight 
body made up of representatives of the professional societies. 
Discussion and feedback from these committees and working or task 
groups formed from their members will provide expert, up-to-date 
evaluation of the plans and ensure that professional guideline advice in 
the field is incorporated into the developments. 
2. Trend analysis of participant performance 
The Scheme monitors the numbers and types of unsatisfactory and 
persistent unsatisfactory UK performers as part of the scheme design 
and the reporting requirements of the professional societies. These 
numbers will increase initially as a result of the proposed changes and 
the numbers of UPs and PUPs will increase significantly if the non-UK 
laboratories are included. However, analysis of the trends in 
performance should demonstrate an eventual downward trend for 
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individual laboratories and method groups, with a removal of less 
effective methodologies. Direct evaluation of individual scenarios, e.g. 
the improvement in performance with a wet sample following a similar, 
educational ‘dry’ case scenario, and the evaluation the interpretation of 
paired cases several months apart will give a measure of the 
effectiveness of the educationanal initiatives. 
3. Comparison of UK and non-UK performance 
The goal of extending performance assessment to non-UK laboratories 
is to align their performance better with that of UK laboratories. This will 
be relatively easy to assess using the numbers of UP and PUP 
laboratories in both categories, which could be further analysed by type 
and work profile of the laboratory, compliance with accreditation 
standards and patterns of practice gathered from questionnaire data 
distributed with surveys. 
4. Customer satisfaction feedback 
For the Scheme to maintain its competitive position it must respond to 
participants’ needs. The maintenance and renewal of participation and a 
continued low number of complaints are measures of satisfaction but 
other metrics may better reflect the opinions of users, e.g. average 
satisfaction scores (Morgan, 2006). The use of customer satisfaction 
surveys can be misleading unless these are well designed, targeted and 
cover a comprehensive and representative cohort of service users. The 
Scheme may benefit from taking expert advice on the construction of an 
effective questionnaire to assess satisfaction with the changes. 
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Appendix 1: Example of a UK NEQAS individual 
performance report to participants 
 
The report includes pages 1 to 5 of the individual participant’s report for distribution 
1602AH (April 2016): 
Page 1: Sickle solubility testing 
Page 2: Cumulative performance score for Hb A2 and Hb S 
Page 3: Hb A2/Hb F/Hb S data analysis specimen 1602AH1 
Page 4: Fraction identification results specimen 1602AH1 
Page 5: Interpretive comments results specimen 1602AH1 
 
The full report would include identical pages to p3 to p5 for the remaining specimens in 
the distribution. They have been omitted from this report to reduce the number of printed 
pages.  
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Appendix 2: Instruction sheet and proforma results sheet 
for experimental exercise 1301NHEX 
  
301 
 
 
 
Appendix 2.1. Sample instruction sheet for exercise 1301NHEX 
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Appendix 2.2. Example Results sheet for exercise 1301NHEX 
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Appendix 3: UK NEQAS Haematology coded interpretive 
comments list for the Abnormal Haemoglobins survey 
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UK NEQAS Haematology 
CODED COMMENTS FOR ABNORMAL HAEMOGLOBINS SURVEY 
 
Code Comment 
400 No evidence of a haemoglobin variant or thalassaemia 
402 No evidence of sickle haemoglobin 
403 No evidence of thalassaemia 
404 No evidence of beta thalassaemia 
411 Sickle cell carrier (Hb AS) 
412 Hb C carrier (Hb AC) 
413 Hb D carrier (Hb AD) 
414 Hb E carrier (Hb AE) 
415 Hb variant carrier (state the variant in the comment box, if known) 
416 Hb A2 variant detected. This is of no clinical importance. 
417 Hb O
Arab 
carrier (Hb AO
Arab
) 
418 Hb Lepore carrier (Hb A/Lepore) 
419 
Hb variant carrier of no known clinical significance (state the variant in the 
comment box, if known) 
421 Hb SC disease (Hb SC) 
422 Hb SD disease (Hb SD) 
423 Hb SE disease (Hb SE) 
424 Hb SO
Arab
 disease (Hb SO
Arab
) 
425 Homozygous sickle cell anaemia (Hb SS) 
426 Sickle – beta thalassaemia disease  
431 Beta thalassaemia carrier 
432 Possible alpha plus thalassaemia carrier and/or iron deficiency 
433 Possible alpha zero thalassaemia carrier and/or iron deficiency 
434 Carrier of Hereditary Persistence of Fetal Haemoglobin (HPFH) 
435 Carrier of delta beta thalassaemia 
441 Raised HbF 
451 Partner testing not required 
452 Partner testing should be offered 
453 
Partner testing should be offered if he is from a high-risk area (for alpha zero 
thalasaemia) 
454 Recommend referral to a Consultant Haematologist 
455 Iron status should be checked 
450 Other comment (please specify in comment box) 
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p.31. 
 
 http://109.68.152.74/index.php/thal/article/view/thal.2013.s1.e31. 
